



## Clinical trial results:

**A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, Japanese Older Adults Aged 60 Years, and RSV-Seropositive Children Aged 12 to 59 Months**

### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2024-000122-18 |
| Trial protocol           | Outside EU/EEA |
| Global end of trial date | 18 July 2024   |

### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1 (current) |
| This version publication date  | 18 May 2025  |
| First version publication date | 18 May 2025  |

### Trial information

#### Trial identification

|                       |                |
|-----------------------|----------------|
| Sponsor protocol code | mRNA-1345-P101 |
|-----------------------|----------------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04528719 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |                                                                                           |
|------------------------------|-------------------------------------------------------------------------------------------|
| Sponsor organisation name    | ModernaTX, Inc.                                                                           |
| Sponsor organisation address | 325 Binney Street, Cambridge, United States, 02142                                        |
| Public contact               | Moderna WeCare Team, ModernaTX, Inc., +1 866-663-3762, WeCareClinicalTrials@modernatx.com |
| Scientific contact           | Moderna WeCare Team, ModernaTX, Inc., +1 866-663-3762, WeCareClinicalTrials@modernatx.com |

Notes:

### Paediatric regulatory details

|                                                                      |                     |
|----------------------------------------------------------------------|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP)       | Yes                 |
| EMA paediatric investigation plan number(s)                          | EMA-003309-PIP01-22 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No                  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes                 |

Notes:

## Results analysis stage

|                                                      |              |
|------------------------------------------------------|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 18 July 2024 |
| Is this the analysis of the primary completion data? | Yes          |
| Primary completion date                              | 18 July 2024 |
| Global end of trial reached?                         | Yes          |
| Global end of trial date                             | 18 July 2024 |
| Was the trial ended prematurely?                     | No           |

Notes:

## General information about the trial

Main objective of the trial:

The primary objectives of this study were to evaluate the tolerability and reactogenicity of a single injection of up to 5 dose levels of mRNA-1345 in younger adults, women of child-bearing potential, and older adults including Japanese older adults; of 3 injections of the middle dose level of mRNA-1345 given 56 days apart in younger adults; of a booster injection of mRNA-1345 given approximately 12 and 24 months after the primary injection in older adults; and of 3 injections of 1 of 2 dose levels of mRNA-1345 given 56 days apart in children who were RSV-seropositive.

Protection of trial subjects:

This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines, applicable International Organization for Standardization (ISO) 14155 medical device guidelines, and other applicable laws and regulations.

Background therapy: -

Evidence for comparator: -

|                                                           |                   |
|-----------------------------------------------------------|-------------------|
| Actual start date of recruitment                          | 30 September 2020 |
| Long term follow-up planned                               | No                |
| Independent data monitoring committee (IDMC) involvement? | Yes               |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 651 |
| Worldwide total number of subjects   | 651                |
| EEA total number of subjects         | 0                  |

Notes:

### Subjects enrolled per age group

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 7 |

|                           |     |
|---------------------------|-----|
| Children (2-11 years)     | 39  |
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 288 |
| From 65 to 84 years       | 317 |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study included 4 Younger Adult Cohorts, 5 Older Adult Cohorts, 1 Japanese Older Adult Cohort, 2 Pediatric Cohorts, and 3 Women of Child-Bearing Potential (WOCBP) Cohorts.

### Period 1

|                              |                                        |
|------------------------------|----------------------------------------|
| Period 1 title               | Overall Study (overall period)         |
| Is this the baseline period? | Yes                                    |
| Allocation method            | Randomised - controlled                |
| Blinding used                | Double blind                           |
| Roles blinded                | Subject, Investigator, Carer, Assessor |

### Arms

|                              |                                                               |
|------------------------------|---------------------------------------------------------------|
| Are arms mutually exclusive? | Yes                                                           |
| <b>Arm title</b>             | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) |

Arm description:

Participants received a single injection of Dose A of mRNA-1345 on Day 1.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | mRNA-1345              |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

mRNA-1345 was administered per dose and schedule specified in the arm description.

|                  |                                                               |
|------------------|---------------------------------------------------------------|
| <b>Arm title</b> | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|------------------|---------------------------------------------------------------|

Arm description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | mRNA-1345              |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

mRNA-1345 was administered per dose and schedule specified in the arm description.

|                  |                                                               |
|------------------|---------------------------------------------------------------|
| <b>Arm title</b> | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|------------------|---------------------------------------------------------------|

Arm description:

Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 per day on Day 1, Day 57, and Day 113.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                                                                                                                                     |                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Investigational medicinal product name                                                                                                              | mRNA-1345                                                     |
| Investigational medicinal product code                                                                                                              |                                                               |
| Other name                                                                                                                                          |                                                               |
| Pharmaceutical forms                                                                                                                                | Solution for injection                                        |
| Routes of administration                                                                                                                            | Intramuscular use                                             |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                            |                                                               |
| <b>Arm title</b>                                                                                                                                    | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) |
| Arm description:<br>Participants received a single injection of Dose C of mRNA-1345 on Day 1.                                                       |                                                               |
| Arm type                                                                                                                                            | Experimental                                                  |
| Investigational medicinal product name                                                                                                              | mRNA-1345                                                     |
| Investigational medicinal product code                                                                                                              |                                                               |
| Other name                                                                                                                                          |                                                               |
| Pharmaceutical forms                                                                                                                                | Solution for injection                                        |
| Routes of administration                                                                                                                            | Intramuscular use                                             |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                            |                                                               |
| <b>Arm title</b>                                                                                                                                    | Single Injection Placebo in Younger Adults (18 to 49 Years)   |
| Arm description:<br>Participants received a single injection of mRNA-1345 matching-placebo on Day 1.                                                |                                                               |
| Arm type                                                                                                                                            | Placebo                                                       |
| Investigational medicinal product name                                                                                                              | Placebo                                                       |
| Investigational medicinal product code                                                                                                              |                                                               |
| Other name                                                                                                                                          |                                                               |
| Pharmaceutical forms                                                                                                                                | Solution for injection                                        |
| Routes of administration                                                                                                                            | Intramuscular use                                             |
| Dosage and administration details:<br>Placebo matched to mRNA-1345 was administered per schedule specified in the arm description.                  |                                                               |
| <b>Arm title</b>                                                                                                                                    | Three Injection Placebo in Younger Adults (18 to 49 Years)    |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113. |                                                               |
| Arm type                                                                                                                                            | Placebo                                                       |
| Investigational medicinal product name                                                                                                              | Placebo                                                       |
| Investigational medicinal product code                                                                                                              |                                                               |
| Other name                                                                                                                                          |                                                               |
| Pharmaceutical forms                                                                                                                                | Solution for injection                                        |
| Routes of administration                                                                                                                            | Intramuscular use                                             |
| Dosage and administration details:<br>Placebo matched to mRNA-1345 was administered per schedule specified in the arm description.                  |                                                               |
| <b>Arm title</b>                                                                                                                                    | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months)      |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose D of mRNA-1345 per day on Day 1, Day 57, and Day 113.        |                                                               |
| Arm type                                                                                                                                            | Experimental                                                  |

|                                                                                                                                                                                                                                                                                     |                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                   |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                             |
| Other name                                                                                                                                                                                                                                                                          |                                                             |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                      |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                           |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                             |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months)    |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose G of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                             |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                |
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                   |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                             |
| Other name                                                                                                                                                                                                                                                                          |                                                             |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                      |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                           |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                             |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Three Injection Placebo in Children (12 to 59 Months)       |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.                                                                                                                                 |                                                             |
| Arm type                                                                                                                                                                                                                                                                            | Placebo                                                     |
| Investigational medicinal product name                                                                                                                                                                                                                                              | Placebo                                                     |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                             |
| Other name                                                                                                                                                                                                                                                                          |                                                             |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                      |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                           |
| Dosage and administration details:<br>Placebo matched to mRNA-1345 was administered per schedule specified in the arm description.                                                                                                                                                  |                                                             |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years) |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose A of mRNA-1345 on Day 1, a booster injection of Dose A of mRNA-1345 approximately 12 months later and a second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1. |                                                             |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                |
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                   |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                             |
| Other name                                                                                                                                                                                                                                                                          |                                                             |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                      |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                           |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                             |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years) |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 on Day 1, a booster injection of Dose B of mRNA-1345 approximately 12 months later and a second booster injection of Dose B of mRNA-1345 approximately 24 months after Day 1. |                                                             |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                |

|                                                                                                                                                                                                                                                                                     |                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                    |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                              |
| Other name                                                                                                                                                                                                                                                                          |                                                              |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                       |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                            |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                              |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years)  |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose C of mRNA-1345 on Day 1, a booster injection of Dose C of mRNA-1345 approximately 12 months later and a second booster injection of Dose C of mRNA-1345 approximately 24 months after Day 1. |                                                              |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                 |
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                    |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                              |
| Other name                                                                                                                                                                                                                                                                          |                                                              |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                       |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                            |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                              |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years) |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose E of mRNA-1345 on Day 1, a booster injection of Dose E of mRNA-1345 approximately 12 months later and a second booster injection of Dose E of mRNA-1345 approximately 24 months after Day 1. |                                                              |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                 |
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                    |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                              |
| Other name                                                                                                                                                                                                                                                                          |                                                              |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                       |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                            |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                              |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of Dose F of mRNA-1345 on Day 1, a booster injection of Dose F of mRNA-1345 approximately 12 months later and a second booster injection of Dose F of mRNA-1345 approximately 24 months after Day 1. |                                                              |
| Arm type                                                                                                                                                                                                                                                                            | Experimental                                                 |
| Investigational medicinal product name                                                                                                                                                                                                                                              | mRNA-1345                                                    |
| Investigational medicinal product code                                                                                                                                                                                                                                              |                                                              |
| Other name                                                                                                                                                                                                                                                                          |                                                              |
| Pharmaceutical forms                                                                                                                                                                                                                                                                | Solution for injection                                       |
| Routes of administration                                                                                                                                                                                                                                                            | Intramuscular use                                            |
| Dosage and administration details:<br>mRNA-1345 was administered per dose and schedule specified in the arm description.                                                                                                                                                            |                                                              |
| <b>Arm title</b>                                                                                                                                                                                                                                                                    | Two Injection Placebo in Older Adults (65 to 79 Years)       |
| Arm description:<br>Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1 and approximately 12 months later. Participants received second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1.         |                                                              |
| Arm type                                                                                                                                                                                                                                                                            | Placebo                                                      |

|                                                                                              |                                                       |
|----------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Investigational medicinal product name                                                       | mRNA-1345                                             |
| Investigational medicinal product code                                                       |                                                       |
| Other name                                                                                   |                                                       |
| Pharmaceutical forms                                                                         | Solution for injection                                |
| Routes of administration                                                                     | Intramuscular use                                     |
| Dosage and administration details:                                                           |                                                       |
| mRNA-1345 was administered per dose and schedule specified in the arm description.           |                                                       |
| Investigational medicinal product name                                                       | Placebo                                               |
| Investigational medicinal product code                                                       |                                                       |
| Other name                                                                                   |                                                       |
| Pharmaceutical forms                                                                         | Solution for injection                                |
| Routes of administration                                                                     | Intramuscular use                                     |
| Dosage and administration details:                                                           |                                                       |
| Placebo matched to mRNA-1345 was administered per schedule specified in the arm description. |                                                       |
| <b>Arm title</b>                                                                             | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) |
| Arm description:                                                                             |                                                       |
| Participants received a single injection of Dose F of mRNA-1345 on Day 1.                    |                                                       |
| Arm type                                                                                     | Experimental                                          |
| Investigational medicinal product name                                                       | mRNA-1345                                             |
| Investigational medicinal product code                                                       |                                                       |
| Other name                                                                                   |                                                       |
| Pharmaceutical forms                                                                         | Solution for injection                                |
| Routes of administration                                                                     | Intramuscular use                                     |
| Dosage and administration details:                                                           |                                                       |
| mRNA-1345 was administered per dose and schedule specified in the arm description.           |                                                       |
| <b>Arm title</b>                                                                             | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
| Arm description:                                                                             |                                                       |
| Participants received a single injection of Dose E of mRNA-1345 on Day 1.                    |                                                       |
| Arm type                                                                                     | Experimental                                          |
| Investigational medicinal product name                                                       | mRNA-1345                                             |
| Investigational medicinal product code                                                       |                                                       |
| Other name                                                                                   |                                                       |
| Pharmaceutical forms                                                                         | Solution for injection                                |
| Routes of administration                                                                     | Intramuscular use                                     |
| Dosage and administration details:                                                           |                                                       |
| mRNA-1345 was administered per dose and schedule specified in the arm description.           |                                                       |
| <b>Arm title</b>                                                                             | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
| Arm description:                                                                             |                                                       |
| Participants received a single injection of Dose A of mRNA-1345 on Day 1.                    |                                                       |
| Arm type                                                                                     | Experimental                                          |
| Investigational medicinal product name                                                       | mRNA-1345                                             |
| Investigational medicinal product code                                                       |                                                       |
| Other name                                                                                   |                                                       |
| Pharmaceutical forms                                                                         | Solution for injection                                |
| Routes of administration                                                                     | Intramuscular use                                     |
| Dosage and administration details:                                                           |                                                       |
| mRNA-1345 was administered per dose and schedule specified in the arm description.           |                                                       |
| <b>Arm title</b>                                                                             | Single Injection Placebo in WOCBP (18 to 40 Years)    |
| Arm description:                                                                             |                                                       |
| Participants received a single injection of mRNA-1345 matching-placebo on Day 1.             |                                                       |

|                                                                                              |                                                                |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Arm type                                                                                     | Placebo                                                        |
| Investigational medicinal product name                                                       | Placebo                                                        |
| Investigational medicinal product code                                                       |                                                                |
| Other name                                                                                   |                                                                |
| Pharmaceutical forms                                                                         | Solution for injection                                         |
| Routes of administration                                                                     | Intramuscular use                                              |
| Dosage and administration details:                                                           |                                                                |
| Placebo matched to mRNA-1345 was administered per schedule specified in the arm description. |                                                                |
| <b>Arm title</b>                                                                             | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults           |
| Arm description:                                                                             |                                                                |
| Participants received a single injection of Dose B of mRNA-1345 on Day 1.                    |                                                                |
| Arm type                                                                                     | Experimental                                                   |
| Investigational medicinal product name                                                       | mRNA-1345                                                      |
| Investigational medicinal product code                                                       |                                                                |
| Other name                                                                                   |                                                                |
| Pharmaceutical forms                                                                         | Solution for injection                                         |
| Routes of administration                                                                     | Intramuscular use                                              |
| Dosage and administration details:                                                           |                                                                |
| mRNA-1345 was administered per dose and schedule specified in the arm description.           |                                                                |
| <b>Arm title</b>                                                                             | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |
| Arm description:                                                                             |                                                                |
| Participants received a single injection of mRNA-1345 matching-placebo on Day 1.             |                                                                |
| Arm type                                                                                     | Placebo                                                        |
| Investigational medicinal product name                                                       | Placebo                                                        |
| Investigational medicinal product code                                                       |                                                                |
| Other name                                                                                   |                                                                |
| Pharmaceutical forms                                                                         | Solution for injection                                         |
| Routes of administration                                                                     | Intramuscular use                                              |
| Dosage and administration details:                                                           |                                                                |
| Placebo matched to mRNA-1345 was administered per schedule specified in the arm description. |                                                                |

| <b>Number of subjects in period 1</b> | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|---------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Started                               | 20                                                            | 20                                                            | 20                                                            |
| Safety Set                            | 19                                                            | 20                                                            | 20                                                            |
| Completed                             | 18                                                            | 19                                                            | 15                                                            |
| Not completed                         | 2                                                             | 1                                                             | 5                                                             |
| Adverse event, serious fatal          | -                                                             | -                                                             | -                                                             |
| Consent withdrawn by subject          | 1                                                             | 1                                                             | 4                                                             |
| Physician decision                    | -                                                             | -                                                             | -                                                             |
| Other Than Specified                  | -                                                             | -                                                             | -                                                             |
| Adverse event, non-fatal              | -                                                             | -                                                             | -                                                             |
| Lost to follow-up                     | 1                                                             | -                                                             | 1                                                             |
| Protocol deviation                    | -                                                             | -                                                             | -                                                             |

| Number of subjects in period 1 | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) | Single Injection Placebo in Younger Adults (18 to 49 Years) | Three Injection Placebo in Younger Adults (18 to 49 Years) |
|--------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|
| Started                        | 20                                                            | 15                                                          | 5                                                          |
| Safety Set                     | 20                                                            | 15                                                          | 5                                                          |
| Completed                      | 19                                                            | 14                                                          | 3                                                          |
| Not completed                  | 1                                                             | 1                                                           | 2                                                          |
| Adverse event, serious fatal   | -                                                             | -                                                           | -                                                          |
| Consent withdrawn by subject   | -                                                             | 1                                                           | 1                                                          |
| Physician decision             | -                                                             | -                                                           | -                                                          |
| Other Than Specified           | -                                                             | -                                                           | -                                                          |
| Adverse event, non-fatal       | -                                                             | -                                                           | -                                                          |
| Lost to follow-up              | 1                                                             | -                                                           | 1                                                          |
| Protocol deviation             | -                                                             | -                                                           | -                                                          |

| Number of subjects in period 1 | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months) | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months) | Three Injection Placebo in Children (12 to 59 Months) |
|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
| Started                        | 16                                                       | 15                                                       | 15                                                    |
| Safety Set                     | 15                                                       | 15                                                       | 15                                                    |
| Completed                      | 11                                                       | 11                                                       | 9                                                     |
| Not completed                  | 5                                                        | 4                                                        | 6                                                     |
| Adverse event, serious fatal   | -                                                        | -                                                        | -                                                     |
| Consent withdrawn by subject   | -                                                        | -                                                        | 2                                                     |
| Physician decision             | -                                                        | -                                                        | -                                                     |
| Other Than Specified           | 2                                                        | -                                                        | 1                                                     |
| Adverse event, non-fatal       | -                                                        | -                                                        | -                                                     |
| Lost to follow-up              | 3                                                        | 4                                                        | 2                                                     |
| Protocol deviation             | -                                                        | -                                                        | 1                                                     |

| Number of subjects in period 1 | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years) | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years) | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years) |
|--------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Started                        | 48                                                          | 48                                                          | 48                                                          |
| Safety Set                     | 47                                                          | 48                                                          | 48                                                          |
| Completed                      | 36                                                          | 31                                                          | 30                                                          |
| Not completed                  | 12                                                          | 17                                                          | 18                                                          |
| Adverse event, serious fatal   | -                                                           | 1                                                           | 1                                                           |
| Consent withdrawn by subject   | 8                                                           | 3                                                           | 12                                                          |
| Physician decision             | 1                                                           | 1                                                           | -                                                           |
| Other Than Specified           | 1                                                           | 2                                                           | 2                                                           |
| Adverse event, non-fatal       | -                                                           | -                                                           | -                                                           |
| Lost to follow-up              | 2                                                           | 10                                                          | 3                                                           |

|                    |   |   |   |
|--------------------|---|---|---|
| Protocol deviation | - | - | - |
|--------------------|---|---|---|

  

| Number of subjects in period 1 | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years) | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) | Two Injection Placebo in Older Adults (65 to 79 Years) |
|--------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|
| Started                        | 48                                                           | 48                                                           | 60                                                     |
| Safety Set                     | 48                                                           | 48                                                           | 59                                                     |
| Completed                      | 40                                                           | 40                                                           | 44                                                     |
| Not completed                  | 8                                                            | 8                                                            | 16                                                     |
| Adverse event, serious fatal   | 1                                                            | 1                                                            | -                                                      |
| Consent withdrawn by subject   | 3                                                            | 4                                                            | 5                                                      |
| Physician decision             | -                                                            | -                                                            | -                                                      |
| Other Than Specified           | 1                                                            | -                                                            | 1                                                      |
| Adverse event, non-fatal       | -                                                            | 1                                                            | -                                                      |
| Lost to follow-up              | 3                                                            | 1                                                            | 10                                                     |
| Protocol deviation             | -                                                            | 1                                                            | -                                                      |

| Number of subjects in period 1 | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
|--------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Started                        | 50                                                    | 50                                                    | 50                                                    |
| Safety Set                     | 50                                                    | 49                                                    | 49                                                    |
| Completed                      | 45                                                    | 44                                                    | 42                                                    |
| Not completed                  | 5                                                     | 6                                                     | 8                                                     |
| Adverse event, serious fatal   | -                                                     | -                                                     | -                                                     |
| Consent withdrawn by subject   | 1                                                     | 4                                                     | 5                                                     |
| Physician decision             | -                                                     | -                                                     | -                                                     |
| Other Than Specified           | 1                                                     | -                                                     | -                                                     |
| Adverse event, non-fatal       | -                                                     | -                                                     | -                                                     |
| Lost to follow-up              | 3                                                     | 2                                                     | 3                                                     |
| Protocol deviation             | -                                                     | -                                                     | -                                                     |

| Number of subjects in period 1 | Single Injection Placebo in WOCBP (18 to 40 Years) | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |
|--------------------------------|----------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------|
| Started                        | 30                                                 | 20                                                   | 5                                                              |
| Safety Set                     | 30                                                 | 20                                                   | 5                                                              |
| Completed                      | 26                                                 | 20                                                   | 5                                                              |
| Not completed                  | 4                                                  | 0                                                    | 0                                                              |
| Adverse event, serious fatal   | -                                                  | -                                                    | -                                                              |
| Consent withdrawn by subject   | 2                                                  | -                                                    | -                                                              |
| Physician decision             | -                                                  | -                                                    | -                                                              |
| Other Than Specified           | -                                                  | -                                                    | -                                                              |
| Adverse event, non-fatal       | -                                                  | -                                                    | -                                                              |

|                    |   |   |   |
|--------------------|---|---|---|
| Lost to follow-up  | 2 | - | - |
| Protocol deviation | - | - | - |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                                                 |                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                                           | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a single injection of Dose A of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a single injection of Dose B of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a single injection of Dose C of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Single Injection Placebo in Younger Adults (18 to 49 Years)   |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a single injection of mRNA-1345 matching-placebo on Day 1.                                                                                                                                                                                |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Three Injection Placebo in Younger Adults (18 to 49 Years)    |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.                                                                                                                                 |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months)      |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose D of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months)      |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose G of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Three Injection Placebo in Children (12 to 59 Months)         |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.                                                                                                                                 |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years)   |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose A of mRNA-1345 on Day 1, a booster injection of Dose A of mRNA-1345 approximately 12 months later and a second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years)   |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 on Day 1, a booster injection of Dose B of mRNA-1345 approximately 12 months later and a second booster injection of Dose B of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years)   |
| Reporting group description:                                                                                                                                                                                                                                    |                                                               |
| Participants received a total of 3 injections: 1 injection of Dose C of mRNA-1345 on Day 1, a booster injection of Dose C of mRNA-1345 approximately 12 months later and a second booster injection of Dose C of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                           | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years)  |

Reporting group description:

Participants received a total of 3 injections: 1 injection of Dose E of mRNA-1345 on Day 1, a booster injection of Dose E of mRNA-1345 approximately 12 months later and a second booster injection of Dose E of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections: 1 injection of Dose F of mRNA-1345 on Day 1, a booster injection of Dose F of mRNA-1345 approximately 12 months later and a second booster injection of Dose F of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                        |
|-----------------------|--------------------------------------------------------|
| Reporting group title | Two Injection Placebo in Older Adults (65 to 79 Years) |
|-----------------------|--------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1 and approximately 12 months later. Participants received second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose F of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose E of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose A of mRNA-1345 on Day 1.

|                       |                                                    |
|-----------------------|----------------------------------------------------|
| Reporting group title | Single Injection Placebo in WOCBP (18 to 40 Years) |
|-----------------------|----------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                      |
|-----------------------|------------------------------------------------------|
| Reporting group title | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults |
|-----------------------|------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                       |                                                                |
|-----------------------|----------------------------------------------------------------|
| Reporting group title | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |
|-----------------------|----------------------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

| Reporting group values | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Number of subjects     | 20                                                            | 20                                                            | 20                                                            |
| Age categorical        |                                                               |                                                               |                                                               |
| Units: Subjects        |                                                               |                                                               |                                                               |

|                           |        |        |        |
|---------------------------|--------|--------|--------|
| Age continuous            |        |        |        |
| Units: years              |        |        |        |
| arithmetic mean           | 36.1   | 33.4   | 32.0   |
| standard deviation        | ± 7.50 | ± 7.56 | ± 9.55 |
| Gender categorical        |        |        |        |
| Units: Subjects           |        |        |        |
| Female                    | 10     | 11     | 16     |
| Male                      | 10     | 9      | 4      |
| Race                      |        |        |        |
| Units: Subjects           |        |        |        |
| White                     | 14     | 16     | 16     |
| Black or African American | 6      | 4      | 4      |

|                                           |    |    |    |
|-------------------------------------------|----|----|----|
| Asian                                     | 0  | 0  | 0  |
| American Indian or Alaska Native          | 0  | 0  | 0  |
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 0  |
| Multiple                                  | 0  | 0  | 0  |
| Other                                     | 0  | 0  | 0  |
| Not Reported                              | 0  | 0  | 0  |
| Ethnicity<br>Units: Subjects              |    |    |    |
| Hispanic or Latino                        | 0  | 1  | 0  |
| Not Hispanic or Latino                    | 20 | 19 | 20 |
| Not Reported                              | 0  | 0  | 0  |

| Reporting group values             | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) | Single Injection Placebo in Younger Adults (18 to 49 Years) | Three Injection Placebo in Younger Adults (18 to 49 Years) |
|------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|
| Number of subjects                 | 20                                                            | 15                                                          | 5                                                          |
| Age categorical<br>Units: Subjects |                                                               |                                                             |                                                            |

|                                           |        |        |        |
|-------------------------------------------|--------|--------|--------|
| Age continuous<br>Units: years            |        |        |        |
| arithmetic mean                           | 31.8   | 37.5   | 24.8   |
| standard deviation                        | ± 4.81 | ± 6.64 | ± 4.09 |
| Gender categorical<br>Units: Subjects     |        |        |        |
| Female                                    | 6      | 12     | 3      |
| Male                                      | 14     | 3      | 2      |
| Race<br>Units: Subjects                   |        |        |        |
| White                                     | 18     | 11     | 3      |
| Black or African American                 | 0      | 4      | 2      |
| Asian                                     | 0      | 0      | 0      |
| American Indian or Alaska Native          | 0      | 0      | 0      |
| Native Hawaiian or Other Pacific Islander | 0      | 0      | 0      |
| Multiple                                  | 2      | 0      | 0      |
| Other                                     | 0      | 0      | 0      |
| Not Reported                              | 0      | 0      | 0      |
| Ethnicity<br>Units: Subjects              |        |        |        |
| Hispanic or Latino                        | 0      | 1      | 0      |
| Not Hispanic or Latino                    | 20     | 14     | 5      |
| Not Reported                              | 0      | 0      | 0      |

| Reporting group values             | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months) | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months) | Three Injection Placebo in Children (12 to 59 Months) |
|------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
| Number of subjects                 | 16                                                       | 15                                                       | 15                                                    |
| Age categorical<br>Units: Subjects |                                                          |                                                          |                                                       |

|                                                                         |               |               |               |
|-------------------------------------------------------------------------|---------------|---------------|---------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 3.6<br>± 1.08 | 3.2<br>± 1.01 | 3.2<br>± 1.17 |
| Gender categorical<br>Units: Subjects                                   |               |               |               |
| Female                                                                  | 11            | 7             | 6             |
| Male                                                                    | 5             | 8             | 9             |
| Race<br>Units: Subjects                                                 |               |               |               |
| White                                                                   | 11            | 10            | 8             |
| Black or African American                                               | 1             | 3             | 6             |
| Asian                                                                   | 0             | 1             | 0             |
| American Indian or Alaska Native                                        | 0             | 0             | 0             |
| Native Hawaiian or Other Pacific Islander                               | 0             | 0             | 0             |
| Multiple                                                                | 1             | 1             | 1             |
| Other                                                                   | 3             | 0             | 0             |
| Not Reported                                                            | 0             | 0             | 0             |
| Ethnicity<br>Units: Subjects                                            |               |               |               |
| Hispanic or Latino                                                      | 2             | 0             | 2             |
| Not Hispanic or Latino                                                  | 14            | 15            | 13            |
| Not Reported                                                            | 0             | 0             | 0             |

| <b>Reporting group values</b>      | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years) | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years) | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years) |
|------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Number of subjects                 | 48                                                          | 48                                                          | 48                                                          |
| Age categorical<br>Units: Subjects |                                                             |                                                             |                                                             |

|                                                                         |                |                |                |
|-------------------------------------------------------------------------|----------------|----------------|----------------|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | 70.1<br>± 3.81 | 70.2<br>± 3.88 | 69.9<br>± 3.94 |
| Gender categorical<br>Units: Subjects                                   |                |                |                |
| Female                                                                  | 25             | 25             | 28             |
| Male                                                                    | 23             | 23             | 20             |
| Race<br>Units: Subjects                                                 |                |                |                |
| White                                                                   | 45             | 42             | 46             |
| Black or African American                                               | 1              | 6              | 1              |
| Asian                                                                   | 1              | 0              | 0              |
| American Indian or Alaska Native                                        | 0              | 0              | 1              |
| Native Hawaiian or Other Pacific Islander                               | 0              | 0              | 0              |
| Multiple                                                                | 1              | 0              | 0              |
| Other                                                                   | 0              | 0              | 0              |
| Not Reported                                                            | 0              | 0              | 0              |
| Ethnicity                                                               |                |                |                |

|                        |    |    |    |
|------------------------|----|----|----|
| Units: Subjects        |    |    |    |
| Hispanic or Latino     | 3  | 0  | 4  |
| Not Hispanic or Latino | 45 | 48 | 44 |
| Not Reported           | 0  | 0  | 0  |

| Reporting group values | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years) | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) | Two Injection Placebo in Older Adults (65 to 79 Years) |
|------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|
| Number of subjects     | 48                                                           | 48                                                           | 60                                                     |
| Age categorical        |                                                              |                                                              |                                                        |
| Units: Subjects        |                                                              |                                                              |                                                        |

|                                           |        |        |        |
|-------------------------------------------|--------|--------|--------|
| Age continuous                            |        |        |        |
| Units: years                              |        |        |        |
| arithmetic mean                           | 70.7   | 69.9   | 69.9   |
| standard deviation                        | ± 3.71 | ± 3.23 | ± 3.71 |
| Gender categorical                        |        |        |        |
| Units: Subjects                           |        |        |        |
| Female                                    | 26     | 29     | 33     |
| Male                                      | 22     | 19     | 27     |
| Race                                      |        |        |        |
| Units: Subjects                           |        |        |        |
| White                                     | 43     | 44     | 50     |
| Black or African American                 | 2      | 4      | 7      |
| Asian                                     | 2      | 0      | 1      |
| American Indian or Alaska Native          | 0      | 0      | 0      |
| Native Hawaiian or Other Pacific Islander | 0      | 0      | 1      |
| Multiple                                  | 0      | 0      | 0      |
| Other                                     | 1      | 0      | 1      |
| Not Reported                              | 0      | 0      | 0      |
| Ethnicity                                 |        |        |        |
| Units: Subjects                           |        |        |        |
| Hispanic or Latino                        | 2      | 2      | 4      |
| Not Hispanic or Latino                    | 46     | 44     | 56     |
| Not Reported                              | 0      | 2      | 0      |

| Reporting group values | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
|------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Number of subjects     | 50                                                    | 50                                                    | 50                                                    |
| Age categorical        |                                                       |                                                       |                                                       |
| Units: Subjects        |                                                       |                                                       |                                                       |

|                    |        |        |        |
|--------------------|--------|--------|--------|
| Age continuous     |        |        |        |
| Units: years       |        |        |        |
| arithmetic mean    | 29.6   | 30.3   | 31.3   |
| standard deviation | ± 6.64 | ± 5.77 | ± 6.24 |
| Gender categorical |        |        |        |
| Units: Subjects    |        |        |        |
| Female             | 50     | 50     | 50     |
| Male               | 0      | 0      | 0      |

|                                           |    |    |    |
|-------------------------------------------|----|----|----|
| Race                                      |    |    |    |
| Units: Subjects                           |    |    |    |
| White                                     | 45 | 37 | 43 |
| Black or African American                 | 5  | 8  | 3  |
| Asian                                     | 0  | 2  | 4  |
| American Indian or Alaska Native          | 0  | 0  | 0  |
| Native Hawaiian or Other Pacific Islander | 0  | 0  | 0  |
| Multiple                                  | 0  | 3  | 0  |
| Other                                     | 0  | 0  | 0  |
| Not Reported                              | 0  | 0  | 0  |
| Ethnicity                                 |    |    |    |
| Units: Subjects                           |    |    |    |
| Hispanic or Latino                        | 6  | 1  | 4  |
| Not Hispanic or Latino                    | 44 | 49 | 46 |
| Not Reported                              | 0  | 0  | 0  |

| Reporting group values | Single Injection<br>Placebo in WOCBP<br>(18 to 40 Years) | Cohort 15: mRNA-<br>1345 Dose B in<br>Japanese Older<br>Adults | Single Injection<br>Placebo in Japanese<br>Older Adults (≥ 60<br>Years) |
|------------------------|----------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|
| Number of subjects     | 30                                                       | 20                                                             | 5                                                                       |
| Age categorical        |                                                          |                                                                |                                                                         |
| Units: Subjects        |                                                          |                                                                |                                                                         |

|                                           |        |        |        |
|-------------------------------------------|--------|--------|--------|
| Age continuous                            |        |        |        |
| Units: years                              |        |        |        |
| arithmetic mean                           | 29.7   | 68.6   | 65.4   |
| standard deviation                        | ± 6.29 | ± 6.89 | ± 4.28 |
| Gender categorical                        |        |        |        |
| Units: Subjects                           |        |        |        |
| Female                                    | 30     | 10     | 2      |
| Male                                      | 0      | 10     | 3      |
| Race                                      |        |        |        |
| Units: Subjects                           |        |        |        |
| White                                     | 27     | 0      | 0      |
| Black or African American                 | 1      | 0      | 0      |
| Asian                                     | 0      | 20     | 5      |
| American Indian or Alaska Native          | 0      | 0      | 0      |
| Native Hawaiian or Other Pacific Islander | 1      | 0      | 0      |
| Multiple                                  | 0      | 0      | 0      |
| Other                                     | 0      | 0      | 0      |
| Not Reported                              | 1      | 0      | 0      |
| Ethnicity                                 |        |        |        |
| Units: Subjects                           |        |        |        |
| Hispanic or Latino                        | 4      | 0      | 0      |
| Not Hispanic or Latino                    | 26     | 20     | 5      |
| Not Reported                              | 0      | 0      | 0      |

| Reporting group values | Total |  |  |
|------------------------|-------|--|--|
| Number of subjects     | 651   |  |  |

|                                                                         |     |  |  |
|-------------------------------------------------------------------------|-----|--|--|
| Age categorical<br>Units: Subjects                                      |     |  |  |
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | -   |  |  |
| Gender categorical<br>Units: Subjects                                   |     |  |  |
| Female                                                                  | 440 |  |  |
| Male                                                                    | 211 |  |  |
| Race<br>Units: Subjects                                                 |     |  |  |
| White                                                                   | 529 |  |  |
| Black or African American                                               | 68  |  |  |
| Asian                                                                   | 36  |  |  |
| American Indian or Alaska Native                                        | 1   |  |  |
| Native Hawaiian or Other Pacific Islander                               | 2   |  |  |
| Multiple                                                                | 9   |  |  |
| Other                                                                   | 5   |  |  |
| Not Reported                                                            | 1   |  |  |
| Ethnicity<br>Units: Subjects                                            |     |  |  |
| Hispanic or Latino                                                      | 36  |  |  |
| Not Hispanic or Latino                                                  | 613 |  |  |
| Not Reported                                                            | 2   |  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                                                                                 |                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) |
| Reporting group description:<br>Participants received a single injection of Dose A of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
| Reporting group description:<br>Participants received a single injection of Dose B of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) |
| Reporting group description:<br>Participants received a single injection of Dose C of mRNA-1345 on Day 1.                                                                                                                                                                                       |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Single Injection Placebo in Younger Adults (18 to 49 Years)   |
| Reporting group description:<br>Participants received a single injection of mRNA-1345 matching-placebo on Day 1.                                                                                                                                                                                |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Three Injection Placebo in Younger Adults (18 to 49 Years)    |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.                                                                                                                                 |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months)      |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose D of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months)      |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose G of mRNA-1345 per day on Day 1, Day 57, and Day 113.                                                                                                                                        |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Three Injection Placebo in Children (12 to 59 Months)         |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.                                                                                                                                 |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years)   |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose A of mRNA-1345 on Day 1, a booster injection of Dose A of mRNA-1345 approximately 12 months later and a second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years)   |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose B of mRNA-1345 on Day 1, a booster injection of Dose B of mRNA-1345 approximately 12 months later and a second booster injection of Dose B of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years)   |
| Reporting group description:<br>Participants received a total of 3 injections: 1 injection of Dose C of mRNA-1345 on Day 1, a booster injection of Dose C of mRNA-1345 approximately 12 months later and a second booster injection of Dose C of mRNA-1345 approximately 24 months after Day 1. |                                                               |
| Reporting group title                                                                                                                                                                                                                                                                           | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years)  |

Reporting group description:

Participants received a total of 3 injections: 1 injection of Dose E of mRNA-1345 on Day 1, a booster injection of Dose E of mRNA-1345 approximately 12 months later and a second booster injection of Dose E of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections: 1 injection of Dose F of mRNA-1345 on Day 1, a booster injection of Dose F of mRNA-1345 approximately 12 months later and a second booster injection of Dose F of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                        |
|-----------------------|--------------------------------------------------------|
| Reporting group title | Two Injection Placebo in Older Adults (65 to 79 Years) |
|-----------------------|--------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections: 1 injection of mRNA-1345 matching-placebo per day on Day 1 and approximately 12 months later. Participants received second booster injection of Dose A of mRNA-1345 approximately 24 months after Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose F of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose E of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose A of mRNA-1345 on Day 1.

|                       |                                                    |
|-----------------------|----------------------------------------------------|
| Reporting group title | Single Injection Placebo in WOCBP (18 to 40 Years) |
|-----------------------|----------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                      |
|-----------------------|------------------------------------------------------|
| Reporting group title | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults |
|-----------------------|------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                       |                                                                      |
|-----------------------|----------------------------------------------------------------------|
| Reporting group title | Single Injection Placebo in Japanese Older Adults ( $\geq 60$ Years) |
|-----------------------|----------------------------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                      |
|----------------------------|------------------------------------------------------|
| Subject analysis set title | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults |
|----------------------------|------------------------------------------------------|

|                           |                 |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                            |                                                                      |
|----------------------------|----------------------------------------------------------------------|
| Subject analysis set title | Single Injection Placebo in Japanese Older Adults ( $\geq 60$ Years) |
|----------------------------|----------------------------------------------------------------------|

|                           |                 |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                       |
|----------------------------|-------------------------------------------------------|
| Subject analysis set title | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) |
|----------------------------|-------------------------------------------------------|

|                           |                 |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants received a single injection of Dose F of mRNA-1345 on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | Two Injection Placebo in Older Adults (After 1st Dose) |
|----------------------------|--------------------------------------------------------|

|                           |                 |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                             |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Cohort 7: mRNA-1345 Dose A in Older Adults (After 1st Dose) |
|----------------------------|-------------------------------------------------------------|

|                           |                 |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

Participants received 1 injection of Dose A of mRNA-1345 on Day 1.

|                            |                                                             |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Cohort 8: mRNA-1345 Dose B in Older Adults (After 1st Dose) |
|----------------------------|-------------------------------------------------------------|

|                                                                                                |                                                               |
|------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose B of mRNA-1345 on Day 1.                             |                                                               |
| Subject analysis set title                                                                     | Cohort 9: mRNA-1345 Dose C in Older Adults (After 1st Dose)   |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose C of mRNA-1345 on Day 1.                             |                                                               |
| Subject analysis set title                                                                     | Cohort 10: mRNA-1345 Dose E in Older Adults (After 1st Dose)  |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose E of mRNA-1345 on Day 1.                             |                                                               |
| Subject analysis set title                                                                     | Cohort 11: mRNA-1345 Dose F in Older Adults (After 1st Dose)  |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose F of mRNA-1345 on Day 1.                             |                                                               |
| Subject analysis set title                                                                     | Two Injection Placebo in Older Adults (After Month 12)        |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of mRNA-1345 matching-placebo approximately 12 months later. |                                                               |
| Subject analysis set title                                                                     | Cohort 7: mRNA-1345 Dose A in Older Adults (After Month 12)   |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose A of mRNA-1345 approximately 12 months later.        |                                                               |
| Subject analysis set title                                                                     | Cohort 8: mRNA-1345 Dose B in Older Adults (After Month 12)   |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose B of mRNA-1345 approximately 12 months later.        |                                                               |
| Subject analysis set title                                                                     | Cohort 9: mRNA-1345 Dose C in Older Adults (After Month 12)   |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose C of mRNA-1345 approximately 12 months later.        |                                                               |
| Subject analysis set title                                                                     | Cohort 10: mRNA-1345 Dose E in Older Adults (After Month 12)  |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose E of mRNA-1345 approximately 12 months later.        |                                                               |
| Subject analysis set title                                                                     | Cohort 11: mRNA-1345 Dose F in Older Adults (After Month 12)  |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose F of mRNA-1345 approximately 12 months later.        |                                                               |
| Subject analysis set title                                                                     | Older Adult Cohorts: After Month 24: mRNA-1345 Dose A         |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received second booster injection of Dose A of mRNA-1345 at Month 24.             |                                                               |
| Subject analysis set title                                                                     | Cohort 3: mRNA-1345 Dose B in Younger Adults (After 1st Dose) |
| Subject analysis set type                                                                      | Safety analysis                                               |
| Subject analysis set description:                                                              |                                                               |
| Participants received 1 injection of Dose B of mRNA-1345 on Day 1.                             |                                                               |
| Subject analysis set title                                                                     | Cohort 3: mRNA-1345 Dose B in Young Adults (After 2nd Dose)   |
| Subject analysis set type                                                                      | Safety analysis                                               |

Subject analysis set description:

Participants received 1 injection of Dose B of mRNA-1345 on Day 57.

|                            |                                                             |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Cohort 3: mRNA-1345 Dose B in Young Adults (After 3rd Dose) |
| Subject analysis set type  | Safety analysis                                             |

Subject analysis set description:

Participants received 1 injection of Dose B of mRNA-1345 on Day 113.

|                            |                                                          |
|----------------------------|----------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Young Adults (After 1st Dose) |
| Subject analysis set type  | Safety analysis                                          |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                            |
|----------------------------|------------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Younger Adults (After 2nd Dose) |
| Subject analysis set type  | Safety analysis                                            |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 57.

|                            |                                                            |
|----------------------------|------------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Younger Adults (After 3rd Dose) |
| Subject analysis set type  | Safety analysis                                            |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 113.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose A in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose A of mRNA-1345 on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose B in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose B of mRNA-1345 on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose C in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose C of mRNA-1345 on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose E in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose E of mRNA-1345 on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose F in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose F of mRNA-1345 on Day 1.

|                            |                                                             |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Two Injection Placebo in Older Adults (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                             |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose A in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose A of mRNA-1345 approximately 12 months later.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose B in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose B of mRNA-1345 approximately 12 months later.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose C in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose C of mRNA-1345 approximately 12 months later.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose E in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose E of mRNA-1345 approximately 12 months later.

|                            |                                                        |
|----------------------------|--------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose F in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                        |

Subject analysis set description:

Participants received 1 injection of Dose F of mRNA-1345 approximately 12 months later.

|                            |                                                             |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Two Injection Placebo in Older Adults (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                             |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo approximately 12 months later.

|                            |                                                               |
|----------------------------|---------------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose A/Dose A in Older Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                               |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                               |
|----------------------------|---------------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose B/Dose A in Older Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                               |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                               |
|----------------------------|---------------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose C/Dose A in Older Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                               |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                               |
|----------------------------|---------------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose E/Dose A in Older Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                               |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                               |
|----------------------------|---------------------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose F/Dose A in Older Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                               |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                                |
|----------------------------|----------------------------------------------------------------|
| Subject analysis set title | 2-Injection Placebo/Dose A in Old Adults (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                                |

Subject analysis set description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose D in Children (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose D of mRNA-1345 on Day 1.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose G in Children (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose G of mRNA-1345 on Day 1.

|                            |                                                           |
|----------------------------|-----------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Children (After 1st Injection) |
| Subject analysis set type  | Safety analysis                                           |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 1.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose D in Children (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose D of mRNA-1345 on Day 57.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose G in Children (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose G of mRNA-1345 on Day 57.

|                            |                                                           |
|----------------------------|-----------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Children (After 2nd Injection) |
| Subject analysis set type  | Safety analysis                                           |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 57.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose D in Children (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose D of mRNA-1345 on Day 113.

|                            |                                                    |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | mRNA-1345 Dose G in Children (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                    |

Subject analysis set description:

Participants received 1 injection of Dose G of mRNA-1345 on Day 113.

|                            |                                                           |
|----------------------------|-----------------------------------------------------------|
| Subject analysis set title | Three Injection Placebo in Children (After 3rd Injection) |
| Subject analysis set type  | Safety analysis                                           |

Subject analysis set description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 113.

### **Primary: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Young Adult Cohorts**

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Young Adult Cohorts <sup>[1][2]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|

End point description:

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Solicited Safety Set included all randomized participants who received any study injection and contributed any solicited AR data (that is, had at least 1 postbaseline solicited safety [eDiary] assessment). Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

7 days after injection

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

|                             |                                                                              |                                                                              |                                                                              |                                                                         |
|-----------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <b>End point values</b>     | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |
| Subject group type          | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                         |
| Number of subjects analysed | 19                                                                           | 20                                                                           | 20                                                                           | 15                                                                      |
| Units: participants         | 15                                                                           | 18                                                                           | 20                                                                           | 6                                                                       |

|                             |                                                                              |                                                                            |                                                                            |                                                                      |
|-----------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------|
| <b>End point values</b>     | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(After 1st<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 2nd<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 3rd<br>Dose) | Three Injection<br>Placebo in<br>Young Adults<br>(After 1st<br>Dose) |
| Subject group type          | Subject analysis set                                                         | Subject analysis set                                                       | Subject analysis set                                                       | Subject analysis set                                                 |
| Number of subjects analysed | 20                                                                           | 16                                                                         | 14                                                                         | 5                                                                    |
| Units: participants         | 20                                                                           | 14                                                                         | 12                                                                         | 2                                                                    |

|                             |                                                                        |                                                                        |  |  |
|-----------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| <b>End point values</b>     | Three Injection<br>Placebo in<br>Younger Adults<br>(After 2nd<br>Dose) | Three Injection<br>Placebo in<br>Younger Adults<br>(After 3rd<br>Dose) |  |  |
| Subject group type          | Subject analysis set                                                   | Subject analysis set                                                   |  |  |
| Number of subjects analysed | 3                                                                      | 3                                                                      |  |  |
| Units: participants         | 0                                                                      | 1                                                                      |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Solicited Local and Systemic ARs in WOCBP Cohorts and Japanese Adult Cohorts

|                 |                                                                                                                            |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Solicited Local and Systemic ARs in WOCBP Cohorts and Japanese Adult Cohorts <sup>[3][4]</sup> |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|

End point description:

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Solicited Safety Set included all randomized participants who received any study injection and contributed any solicited AR data (that is, had at least 1 postbaseline solicited safety [eDiary] assessment). Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

7 days after injection

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults |
|-----------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------|
| Subject group type          | Reporting group                                                   | Reporting group                                                   | Reporting group                                             | Subject analysis set                                             |
| Number of subjects analysed | 49                                                                | 48                                                                | 30                                                          | 21                                                               |
| Units: participants         | 46                                                                | 44                                                                | 11                                                          | 20                                                               |

| End point values            | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) |  |  |
|-----------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                                       | Subject analysis set                                              |  |  |
| Number of subjects analysed | 4                                                                          | 51                                                                |  |  |
| Units: participants         | 3                                                                          | 48                                                                |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Solicited Local and Systemic ARs in Older Adult Cohorts

|                 |                                                                                                    |
|-----------------|----------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Solicited Local and Systemic ARs in Older Adult Cohorts <sup>[5]</sup> |
|-----------------|----------------------------------------------------------------------------------------------------|

End point description:

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Solicited Safety Set included all randomized participants who received any study injection and contributed any solicited AR data (that is, had at least 1 postbaseline solicited safety [eDiary] assessment). Participants were included in the treatment arm corresponding to the study drug they actually received. Number analyzed = participants evaluable for this endpoint.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

7 days after each injection

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

| End point values            | mRNA-1345<br>Dose A in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose B in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose C in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose E in Older<br>Adults (After<br>1st Injection) |
|-----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            |
| Number of subjects analysed | 47                                                              | 47                                                              | 47                                                              | 44                                                              |
| Units: participants         | 34                                                              | 42                                                              | 42                                                              | 35                                                              |

| End point values            | mRNA-1345<br>Dose F in Older<br>Adults (After<br>1st Injection) | Two Injection<br>Placebo in<br>Older Adults<br>(After 1st<br>Injection) | mRNA-1345<br>Dose A in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose B in Older<br>Adults (After<br>2nd Injection) |
|-----------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                                    | Subject analysis set                                            | Subject analysis set                                            |
| Number of subjects analysed | 46                                                              | 55                                                                      | 21                                                              | 18                                                              |
| Units: participants         | 31                                                              | 25                                                                      | 7                                                               | 8                                                               |

| End point values            | mRNA-1345<br>Dose C in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose E in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose F in Older<br>Adults (After<br>2nd Injection) | Two Injection<br>Placebo in<br>Older Adults<br>(After 2nd<br>Injection) |
|-----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                                    |
| Number of subjects analysed | 16                                                              | 20                                                              | 19                                                              | 51                                                                      |
| Units: participants         | 3                                                               | 10                                                              | 7                                                               | 14                                                                      |

| End point values            | mRNA-1345<br>Dose A/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose B/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose C/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose E/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) |
|-----------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                                      | Subject analysis set                                                      | Subject analysis set                                                      | Subject analysis set                                                      |
| Number of subjects analysed | 10                                                                        | 7                                                                         | 3                                                                         | 10                                                                        |
| Units: participants         | 8                                                                         | 7                                                                         | 2                                                                         | 9                                                                         |

| End point values            | mRNA-1345<br>Dose F/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | 2-Injection<br>Placebo/Dose A<br>in Old Adults<br>(After 3rd<br>Injection) |  |  |
|-----------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                                      | Subject analysis set                                                       |  |  |
| Number of subjects analysed | 12                                                                        | 22                                                                         |  |  |
| Units: participants         | 11                                                                        | 15                                                                         |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Solicited Local and Systemic ARs in Children Cohorts

|                 |                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Solicited Local and Systemic ARs in Children Cohorts <sup>[6]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------|

End point description:

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Solicited Safety Set included all randomized participants who received any study injection and contributed any solicited AR data (that is, had at least 1 postbaseline solicited safety [eDiary] assessment). Participants were included in the treatment arm corresponding to the study drug they actually received. Number analyzed = participants evaluable for this endpoint.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

7 days after each injection

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

| End point values            | mRNA-1345 Dose D in Children (After 1st Injection) | mRNA-1345 Dose G in Children (After 1st Injection) | Three Injection Placebo in Children (After 1st Injection) | mRNA-1345 Dose D in Children (After 2nd Injection) |
|-----------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------|
| Subject group type          | Subject analysis set                               | Subject analysis set                               | Subject analysis set                                      | Subject analysis set                               |
| Number of subjects analysed | 15                                                 | 14                                                 | 15                                                        | 8                                                  |
| Units: participants         | 8                                                  | 7                                                  | 7                                                         | 5                                                  |

| End point values            | mRNA-1345 Dose G in Children (After 2nd Injection) | Three Injection Placebo in Children (After 2nd Injection) | mRNA-1345 Dose D in Children (After 3rd Injection) | mRNA-1345 Dose G in Children (After 3rd Injection) |
|-----------------------------|----------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Subject group type          | Subject analysis set                               | Subject analysis set                                      | Subject analysis set                               | Subject analysis set                               |
| Number of subjects analysed | 14                                                 | 11                                                        | 9                                                  | 11                                                 |
| Units: participants         | 9                                                  | 7                                                         | 6                                                  | 5                                                  |

| End point values            | Three Injection Placebo in Children (After 3rd Injection) |  |  |  |
|-----------------------------|-----------------------------------------------------------|--|--|--|
| Subject group type          | Subject analysis set                                      |  |  |  |
| Number of subjects analysed | 9                                                         |  |  |  |
| Units: participants         | 5                                                         |  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Unsolicited AEs in Younger Adult Cohorts

|                 |                                                                                        |
|-----------------|----------------------------------------------------------------------------------------|
| End point title | Number of Participants with Unsolicited AEs in Younger Adult Cohorts <sup>[7][8]</sup> |
|-----------------|----------------------------------------------------------------------------------------|

End point description:

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time [PT]/partial thromboplastin time [PTT]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 days after each injection

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |
|-----------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Subject group type          | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                         |
| Number of subjects analysed | 19                                                                           | 20                                                                           | 20                                                                           | 15                                                                      |
| Units: participants         | 2                                                                            | 2                                                                            | 15                                                                           | 5                                                                       |

| End point values            | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(After 1st<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 2nd<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 3rd<br>Dose) | Three Injection<br>Placebo in<br>Young Adults<br>(After 1st<br>Dose) |
|-----------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                                         | Subject analysis set                                                       | Subject analysis set                                                       | Subject analysis set                                                 |
| Number of subjects analysed | 20                                                                           | 16                                                                         | 15                                                                         | 5                                                                    |
| Units: participants         | 6                                                                            | 1                                                                          | 3                                                                          | 0                                                                    |

|                             |                                                            |                                                            |  |  |
|-----------------------------|------------------------------------------------------------|------------------------------------------------------------|--|--|
| <b>End point values</b>     | Three Injection Placebo in Younger Adults (After 2nd Dose) | Three Injection Placebo in Younger Adults (After 3rd Dose) |  |  |
| Subject group type          | Subject analysis set                                       | Subject analysis set                                       |  |  |
| Number of subjects analysed | 4                                                          | 3                                                          |  |  |
| Units: participants         | 0                                                          | 0                                                          |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Unsolicited AEs in Older Adult Cohorts

|                 |                                                                                                   |
|-----------------|---------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Unsolicited AEs in Older Adult Cohorts <sup>[9]</sup> <sup>[10]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------|

End point description:

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 days after each injection

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

|                             |                                                             |                                                             |                                                             |                                                              |
|-----------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|
| <b>End point values</b>     | Cohort 7: mRNA-1345 Dose A in Older Adults (65 to 79 Years) | Cohort 8: mRNA-1345 Dose B in Older Adults (65 to 79 Years) | Cohort 9: mRNA-1345 Dose C in Older Adults (65 to 79 Years) | Cohort 10: mRNA-1345 Dose E in Older Adults (65 to 79 Years) |
| Subject group type          | Reporting group                                             | Reporting group                                             | Reporting group                                             | Reporting group                                              |
| Number of subjects analysed | 47                                                          | 48                                                          | 48                                                          | 48                                                           |
| Units: participants         | 19                                                          | 15                                                          | 19                                                          | 19                                                           |

|                         |                                             |                                       |  |  |
|-------------------------|---------------------------------------------|---------------------------------------|--|--|
| <b>End point values</b> | Cohort 11: mRNA-1345 Dose F in Older Adults | Two Injection Placebo in Older Adults |  |  |
|-------------------------|---------------------------------------------|---------------------------------------|--|--|

|                             | Adults (65 to 79 Years) | (65 to 79 Years) |  |  |
|-----------------------------|-------------------------|------------------|--|--|
| Subject group type          | Reporting group         | Reporting group  |  |  |
| Number of subjects analysed | 48                      | 59               |  |  |
| Units: participants         | 21                      | 14               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Unsolicited AE in WOCBP Cohorts and Japanese Adult Cohorts

|                 |                                                                                                            |
|-----------------|------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with Unsolicited AE in WOCBP Cohorts and Japanese Adult Cohorts <sup>[11][12]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------|

End point description:

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 days after each injection

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to 40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to 40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to 40 Years) | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults |
|-----------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------|
| Subject group type          | Reporting group                                                | Reporting group                                                | Reporting group                                          | Subject analysis set                                             |
| Number of subjects analysed | 49                                                             | 48                                                             | 30                                                       | 21                                                               |
| Units: participants         | 12                                                             | 5                                                              | 4                                                        | 1                                                                |

| End point values            | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to 40 Years) |  |  |
|-----------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                                       | Subject analysis set                                           |  |  |
| Number of subjects analysed | 4                                                                          | 51                                                             |  |  |
| Units: participants         | 2                                                                          | 11                                                             |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with SAEs or Medically Attended AEs (MAAEs) in Younger Adult Cohorts

|                 |                                                                                                                 |
|-----------------|-----------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with SAEs or Medically Attended AEs (MAAEs) in Younger Adult Cohorts <sup>[13][14]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------|

End point description:

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Day 1095 (End of Study)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |
|-----------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Subject group type          | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                         |
| Number of subjects analysed | 19                                                                           | 20                                                                           | 20                                                                           | 15                                                                      |
| Units: participants         |                                                                              |                                                                              |                                                                              |                                                                         |
| SAEs                        | 0                                                                            | 0                                                                            | 0                                                                            | 0                                                                       |
| MAAEs                       | 0                                                                            | 0                                                                            | 9                                                                            | 4                                                                       |

| End point values            | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(After 1st<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 2nd<br>Dose) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Young Adults<br>(After 3rd<br>Dose) | Three Injection<br>Placebo in<br>Young Adults<br>(After 1st<br>Dose) |
|-----------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                                         | Subject analysis set                                                       | Subject analysis set                                                       | Subject analysis set                                                 |
| Number of subjects analysed | 20                                                                           | 16                                                                         | 15                                                                         | 5                                                                    |

|                     |   |   |   |   |
|---------------------|---|---|---|---|
| Units: participants |   |   |   |   |
| SAEs                | 0 | 0 | 0 | 0 |
| MAAEs               | 2 | 1 | 2 | 0 |

| End point values            | Three Injection Placebo in Younger Adults (After 2nd Dose) | Three Injection Placebo in Younger Adults (After 3rd Dose) |  |  |
|-----------------------------|------------------------------------------------------------|------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                       | Subject analysis set                                       |  |  |
| Number of subjects analysed | 4                                                          | 3                                                          |  |  |
| Units: participants         |                                                            |                                                            |  |  |
| SAEs                        | 0                                                          | 0                                                          |  |  |
| MAAEs                       | 0                                                          | 0                                                          |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Unsolicited AEs in Children Cohorts

|                 |                                                         |
|-----------------|---------------------------------------------------------|
| End point title | Number of Participants with Unsolicited AEs in Children |
|-----------------|---------------------------------------------------------|

End point description:

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 days after each injection

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months) | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months) | Three Injection Placebo in Children (12 to 59 Months) |  |
|-----------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|--|
| Subject group type          | Reporting group                                          | Reporting group                                          | Reporting group                                       |  |
| Number of subjects analysed | 15                                                       | 15                                                       | 15                                                    |  |
| Units: participants         | 4                                                        | 6                                                        | 7                                                     |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with SAEs or MAAEs in WOCBP Cohorts and Japanese Adult Cohorts

|                 |                                                                                                                       |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|
| End point title | Number of Participants with SAEs or MAAEs in WOCBP Cohorts and Japanese Adult Cohorts <sup>[17]</sup> <sup>[18]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|

End point description:

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Day 1095 (End of Study)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults |
|-----------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------------|
| Subject group type          | Reporting group                                                   | Reporting group                                                   | Reporting group                                             | Subject analysis set                                             |
| Number of subjects analysed | 48                                                                | 49                                                                | 30                                                          | 21                                                               |
| Units: participants         |                                                                   |                                                                   |                                                             |                                                                  |
| SAEs                        | 0                                                                 | 0                                                                 | 0                                                           | 0                                                                |
| MAAEs                       | 11                                                                | 17                                                                | 10                                                          | 1                                                                |

| End point values            | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) |  |  |
|-----------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                                       | Subject analysis set                                              |  |  |
| Number of subjects analysed | 4                                                                          | 51                                                                |  |  |
| Units: participants         |                                                                            |                                                                   |  |  |

|       |   |    |  |  |
|-------|---|----|--|--|
| SAEs  | 0 | 1  |  |  |
| MAAEs | 1 | 15 |  |  |

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with SAEs or MAAEs in Older Adult Cohorts

|                 |                                                                                  |
|-----------------|----------------------------------------------------------------------------------|
| End point title | Number of Participants with SAEs or MAAEs in Older Adult Cohorts <sup>[19]</sup> |
|-----------------|----------------------------------------------------------------------------------|

End point description:

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments and visits to healthcare practitioners external to the study site. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section. Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to Day 1095 (End of Study)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

| End point values            | mRNA-1345<br>Dose A in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose B in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose C in Older<br>Adults (After<br>1st Injection) | mRNA-1345<br>Dose E in Older<br>Adults (After<br>1st Injection) |
|-----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            |
| Number of subjects analysed | 47                                                              | 48                                                              | 48                                                              | 48                                                              |
| Units: participants         |                                                                 |                                                                 |                                                                 |                                                                 |
| SAEs                        | 4                                                               | 0                                                               | 1                                                               | 3                                                               |
| MAAEs                       | 8                                                               | 4                                                               | 7                                                               | 6                                                               |

| End point values            | mRNA-1345<br>Dose F in Older<br>Adults (After<br>1st Injection) | Two Injection<br>Placebo in<br>Older Adults<br>(After 1st<br>Injection) | mRNA-1345<br>Dose A in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose B in Older<br>Adults (After<br>2nd Injection) |
|-----------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                                    | Subject analysis set                                            | Subject analysis set                                            |
| Number of subjects analysed | 48                                                              | 59                                                                      | 21                                                              | 18                                                              |
| Units: participants         |                                                                 |                                                                         |                                                                 |                                                                 |
| SAEs                        | 5                                                               | 1                                                                       | 1                                                               | 1                                                               |
| MAAEs                       | 8                                                               | 4                                                                       | 2                                                               | 0                                                               |

| End point values            | mRNA-1345<br>Dose C in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose E in Older<br>Adults (After<br>2nd Injection) | mRNA-1345<br>Dose F in Older<br>Adults (After<br>2nd Injection) | Two Injection<br>Placebo in<br>Older Adults<br>(After 2nd<br>Injection) |
|-----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                            | Subject analysis set                                                    |
| Number of subjects analysed | 17                                                              | 20                                                              | 20                                                              | 52                                                                      |
| Units: participants         |                                                                 |                                                                 |                                                                 |                                                                         |
| SAEs                        | 2                                                               | 1                                                               | 1                                                               | 1                                                                       |
| MAAEs                       | 2                                                               | 2                                                               | 2                                                               | 4                                                                       |

| End point values            | mRNA-1345<br>Dose A/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose B/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose C/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | mRNA-1345<br>Dose E/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) |
|-----------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Subject group type          | Subject analysis set                                                      | Subject analysis set                                                      | Subject analysis set                                                      | Subject analysis set                                                      |
| Number of subjects analysed | 10                                                                        | 7                                                                         | 3                                                                         | 10                                                                        |
| Units: participants         |                                                                           |                                                                           |                                                                           |                                                                           |
| SAEs                        | 0                                                                         | 1                                                                         | 0                                                                         | 1                                                                         |
| MAAEs                       | 2                                                                         | 0                                                                         | 0                                                                         | 1                                                                         |

| End point values            | mRNA-1345<br>Dose F/Dose A<br>in Older Adults<br>(After 3rd<br>Injection) | 2-Injection<br>Placebo/Dose A<br>in Old Adults<br>(After 3rd<br>Injection) |  |  |
|-----------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| Subject group type          | Subject analysis set                                                      | Subject analysis set                                                       |  |  |
| Number of subjects analysed | 12                                                                        | 22                                                                         |  |  |
| Units: participants         |                                                                           |                                                                            |  |  |
| SAEs                        | 1                                                                         | 1                                                                          |  |  |
| MAAEs                       | 2                                                                         | 1                                                                          |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with SAEs or MAAEs in Children Cohorts

|                                                                                                                                                                                                                     |                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| End point title                                                                                                                                                                                                     | Number of Participants with SAEs or MAAEs in Children |
| End point description:<br>Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received. |                                                       |
| End point type                                                                                                                                                                                                      | Primary                                               |

End point timeframe:

Up to Day 1095 (End of Study)

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The endpoint is descriptive in nature.

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values            | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|-----------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type          | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed | 15                                                                   | 15                                                                   | 15                                                             |  |
| Units: participants         |                                                                      |                                                                      |                                                                |  |
| SAEs                        | 0                                                                    | 0                                                                    | 0                                                              |  |
| MAAEs                       | 5                                                                    | 11                                                                   | 8                                                              |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibodies (Abs) (RSV-A and RSV-B) for Young Adult Cohorts

|                 |                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibodies (Abs) (RSV-A and RSV-B) for Young Adult Cohorts <sup>[22]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. LLOQ was 11 international units (IU)/milliliter (mL) for RSV-A and 8 IU/mL for RSV-B. Per-protocol (PP) Set: Full Analysis Set (FAS) participants (all randomized participants who received any study injection, had baseline data for analyses that require baseline data, and had at least 1 postinjection assessment for analysis endpoint) who a) complied with injection schedule, b) complied with timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during period corresponding to immunogenicity analysis objective. Participants were included in the arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, 113, 141, 169, and 281

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|---------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                          | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed                 | 18                                                                           | 19                                                                           | 19                                                                           | 19                                                                           |
| Units: IU/mL                                |                                                                              |                                                                              |                                                                              |                                                                              |
| geometric mean (confidence interval<br>95%) |                                                                              |                                                                              |                                                                              |                                                                              |
| RSV-A: Day 1 (n=18,19,19,19,15,4)           | 981.7 (688.4<br>to 1399.8)                                                   | 750.1 (472.8<br>to 1190.0)                                                   | 811.9 (525.6<br>to 1254.1)                                                   | 1252.6 (767.5<br>to 2044.3)                                                  |
| RSV-A: Day 29 (n=18,19,19,19,15,4)          | 20140.7<br>(13749.6 to<br>29502.4)                                           | 16687.8<br>(11984.9 to<br>23236.2)                                           | 19111.9<br>(12383.9 to<br>29495.1)                                           | 22312.3<br>(15470.8 to<br>32179.3)                                           |
| RSV-A: Day 57 (n=18,19,15,17,14,4)          | 17184.7<br>(11128.9 to<br>26535.8)                                           | 12624.2<br>(8407.6 to<br>18955.4)                                            | 11856.0<br>(5981.3 to<br>23500.7)                                            | 17390.2<br>(10457.9 to<br>28917.8)                                           |
| RSV-A: Day 85 (n=18,19,13,17,13,3)          | 15484.6<br>(10242.6 to<br>23409.4)                                           | 8838.7 (6448.5<br>to 12114.9)                                                | 17802.2<br>(9821.8 to<br>32267.0)                                            | 12581.7<br>(8142.4 to<br>19441.4)                                            |
| RSV-A: Day 113 (n=18,17,12,16,13,3)         | 13991.8<br>(9014.2 to<br>21718.1)                                            | 7034.8 (5109.9<br>to 9684.7)                                                 | 12571.6<br>(6782.8 to<br>23300.7)                                            | 14692.4<br>(9907.9 to<br>21787.4)                                            |
| RSV-A: Day 141 (n=18,19,13,16,14,3)         | 9561.8 (5982.5<br>to 15282.5)                                                | 5582.9 (4028.9<br>to 7736.2)                                                 | 10500.2<br>(6144.7 to<br>17942.8)                                            | 14375.8<br>(9374.3 to<br>22045.8)                                            |
| RSV-A: Day 169 (n=18,19,13,17,13,3)         | 9448.0 (6169.7<br>to 14468.4)                                                | 5232.8 (3684.1<br>to 7432.5)                                                 | 13287.2<br>(7992.9 to<br>22088.2)                                            | 11516.4<br>(6681.9 to<br>19848.7)                                            |
| RSV-A: Day 281 (n=0,0,12,0,0,3)             | 9999 (9999 to<br>9999)                                                       | 9999 (9999 to<br>9999)                                                       | 8669.8 (5301.3<br>to 14178.7)                                                | 9999 (9999 to<br>9999)                                                       |
| RSV-B: Day 1 (n=18,19,19,19,15,4)           | 795.3 (532.8<br>to 1187.3)                                                   | 1091.6 (560.2<br>to 2127.3)                                                  | 842.7 (494.3<br>to 1436.5)                                                   | 1097.4 (533.8<br>to 2255.8)                                                  |
| RSV-B: Day 29 (n=18,19,19,18,15,4)          | 11487.5<br>(7894.8 to<br>16715.3)                                            | 12741.6<br>(9388.1 to<br>17293.0)                                            | 13496.5<br>(8379.8 to<br>21737.4)                                            | 12901.6<br>(8474.9 to<br>19640.5)                                            |
| RSV-B: Day 57 (n=18,19,15,17,14,4)          | 12156.5<br>(7773.0 to<br>19012.1)                                            | 14221.7<br>(9366.5 to<br>21593.6)                                            | 15341.5<br>(10067.7 to<br>23378.0)                                           | 9374.5 (5178.1<br>to 16971.7)                                                |
| RSV-B: Day 85 (n=18,19,13,17,13,3)          | 8380.0 (5212.3<br>to 13472.9)                                                | 8996.4 (5678.6<br>to 14252.8)                                                | 13400.3<br>(8814.8 to<br>20371.2)                                            | 9007.3 (4360.2<br>to 18607.0)                                                |
| RSV-B: Day 113 (n=18,17,12,16,13,3)         | 8255.0 (5581.9<br>to 12208.0)                                                | 10657.0<br>(6790.7 to<br>16724.4)                                            | 13515.1<br>(8581.1 to<br>21286.0)                                            | 8744.3 (4545.8<br>to 16820.5)                                                |
| RSV-B: Day 141 (n=18,19,13,16,14,3)         | 8478.6 (5461.9<br>to 13161.5)                                                | 8019.8 (5289.7<br>to 12159.0)                                                | 14408.6<br>(8599.6 to<br>24141.7)                                            | 7313.6 (3859.4<br>to 13859.6)                                                |
| RSV-B: Day 169 (n=18,19,13,17,13,3)         | 7078.4 (4563.6<br>to 10978.8)                                                | 5769.0 (3878.2<br>to 8581.6)                                                 | 11801.7<br>(7020.9 to<br>19837.7)                                            | 6276.6 (3418.9<br>to 11522.9)                                                |
| RSV-B: Day 281 (n=0,0,12,0,0,3)             | 9999 (9999 to<br>9999)                                                       | 9999 (9999 to<br>9999)                                                       | 7081.8 (4123.2<br>to 12163.2)                                                | 819.2 (22.2 to<br>30249.3)                                                   |

| End point values | Single Injection<br>Placebo in | Three Injection<br>Placebo in |  |  |
|------------------|--------------------------------|-------------------------------|--|--|
|------------------|--------------------------------|-------------------------------|--|--|

|                                             | Younger Adults<br>(18 to 49<br>Years) | Younger Adults<br>(18 to 49<br>Years) |  |  |
|---------------------------------------------|---------------------------------------|---------------------------------------|--|--|
| Subject group type                          | Reporting group                       | Reporting group                       |  |  |
| Number of subjects analysed                 | 15                                    | 4                                     |  |  |
| Units: IU/mL                                |                                       |                                       |  |  |
| geometric mean (confidence interval<br>95%) |                                       |                                       |  |  |
| RSV-A: Day 1 (n=18,19,19,19,15,4)           | 1581.0 (1113.2<br>to 2245.4)          | 2054.7 (1262.7<br>to 3343.4)          |  |  |
| RSV-A: Day 29 (n=18,19,19,19,15,4)          | 1461.0 (941.7<br>to 2266.6)           | 1988.9 (930.6<br>to 4251.1)           |  |  |
| RSV-A: Day 57 (n=18,19,15,17,14,4)          | 1321.8 (928.2<br>to 1882.3)           | 1564.6 (665.8<br>to 3676.6)           |  |  |
| RSV-A: Day 85 (n=18,19,13,17,13,3)          | 1426.1 (926.5<br>to 2195.2)           | 1400.5 (555.1<br>to 3533.8)           |  |  |
| RSV-A: Day 113 (n=18,17,12,16,13,3)         | 1230.2 (815.4<br>to 1856.0)           | 1940.4 (297.7<br>to 12646.6)          |  |  |
| RSV-A: Day 141 (n=18,19,13,16,14,3)         | 1378.9 (857.8<br>to 2216.6)           | 1909.1 (522.8<br>to 6970.7)           |  |  |
| RSV-A: Day 169 (n=18,19,13,17,13,3)         | 1334.8 (902.7<br>to 1973.7)           | 1345.1 (363.4<br>to 4978.4)           |  |  |
| RSV-A: Day 281 (n=0,0,12,0,0,3)             | 9999 (9999 to<br>9999)                | 1103.5 (776.9<br>to 1567.4)           |  |  |
| RSV-B: Day 1 (n=18,19,19,19,15,4)           | 1144.2 (694.9<br>to 1884.1)           | 1373.7 (448.2<br>to 4210.6)           |  |  |
| RSV-B: Day 29 (n=18,19,19,18,15,4)          | 1009.5 (612.3<br>to 1664.5)           | 1640.5 (294.4<br>to 9143.0)           |  |  |
| RSV-B: Day 57 (n=18,19,15,17,14,4)          | 1053.3 (527.6<br>to 2102.6)           | 2168.5 (411.5<br>to 11428.7)          |  |  |
| RSV-B: Day 85 (n=18,19,13,17,13,3)          | 939.1 (513.2<br>to 1718.6)            | 1324.8 (98.6<br>to 17800.2)           |  |  |
| RSV-B: Day 113 (n=18,17,12,16,13,3)         | 874.2 (447.1<br>to 1709.4)            | 1459.2 (162.8<br>to 13081.1)          |  |  |
| RSV-B: Day 141 (n=18,19,13,16,14,3)         | 963.4 (571.5<br>to 1624.0)            | 1478.9 (79.2<br>to 27622.2)           |  |  |
| RSV-B: Day 169 (n=18,19,13,17,13,3)         | 730.6 (394.3<br>to 1353.8)            | 1119.5 (66.8<br>to 18749.5)           |  |  |
| RSV-B: Day 281 (n=0,0,12,0,0,3)             | 9999 (9999 to<br>9999)                | 9999 (9999 to<br>9999)                |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Older Adults Cohorts

|                 |                                                                                              |
|-----------------|----------------------------------------------------------------------------------------------|
| End point title | GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Older Adults Cohorts <sup>[23]</sup> |
|-----------------|----------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding

to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, 169, and 365

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|---------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                          | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed                 | 47                                                                      | 46                                                                      | 47                                                                      | 46                                                                       |
| Units: IU/mL                                |                                                                         |                                                                         |                                                                         |                                                                          |
| geometric mean (confidence interval<br>95%) |                                                                         |                                                                         |                                                                         |                                                                          |
| RSV-A: Day 1 (n=47,46,47,46,46,58)          | 1204.7 (918.5<br>to 1580.0)                                             | 1224.9 (877.7<br>to 1709.4)                                             | 1879.9 (1403.5<br>to 2517.9)                                            | 1519.0 (1128.8<br>to 2044.0)                                             |
| RSV-A: Day 29 (n=44,43,47,45,44,56)         | 13739.0<br>(9875.5 to<br>19113.8)                                       | 17053.4<br>(12486.8 to<br>23289.9)                                      | 31341.0<br>(24366.7 to<br>40311.4)                                      | 19008.4<br>(14470.5 to<br>24969.5)                                       |
| RSV-A: Day 57 (n=46,39,44,42,45,58)         | 10967.5<br>(7762.9 to<br>15494.9)                                       | 15494.9<br>(8445.9 to<br>16648.4)                                       | 24600.2<br>(18782.3 to<br>32220.3)                                      | 15121.9<br>(10705.9 to<br>21359.5)                                       |
| RSV-A: Day 85 (n=44,42,46,45,43,55)         | 9020.8 (6523.6<br>to 12474.0)                                           | 9947.3 (7262.5<br>to 13624.5)                                           | 17772.8<br>(13062.3 to<br>24182.0)                                      | 11372.8<br>(8253.5 to<br>15671.1)                                        |
| RSV-A: Day 169 (n=43,42,44,44,44,55)        | 5746.9 (4133.8<br>to 7989.4)                                            | 4815.2 (3517.0<br>to 6592.4)                                            | 10674.2<br>(7754.6 to<br>14693.1)                                       | 5936.5 (4280.0<br>to 8234.3)                                             |
| RSV-A: Day 365 (n=38,33,36,41,40,49)        | 3399.6 (2279.9<br>to 5069.2)                                            | 2525.7 (1795.9<br>to 3551.9)                                            | 6141.1 (4144.2<br>to 9100.1)                                            | 4592.4 (3343.7<br>to 6307.5)                                             |
| RSV-B: Day 1 (n=47,46,47,46,46,58)          | 1135.3 (833.2<br>to 1547.0)                                             | 941.0 (681.6<br>to 1299.1)                                              | 1455.4 (1008.2<br>to 2100.9)                                            | 1507.7 (1055.3<br>to 2153.9)                                             |
| RSV-B: Day 29 (n=44,43,47,45,44,56)         | 9432.1 (6706.2<br>to 13266.0)                                           | 9319.9 (6754.5<br>to 12859.7)                                           | 18187.1<br>(13207.4 to<br>25044.4)                                      | 10235.2<br>(7445.9 to<br>14069.5)                                        |
| RSV-B: Day 57 (n=46,39,44,42,45,58)         | 7905.3 (5765.3<br>to 10839.5)                                           | 8869.0 (6455.4<br>to 12185.0)                                           | 15182.3<br>(11431.9 to<br>20163.0)                                      | 8004.0 (5684.9<br>to 11269.1)                                            |
| RSV-B: Day 85 (n=44,42,46,45,43,55)         | 6385.1 (4652.7<br>to 8762.4)                                            | 6931.0 (4873.8<br>to 9856.6)                                            | 11985.6<br>(8513.6 to<br>16873.6)                                       | 6754.9 (4823.0<br>to 9460.6)                                             |
| RSV-B: Day 169 (n=43,42,44,44,44,55)        | 5226.3 (3747.5<br>to 7288.8)                                            | 4313.9 (3166.9<br>to 5876.2)                                            | 8171.7 (6023.4<br>to 11086.3)                                           | 4873.5 (3518.5<br>to 6750.3)                                             |
| RSV-B: Day 365 (n=38,33,36,41,40,49)        | 2586.2 (1849.1<br>to 3617.2)                                            | 2475.8 (1791.4<br>to 3421.5)                                            | 4262.6 (3088.9<br>to 5882.2)                                            | 2321.2 (1657.2<br>to 3251.1)                                             |

| End point values                            | Cohort 11:<br>mRNA-1345<br>Dose F in Older<br>Adults (65 to<br>79 Years) | Two Injection<br>Placebo in<br>Older Adults<br>(65 to 79<br>Years) |  |  |
|---------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|--|
| Subject group type                          | Reporting group                                                          | Reporting group                                                    |  |  |
| Number of subjects analysed                 | 46                                                                       | 58                                                                 |  |  |
| Units: IU/mL                                |                                                                          |                                                                    |  |  |
| geometric mean (confidence interval<br>95%) |                                                                          |                                                                    |  |  |
| RSV-A: Day 1 (n=47,46,47,46,46,58)          | 1329.8 (969.1<br>to 1824.8)                                              | 1590.7 (1141.8<br>to 2215.9)                                       |  |  |
| RSV-A: Day 29 (n=44,43,47,45,44,56)         | 13619.5<br>(9340.7 to<br>19858.3)                                        | 1827.2 (1306.1<br>to 2556.2)                                       |  |  |
| RSV-A: Day 57 (n=46,39,44,42,45,58)         | 9476.3 (6537.5<br>to 13736.3)                                            | 1783.9 (1257.5<br>to 2530.7)                                       |  |  |
| RSV-A: Day 85 (n=44,42,46,45,43,55)         | 7192.1 (4987.4<br>to 10371.4)                                            | 1761.0 (1243.8<br>to 2493.3)                                       |  |  |
| RSV-A: Day 169 (n=43,42,44,44,44,55)        | 4263.2 (3028.4<br>to 6001.6)                                             | 1652.6 (1186.1<br>to 2302.6)                                       |  |  |
| RSV-A: Day 365 (n=38,33,36,41,40,49)        | 3161.4 (2187.0<br>to 4570.0)                                             | 2035.5 (1403.1<br>to 2952.8)                                       |  |  |
| RSV-B: Day 1 (n=47,46,47,46,46,58)          | 1437.5 (1015.1<br>to 2035.4)                                             | 1451.0 (1053.2<br>to 1998.9)                                       |  |  |
| RSV-B: Day 29 (n=44,43,47,45,44,56)         | 8154.9 (5568.3<br>to 11943.0)                                            | 1580.1 (1102.0<br>to 2265.5)                                       |  |  |
| RSV-B: Day 57 (n=46,39,44,42,45,58)         | 6196.1 (4369.6<br>to 8786.0)                                             | 1840.8 (1332.2<br>to 2543.5)                                       |  |  |
| RSV-B: Day 85 (n=44,42,46,45,43,55)         | 5065.2 (3432.3<br>to 7474.8)                                             | 1874.2 (1375.7<br>to 2553.3)                                       |  |  |
| RSV-B: Day 169 (n=43,42,44,44,44,55)        | 4164.0 (2876.3<br>to 6028.0)                                             | 2034.3 (1484.3<br>to 2788.2)                                       |  |  |
| RSV-B: Day 365 (n=38,33,36,41,40,49)        | 2113.9 (1548.6<br>to 2885.6)                                             | 1673.2 (1190.9<br>to 2350.8)                                       |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Japanese Adults Cohorts

|                 |                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------|
| End point title | GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Japanese Adults Cohorts <sup>[24]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 11 IU/mL for RSV-A and 8 IU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1

postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, and 169

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |  |  |
|------------------------------------------|------------------------------------------------------|----------------------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                      | Reporting group                                                |  |  |
| Number of subjects analysed              | 20                                                   | 4                                                              |  |  |
| Units: IU/mL                             |                                                      |                                                                |  |  |
| geometric mean (confidence interval 95%) |                                                      |                                                                |  |  |
| RSV-A: Day 1 (n=20,4)                    | 1602.1 (1042.5 to 2462.1)                            | 1798.9 (1125.1 to 2876.2)                                      |  |  |
| RSV-A: Day 29 (n=20,4)                   | 17861.7 (10929.3 to 29191.4)                         | 1476.5 (918.1 to 2374.5)                                       |  |  |
| RSV-A: Day 57 (n=20,4)                   | 15627.7 (9983.1 to 24463.9)                          | 1508.3 (554.5 to 4102.6)                                       |  |  |
| RSV-A: Day 85 (n=19,4)                   | 12447.6 (7781.3 to 19912.1)                          | 1449.6 (606.4 to 3465.0)                                       |  |  |
| RSV-A: Day 169 (n=20,4)                  | 6658.1 (4213.0 to 10522.3)                           | 1292.8 (810.1 to 2062.9)                                       |  |  |
| RSV-B: Day 1 (n=20,4)                    | 1029.4 (732.8 to 1446.1)                             | 1275.6 (368.5 to 4415.3)                                       |  |  |
| RSV-B: Day 29 (n=20,4)                   | 6791.7 (4432.3 to 10406.8)                           | 1033.4 (293.4 to 3640.0)                                       |  |  |
| RSV-B: Day 57 (n=20,4)                   | 4862.2 (3312.9 to 7136.1)                            | 1086.3 (261.0 to 4521.1)                                       |  |  |
| RSV-B: Day 85 (n=19,4)                   | 3818.4 (2655.8 to 5490.0)                            | 1039.1 (302.4 to 3571.0)                                       |  |  |
| RSV-B: Day 169 (n=20,4)                  | 2751.5 (1933.2 to 3916.1)                            | 879.9 (342.0 to 2263.6)                                        |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for WOCBP Cohorts

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for WOCBP Cohorts <sup>[25]</sup> |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                       |
| Antibody values reported as below LLOQ were replaced by 0.5*LLOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. |                                                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Secondary                                                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                       |
| Days 1, 29, 57, 85, 113, 141, and 169                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                       |

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                       | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed              | 49                                                                | 48                                                                | 44                                                                | 29                                                          |
| Units: IU/mL                             |                                                                   |                                                                   |                                                                   |                                                             |
| geometric mean (confidence interval 95%) |                                                                   |                                                                   |                                                                   |                                                             |
| RSV-A: Day 1 (n=49,48,44,29)             | 902.8 (688.4 to 1184.1)                                           | 1111.6 (858.6 to 1439.3)                                          | 1135.1 (844.5 to 1525.8)                                          | 1358.4 (879.1 to 2099.0)                                    |
| RSV-A: Day 29 (n=49,46,41,28)            | 8497.2 (6631.2 to 10888.3)                                        | 12362.2 (8923.0 to 17127.0)                                       | 12635.8 (9143.8 to 17461.5)                                       | 1348.6 (855.1 to 2127.1)                                    |
| RSV-A: Day 57 (n=45,45,42,28)            | 8250.2 (6278.4 to 10841.3)                                        | 11270.7 (8269.0 to 15362.1)                                       | 12722.4 (9594.7 to 16869.7)                                       | 1940.5 (1200.9 to 3135.7)                                   |
| RSV-A: Day 85 (n=43,41,37,24)            | 6364.7 (4855.0 to 8343.8)                                         | 10169.9 (7272.4 to 14221.8)                                       | 10568.9 (7406.5 to 15081.5)                                       | 1683.1 (996.9 to 2841.7)                                    |
| RSV-A: Day 113 (n=44,43,37,25)           | 5231.9 (3797.5 to 7207.9)                                         | 7675.4 (5725.6 to 10289.2)                                        | 8439.8 (5882.5 to 12109.0)                                        | 1885.9 (1118.6 to 3179.5)                                   |
| RSV-A: Day 141 (n=40,42,36,25)           | 4518.2 (3263.9 to 6254.7)                                         | 6315.6 (4534.8 to 8795.8)                                         | 7059.2 (4777.3 to 10431.2)                                        | 1519.5 (943.7 to 2446.5)                                    |
| RSV-A: Day 169 (n=41,43,34,23)           | 3731.9 (2736.9 to 5088.7)                                         | 5476.8 (3924.4 to 7643.2)                                         | 5387.8 (3720.1 to 7803.1)                                         | 1620.7 (988.3 to 2657.9)                                    |
| RSV-B: Day 1 (n=49,48,44,29)             | 958.4 (724.4 to 1267.8)                                           | 1676.1 (1197.0 to 2346.8)                                         | 1148.9 (789.9 to 1670.9)                                          | 930.8 (597.4 to 1450.2)                                     |
| RSV-B: Day 29 (n=49,46,41,28)            | 7236.5 (5573.6 to 9395.4)                                         | 11368.3 (8304.0 to 15563.4)                                       | 10591.9 (7302.2 to 15363.5)                                       | 903.0 (554.2 to 1471.3)                                     |
| RSV-B: Day 57 (n=45,45,42,28)            | 5129.7 (3937.6 to 6682.7)                                         | 7873.5 (5922.9 to 10466.6)                                        | 8072.7 (6072.3 to 10732.0)                                        | 1333.1 (832.2 to 2135.7)                                    |

|                                |                           |                            |                           |                          |
|--------------------------------|---------------------------|----------------------------|---------------------------|--------------------------|
| RSV-B: Day 85 (n=43,41,37,24)  | 4592.4 (3542.9 to 5952.6) | 7877.3 (5767.7 to 10758.6) | 6470.1 (4836.7 to 8655.1) | 1536.9 (952.1 to 2481.0) |
| RSV-B: Day 113 (n=44,43,37,25) | 3453.3 (2743.4 to 4346.9) | 6448.3 (4858.8 to 8557.7)  | 5348.4 (3996.3 to 7158.0) | 1319.7 (833.5 to 2089.6) |
| RSV-B: Day 141 (n=40,42,36,25) | 3470.7 (2626.8 to 4585.9) | 5421.0 (3977.3 to 7388.7)  | 4670.8 (3375.0 to 6464.2) | 1317.5 (848.1 to 2046.7) |
| RSV-B: Day 169 (n=41,43,34,23) | 3112.6 (2372.6 to 4083.4) | 4959.7 (3637.6 to 6762.3)  | 3879.0 (2771.7 to 5428.7) | 1151.9 (704.6 to 1883.3) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Children Cohorts

|                 |                                                                                          |
|-----------------|------------------------------------------------------------------------------------------|
| End point title | GMT of Serum RSV Neutralizing Abs (RSV-A and RSV-B) for Children Cohorts <sup>[26]</sup> |
|-----------------|------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 85, and 141

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type                       | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed              | 14                                                                   | 13                                                                   | 11                                                             |  |
| Units: IU/mL                             |                                                                      |                                                                      |                                                                |  |
| geometric mean (confidence interval 95%) |                                                                      |                                                                      |                                                                |  |
| RSV-A: Day 1 (n=14,13,11)                | 240.1 (96.4 to 597.8)                                                | 602.1 (185.8 to 1951.4)                                              | 447.2 (152.3 to 1312.9)                                        |  |
| RSV-A: Day 29 (n=14,12,11)               | 8376.1 (3354.9 to 20912.2)                                           | 11440.4 (6477.0 to 20207.1)                                          | 642.6 (236.9 to 1743.4)                                        |  |
| RSV-A: Day 85 (n=5,9,4)                  | 5114.0 (1255.2 to 20835.8)                                           | 4820.1 (1823.9 to 12737.9)                                           | 145.2 (23.5 to 896.3)                                          |  |

|                            |                            |                             |                         |  |
|----------------------------|----------------------------|-----------------------------|-------------------------|--|
| RSV-A: Day 141 (n=4,5,5)   | 4660.8 (1141.8 to 19025.7) | 13233.4 (3136.2 to 55840.1) | 735.9 (199.3 to 2716.9) |  |
| RSV-B: Day 1 (n=14,13,11)  | 345.7 (152.1 to 785.9)     | 832.9 (312.6 to 2219.5)     | 394.4 (138.3 to 1124.5) |  |
| RSV-B: Day 29 (n=14,12,11) | 4931.9 (2080.0 to 11693.7) | 5940.3 (3446.4 to 10238.9)  | 490.2 (178.2 to 1348.1) |  |
| RSV-B: Day 85 (n=5,9,4)    | 2534.8 (1213.6 to 5294.1)  | 2622.2 (1453.8 to 4729.7)   | 107.2 (25.2 to 455.3)   |  |
| RSV-B: Day 141 (n=4,5,5)   | 2899.9 (419.8 to 20031.0)  | 5038.4 (2241.8 to 11323.7)  | 957.0 (192.0 to 4770.9) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Concentration (GMC) of Serum Binding Abs (PreF and PostF) for Young Adult Cohorts

|                 |                                                                                                                  |
|-----------------|------------------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Concentration (GMC) of Serum Binding Abs (PreF and PostF) for Young Adult Cohorts <sup>[27]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 19 arbitrary unit (AU)/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, 113, 141, 169, and 281

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                       | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed              | 18                                                                           | 19                                                                           | 15                                                                           | 19                                                                           |
| Units: AU/mL                             |                                                                              |                                                                              |                                                                              |                                                                              |
| geometric mean (confidence interval 95%) |                                                                              |                                                                              |                                                                              |                                                                              |
| PreF-bAb: Day 1 (n=18,19,15,19,14,4)     | 7467.2 (5552.0 to 10043.2)                                                   | 5812.9 (4162.1 to 8118.4)                                                    | 6215.6 (4738.9 to 8152.4)                                                    | 7722.4 (5034.0 to 11846.5)                                                   |

|                                            |                                   |                                    |                                   |                                   |
|--------------------------------------------|-----------------------------------|------------------------------------|-----------------------------------|-----------------------------------|
| PreF-bAb: Day 29 (n=18,19,15,18,14,4)      | 120491.6<br>(92412.4 to 157102.6) | 125952.6<br>(103884.6 to 152708.3) | 135260.0<br>(95356.2 to 191862.2) | 116742.7<br>(89152.0 to 152872.1) |
| PreF-bAb: Day 57 (n=18,19,14,17,14,4)      | 98849.5<br>(75545.8 to 129341.8)  | 89896.9<br>(70717.8 to 114277.4)   | 98889.3<br>(65188.1 to 150013.4)  | 90612.8<br>(65451.1 to 125447.6)  |
| PreF-bAb: Day 85 (n=18,19,12,17,13,3)      | 69574.6<br>(50071.5 to 96674.2)   | 67912.3<br>(51691.0 to 89224.0)    | 112481.0<br>(76987.5 to 164337.9) | 70057.9<br>(49495.6 to 99162.5)   |
| PreF-bAb: Day 113<br>(n=18,17,12,16,13,3)  | 61182.6<br>(43795.1 to 85473.2)   | 58058.4<br>(43549.8 to 77400.6)    | 103093.5<br>(66326.3 to 160241.9) | 61171.5<br>(44176.0 to 84705.6)   |
| PreF-bAb: Day 141<br>(n=18,19,13,16,14,3)  | 57291.0<br>(40876.2 to 80297.6)   | 48121.1<br>(37794.8 to 61268.8)    | 99738.7<br>(70499.4 to 141104.8)  | 59941.7<br>(46326.6 to 77558.0)   |
| PreF-bAb: Day 169<br>(n=18,19,13,17,13,3)  | 48392.9<br>(34510.9 to 67858.8)   | 40948.1<br>(31357.1 to 53472.6)    | 83648.6<br>(56870.6 to 123035.3)  | 49499.8<br>(35508.9 to 69003.3)   |
| PreF-bAb: Day 281 (n=0,0,12,0,0,3)         | 9999 (9999 to 9999)               | 9999 (9999 to 9999)                | 54418.7<br>(36137.6 to 81947.8)   | 9999 (9999 to 9999)               |
| PostF-bAb: Day 1 (n=18,19,15,19,14,4)      | 7781.5 (5367.0 to 11282.3)        | 6372.2 (4670.2 to 8694.6)          | 8569.1 (5972.0 to 12295.8)        | 9605.3 (5951.6 to 15502.0)        |
| PostF-bAb: Day 29<br>(n=18,19,15,18,14,4)  | 108811.5<br>(72461.7 to 163395.8) | 112799.6<br>(82736.5 to 153786.4)  | 132127.9<br>(84337.9 to 206998.2) | 130974.4<br>(97851.3 to 175309.8) |
| PostF-bAb: Day 57<br>(n=18,19,14,17,14,4)  | 85196.0<br>(58250.0 to 124606.9)  | 75628.1<br>(51928.5 to 110143.8)   | 94125.8<br>(56861.6 to 155811.0)  | 81923.9<br>(56585.6 to 118608.3)  |
| PostF-bAb: Day 85<br>(n=18,19,12,17,13,3)  | 60967.0<br>(39795.8 to 93401.0)   | 59128.0<br>(40040.4 to 87314.9)    | 89605.4<br>(50873.4 to 157825.7)  | 61176.8<br>(42975.5 to 87086.9)   |
| PostF-bAb: Day 113<br>(n=18,17,12,16,13,3) | 53258.8<br>(35653.9 to 79556.5)   | 51435.0<br>(33669.1 to 78575.2)    | 85589.8<br>(48631.9 to 150634.0)  | 53606.8<br>(36326.1 to 79108.0)   |
| PostF-bAb: Day 141<br>(n=18,19,13,16,14,3) | 48311.1<br>(32332.8 to 72185.7)   | 41981.1<br>(27984.5 to 62977.9)    | 71562.6<br>(43250.9 to 118406.8)  | 52803.7<br>(35845.3 to 77785.3)   |
| PostF-bAb: Day 169<br>(n=18,19,13,17,13,3) | 41471.6<br>(27763.8 to 61947.1)   | 34074.2<br>(23529.9 to 49343.5)    | 63113.6<br>(37586.8 to 105976.6)  | 44688.8<br>(30203.3 to 66121.4)   |
| PostF-bAb: Day 281 (n=0,0,12,0,0,3)        | 9999 (9999 to 9999)               | 9999 (9999 to 9999)                | 43784.2<br>(24668.6 to 77712.5)   | 9999 (9999 to 9999)               |

| End point values                         | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) | Three Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |  |  |
|------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                                         | Reporting group                                                        |  |  |
| Number of subjects analysed              | 14                                                                      | 4                                                                      |  |  |
| Units: AU/mL                             |                                                                         |                                                                        |  |  |
| geometric mean (confidence interval 95%) |                                                                         |                                                                        |  |  |
| PreF-bAb: Day 1 (n=18,19,15,19,14,4)     | 7272.6 (5784.0 to 9144.5)                                               | 9290.5 (6403.5 to 13479.2)                                             |  |  |

|                                         |                            |                             |  |  |
|-----------------------------------------|----------------------------|-----------------------------|--|--|
| PreF-bAb: Day 29 (n=18,19,15,18,14,4)   | 7226.1 (5489.8 to 9511.7)  | 10307.3 (7281.3 to 14590.9) |  |  |
| PreF-bAb: Day 57 (n=18,19,14,17,14,4)   | 7659.7 (5931.1 to 9892.2)  | 9097.5 (7091.1 to 11671.6)  |  |  |
| PreF-bAb: Day 85 (n=18,19,12,17,13,3)   | 7154.4 (5232.9 to 9781.4)  | 10664.3 (8260.2 to 13768.0) |  |  |
| PreF-bAb: Day 113 (n=18,17,12,16,13,3)  | 6877.3 (5199.8 to 9096.0)  | 10317.7 (9299.1 to 11447.8) |  |  |
| PreF-bAb: Day 141 (n=18,19,13,16,14,3)  | 7077.7 (5307.6 to 9438.1)  | 10026.5 (6884.4 to 14602.7) |  |  |
| PreF-bAb: Day 169 (n=18,19,13,17,13,3)  | 6953.1 (5161.5 to 9366.6)  | 9958.8 (9347.1 to 10610.6)  |  |  |
| PreF-bAb: Day 281 (n=0,0,12,0,0,3)      | 9999 (9999 to 9999)        | 8330.4 (3649.2 to 19016.7)  |  |  |
| PostF-bAb: Day 1 (n=18,19,15,19,14,4)   | 7788.2 (5463.6 to 11101.9) | 7759.1 (996.6 to 60412.1)   |  |  |
| PostF-bAb: Day 29 (n=18,19,15,18,14,4)  | 8011.2 (5514.7 to 11637.9) | 8495.6 (1077.7 to 66969.9)  |  |  |
| PostF-bAb: Day 57 (n=18,19,14,17,14,4)  | 7984.5 (5469.2 to 11656.5) | 7997.4 (909.5 to 70318.9)   |  |  |
| PostF-bAb: Day 85 (n=18,19,12,17,13,3)  | 7318.3 (5049.8 to 10605.9) | 7683.9 (166.3 to 354981.2)  |  |  |
| PostF-bAb: Day 113 (n=18,17,12,16,13,3) | 8374.5 (5784.3 to 12124.5) | 7441.6 (150.4 to 368224.0)  |  |  |
| PostF-bAb: Day 141 (n=18,19,13,16,14,3) | 8019.4 (5567.2 to 11551.7) | 7352.4 (177.1 to 305240.2)  |  |  |
| PostF-bAb: Day 169 (n=18,19,13,17,13,3) | 8438.3 (5792.5 to 12292.6) | 7024.3 (110.4 to 446737.5)  |  |  |
| PostF-bAb: Day 281 (n=0,0,12,0,0,3)     | 9999 (9999 to 9999)        | 5859.6 (134.3 to 255601.8)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMC of Serum Binding Abs (PreF and PostF) for Older Adults Cohorts

|                 |                                                                                    |
|-----------------|------------------------------------------------------------------------------------|
| End point title | GMC of Serum Binding Abs (PreF and PostF) for Older Adults Cohorts <sup>[28]</sup> |
|-----------------|------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the

period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, 169, and 365

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|---------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                          | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed                 | 47                                                                      | 46                                                                      | 47                                                                      | 46                                                                       |
| Units: AU/mL                                |                                                                         |                                                                         |                                                                         |                                                                          |
| geometric mean (confidence interval<br>95%) |                                                                         |                                                                         |                                                                         |                                                                          |
| PreF-bAb: Day 1 (n=47,46,47,46,46,58)       | 7184.6 (5872.3 to 8790.1)                                               | 6960.5 (5456.3 to 8879.3)                                               | 9173.2 (7267.6 to 11578.5)                                              | 9134.1 (7414.4 to 11252.7)                                               |
| PreF-bAb: Day 29<br>(n=44,43,47,45,44,56)   | 58206.6<br>(46911.4 to 72221.3)                                         | 80760.1<br>(67929.5 to 96014.0)                                         | 111145.6<br>(87974.7 to 140419.4)                                       | 77569.9<br>(62867.0 to 95711.4)                                          |
| PreF-bAb: Day 57<br>(n=46,39,44,42,45,58)   | 50630.1<br>(41214.3 to 62197.1)                                         | 56860.8<br>(47987.0 to 67375.5)                                         | 85785.4<br>(70699.4 to 104090.5)                                        | 56901.4<br>(44316.0 to 73060.9)                                          |
| PreF-bAb: Day 85<br>(n=44,42,46,45,43,55)   | 39390.5<br>(31889.7 to 48655.6)                                         | 47141.3<br>(40078.1 to 55449.3)                                         | 64628.3<br>(52007.5 to 80311.8)                                         | 48550.6<br>(38678.9 to 60941.8)                                          |
| PreF-bAb: Day 169<br>(n=43,42,44,44,44,55)  | 27977.0<br>(22479.6 to 34818.8)                                         | 27948.6<br>(22579.4 to 34594.4)                                         | 41137.0<br>(33523.9 to 50479.0)                                         | 29704.2<br>(23626.6 to 37345.1)                                          |
| PreF-bAb: Day 365<br>(n=38,33,36,41,40,49)  | 19409.7<br>(15017.6 to 25086.3)                                         | 19632.9<br>(15902.1 to 24238.9)                                         | 31346.1<br>(24301.8 to 40432.2)                                         | 21454.1<br>(17263.3 to 26662.3)                                          |
| PostF-bAb: Day 1<br>(n=47,46,47,46,46,58)   | 12066.0<br>(9323.5 to 15615.2)                                          | 10638.2<br>(8135.1 to 13911.5)                                          | 10424.6<br>(8167.5 to 13305.5)                                          | 14206.6<br>(10853.0 to 18596.5)                                          |
| PostF-bAb: Day 29<br>(n=44,43,47,45,44,56)  | 69105.0<br>(52552.2 to 90871.5)                                         | 85033.1<br>(66619.6 to 108535.9)                                        | 95879.2<br>(71829.4 to 127981.4)                                        | 84909.7<br>(64905.4 to 111079.5)                                         |
| PostF-bAb: Day 57<br>(n=46,39,44,42,45,58)  | 57804.6<br>(45307.2 to 73749.2)                                         | 51619.0<br>(40747.4 to 65391.2)                                         | 78968.1<br>(61971.7 to 100626.0)                                        | 59943.4<br>(43861.2 to 81922.2)                                          |
| PostF-bAb: Day 85<br>(n=44,42,46,45,43,55)  | 45084.0<br>(34300.5 to 59257.6)                                         | 48819.9<br>(39107.1 to 60945.1)                                         | 59983.2<br>(45895.2 to 78395.6)                                         | 54054.5<br>(40304.3 to 72495.8)                                          |
| PostF-bAb: Day 169<br>(n=43,42,44,44,44,55) | 35691.0<br>(27328.8 to 46611.8)                                         | 29608.9<br>(22904.2 to 38276.1)                                         | 39154.9<br>(30112.5 to 50912.6)                                         | 37080.4<br>(27865.2 to 49343.2)                                          |
| PostF-bAb: Day 365<br>(n=38,33,36,41,40,49) | 25144.5<br>(18758.7 to 33704.2)                                         | 21589.3<br>(16517.4 to 28218.6)                                         | 27730.5<br>(20151.4 to 38160.1)                                         | 26193.9<br>(19873.3 to 34524.7)                                          |

| End point values                            | Cohort 11:<br>mRNA-1345<br>Dose F in Older<br>Adults (65 to<br>79 Years) | Two Injection<br>Placebo in<br>Older Adults<br>(65 to 79<br>Years) |  |  |
|---------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|--|
| Subject group type                          | Reporting group                                                          | Reporting group                                                    |  |  |
| Number of subjects analysed                 | 46                                                                       | 58                                                                 |  |  |
| Units: AU/mL                                |                                                                          |                                                                    |  |  |
| geometric mean (confidence interval<br>95%) |                                                                          |                                                                    |  |  |
| PreF-bAb: Day 1 (n=47,46,47,46,46,58)       | 8077.0 (6430.5<br>to 10145.0)                                            | 7871.3 (6388.4<br>to 9698.5)                                       |  |  |
| PreF-bAb: Day 29<br>(n=44,43,47,45,44,56)   | 59833.7<br>(45903.3 to<br>77991.6)                                       | 8119.5 (6379.3<br>to 10334.4)                                      |  |  |
| PreF-bAb: Day 57<br>(n=46,39,44,42,45,58)   | 41427.1<br>(31766.9 to<br>54025.1)                                       | 8164.6 (6555.1<br>to 10169.3)                                      |  |  |
| PreF-bAb: Day 85<br>(n=44,42,46,45,43,55)   | 35150.3<br>(26811.4 to<br>46082.7)                                       | 8157.9 (6427.1<br>to 10354.9)                                      |  |  |
| PreF-bAb: Day 169<br>(n=43,42,44,44,44,55)  | 23376.4<br>(18019.0 to<br>30326.6)                                       | 8338.6 (6717.2<br>to 10351.4)                                      |  |  |
| PreF-bAb: Day 365<br>(n=38,33,36,41,40,49)  | 16715.1<br>(12878.1 to<br>21695.2)                                       | 9660.9 (7556.6<br>to 12351.2)                                      |  |  |
| PostF-bAb: Day 1<br>(n=47,46,47,46,46,58)   | 10454.3<br>(7820.9 to<br>13974.4)                                        | 11806.0<br>(9501.6 to<br>14669.2)                                  |  |  |
| PostF-bAb: Day 29<br>(n=44,43,47,45,44,56)  | 47736.3<br>(35493.9 to<br>64201.5)                                       | 12067.1<br>(9309.9 to<br>15640.8)                                  |  |  |
| PostF-bAb: Day 57<br>(n=46,39,44,42,45,58)  | 35785.6<br>(26916.4 to<br>47577.3)                                       | 12029.2<br>(9463.0 to<br>15291.4)                                  |  |  |
| PostF-bAb: Day 85<br>(n=44,42,46,45,43,55)  | 30765.7<br>(22703.4 to<br>41691.1)                                       | 12343.8<br>(9609.4 to<br>15856.1)                                  |  |  |
| PostF-bAb: Day 169<br>(n=43,42,44,44,44,55) | 20712.5<br>(15371.7 to<br>27908.9)                                       | 12392.0<br>(9900.6 to<br>15510.5)                                  |  |  |
| PostF-bAb: Day 365<br>(n=38,33,36,41,40,49) | 16381.1<br>(11727.9 to<br>22880.5)                                       | 13768.8<br>(10464.4 to<br>18116.6)                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMC of Serum Binding Abs (PreF and PostF) for Japanese Adults Cohorts

|                 |                                                                                       |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | GMC of Serum Binding Abs (PreF and PostF) for Japanese Adults Cohorts <sup>[29]</sup> |
|-----------------|---------------------------------------------------------------------------------------|

### End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule,

b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, and 169

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) |  |  |
|------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                                  | Reporting group                                                            |  |  |
| Number of subjects analysed              | 20                                                               | 4                                                                          |  |  |
| Units: AU/mL                             |                                                                  |                                                                            |  |  |
| geometric mean (confidence interval 95%) |                                                                  |                                                                            |  |  |
| PreF-bAb: Day 1 (n=20,4)                 | 7545.4 (5542.0 to 10273.0)                                       | 6680.8 (1973.6 to 22614.3)                                                 |  |  |
| PreF-bAb: Day 29 (n=20,4)                | 68684.0 (53080.2 to 88874.6)                                     | 7135.5 (2085.4 to 24414.7)                                                 |  |  |
| PreF-bAb: Day 57 (n=20,4)                | 54618.2 (41547.3 to 71801.3)                                     | 7424.1 (1926.2 to 28614.2)                                                 |  |  |
| PreF-bAb: Day 85 (n=19,4)                | 44979.3 (33718.5 to 60000.7)                                     | 7024.4 (1766.1 to 27939.0)                                                 |  |  |
| PreF-bAb: Day 169 (n=20,4)               | 29334.8 (22147.5 to 38854.6)                                     | 6674.7 (1804.1 to 24694.1)                                                 |  |  |
| PostF-bAb: Day 1 (n=20,4)                | 9925.8 (6459.4 to 15252.6)                                       | 8374.0 (1665.8 to 42096.2)                                                 |  |  |
| PostF-bAb: Day 29 (n=20,4)               | 75173.8 (55351.4 to 102095.1)                                    | 7936.5 (1775.1 to 35483.8)                                                 |  |  |
| PostF-bAb: Day 57 (n=20,4)               | 57428.6 (42049.2 to 78433.0)                                     | 8492.2 (1601.8 to 45021.9)                                                 |  |  |
| PostF-bAb: Day 85 (n=19,4)               | 47821.3 (33458.4 to 68349.9)                                     | 8387.1 (1575.0 to 44663.5)                                                 |  |  |
| PostF-bAb: Day 169 (n=20,4)              | 32673.4 (23417.0 to 45588.9)                                     | 8090.6 (1394.2 to 46950.5)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMC of Serum Binding Abs (PreF and PostF) for WOCBP Cohorts

|                 |                                                                             |
|-----------------|-----------------------------------------------------------------------------|
| End point title | GMC of Serum Binding Abs (PreF and PostF) for WOCBP Cohorts <sup>[30]</sup> |
|-----------------|-----------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 57, 85, 113, 141, and 169

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|---------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                          | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed                 | 49                                                                | 48                                                                | 44                                                                | 29                                                          |
| Units: AU/mL                                |                                                                   |                                                                   |                                                                   |                                                             |
| geometric mean (confidence interval<br>95%) |                                                                   |                                                                   |                                                                   |                                                             |
| PreF-bAb: Day 1 (n=49,48,44,29)             | 5928.0 (4863.4<br>to 7225.7)                                      | 7202.1 (6057.1<br>to 8563.7)                                      | 7343.9 (5928.6<br>to 9097.1)                                      | 7304.7 (5506.0<br>to 9691.1)                                |
| PreF-bAb: Day 29 (n=49,46,41,28)            | 49988.1<br>(42696.9 to<br>58524.3)                                | 67953.4<br>(57275.4 to<br>80622.1)                                | 73032.9<br>(57716.9 to<br>92413.0)                                | 7096.0 (5310.3<br>to 9482.3)                                |
| PreF-bAb: Day 57 (n=45,45,42,28)            | 38705.6<br>(31796.3 to<br>47116.3)                                | 53448.8<br>(45016.1 to<br>63461.1)                                | 60971.6<br>(49956.9 to<br>74414.9)                                | 7249.7 (5279.3<br>to 9955.6)                                |
| PreF-bAb: Day 85 (n=43,41,37,24)            | 32336.5<br>(26872.1 to<br>38912.0)                                | 44024.8<br>(36651.3 to<br>52881.8)                                | 47681.9<br>(37818.8 to<br>60117.3)                                | 7439.4 (5228.9<br>to 10584.4)                               |
| PreF-bAb: Day 113 (n=44,43,37,25)           | 27226.3<br>(22498.5 to<br>32947.5)                                | 37691.8<br>(31871.8 to<br>44574.5)                                | 39558.4<br>(30970.3 to<br>50528.0)                                | 8630.9 (6060.7<br>to 12290.8)                               |
| PreF-bAb: Day 141 (n=40,42,36,24)           | 24463.1<br>(19820.3 to<br>30193.3)                                | 33916.5<br>(28517.4 to<br>40337.9)                                | 34388.8<br>(27339.6 to<br>43255.6)                                | 8582.2 (6206.3<br>to 11867.8)                               |
| PreF-bAb: Day 169 (n=41,43,34,23)           | 22511.6<br>(18527.1 to<br>27353.0)                                | 30274.0<br>(25749.3 to<br>35593.8)                                | 33390.0<br>(26145.5 to<br>42641.8)                                | 8374.0 (6075.5<br>to 11542.1)                               |
| PostF-bAb: Day 1 (n=49,48,44,29)            | 7337.1 (5793.8<br>to 9291.5)                                      | 8284.3 (6672.7<br>to 10285.2)                                     | 10108.1<br>(8068.3 to<br>12663.7)                                 | 9374.8 (6909.2<br>to 12720.3)                               |
| PostF-bAb: Day 29 (n=49,46,41,28)           | 56083.1<br>(44704.7 to<br>70357.5)                                | 58023.9<br>(44840.2 to<br>75083.8)                                | 79654.7<br>(60853.5 to<br>104264.7)                               | 8807.1 (6531.0<br>to 11876.5)                               |
| PostF-bAb: Day 57 (n=45,45,42,28)           | 43453.5<br>(34303.0 to<br>55045.0)                                | 43215.3<br>(33324.0 to<br>56042.6)                                | 60988.0<br>(46949.1 to<br>79225.0)                                | 9300.0 (6784.0<br>to 12749.0)                               |

|                                    |                                 |                                 |                                 |                                |
|------------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------------------------|
| PostF-bAb: Day 85 (n=43,41,37,24)  | 34371.5<br>(26637.2 to 44351.6) | 32642.4<br>(24808.7 to 42949.7) | 49095.5<br>(36720.7 to 65640.7) | 9031.4 (6213.4 to 13127.4)     |
| PostF-bAb: Day 113 (n=44,43,37,25) | 29414.6<br>(23233.3 to 37240.6) | 31019.5<br>(23547.8 to 40862.1) | 43359.9<br>(32563.0 to 57736.6) | 10585.1<br>(7253.6 to 15446.6) |
| PostF-bAb: Day 141 (n=40,42,36,24) | 26740.9<br>(20593.7 to 34722.9) | 26633.4<br>(20241.6 to 35043.6) | 37108.7<br>(27752.6 to 49618.8) | 10775.7<br>(7529.3 to 15421.8) |
| PostF-bAb: Day 169 (n=41,43,34,23) | 23089.1<br>(18052.3 to 29531.4) | 24488.3<br>(18865.9 to 31786.3) | 36499.6<br>(27296.8 to 48804.9) | 9459.4 (6424.5 to 13927.9)     |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMC of Serum Binding Abs (PreF and PostF) for Children Cohorts

|                 |                                                                                |
|-----------------|--------------------------------------------------------------------------------|
| End point title | GMC of Serum Binding Abs (PreF and PostF) for Children Cohorts <sup>[31]</sup> |
|-----------------|--------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 1, 29, 85, and 141

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to 59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to 59 Months) | Three Injection<br>Placebo in<br>Children (12 to 59 Months) |  |
|------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|--|
| Subject group type                       | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |  |
| Number of subjects analysed              | 14                                                                | 13                                                                | 11                                                          |  |
| Units: AU/mL                             |                                                                   |                                                                   |                                                             |  |
| geometric mean (confidence interval 95%) |                                                                   |                                                                   |                                                             |  |
| PreF-bAb: Day 1 (n=14,13,11)             | 2917.4 (1032.3 to 8244.7)                                         | 8082.8 (3651.1 to 17893.8)                                        | 3049.5 (646.4 to 14387.0)                                   |  |
| PreF-bAb: Day 29 (n=14,11,11)            | 77346.4<br>(40482.2 to 147780.1)                                  | 85262.9<br>(58818.3 to 123596.7)                                  | 5607.0 (2180.6 to 14417.8)                                  |  |
| PreF-bAb: Day 85 (n=5,9,4)               | 52637.4<br>(24725.1 to 112059.9)                                  | 47425.7<br>(29293.9 to 76780.5)                                   | 1340.6 (188.5 to 9535.5)                                    |  |

|                                |                                  |                                   |                            |  |
|--------------------------------|----------------------------------|-----------------------------------|----------------------------|--|
| PreF-bAb: Day 141 (n=4,5,5)    | 56838.9<br>(27535.9 to 117325.1) | 85960.5<br>(53327.1 to 138564.0)  | 9477.9 (2516.4 to 35699.0) |  |
| PostF-bAb: Day 1 (n=14,13,11)  | 4452.1 (2103.2 to 9424.4)        | 14341.2<br>(7611.3 to 27021.9)    | 5101.7 (991.9 to 26240.5)  |  |
| PostF-bAb: Day 29 (n=14,11,11) | 71426.3<br>(34951.2 to 145966.8) | 121809.4<br>(69071.8 to 214813.1) | 9566.1 (3803.8 to 24057.8) |  |
| PostF-bAb: Day 85 (n=5,9,4)    | 36288.6<br>(12278.4 to 107250.9) | 57293.0<br>(31394.4 to 104556.5)  | 1906.1 (647.6 to 5610.0)   |  |
| PostF-bAb: Day 141 (n=4,5,5)   | 42645.7<br>(8769.3 to 207389.1)  | 87523.8<br>(36792.6 to 208205.3)  | 7012.1 (1396.5 to 35207.5) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Fold-Rise (GMFR) of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Young Adults Cohorts

|                 |                                                                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Fold-Rise (GMFR) of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Young Adults Cohorts <sup>[32]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 11 AU/mL for RSV-A and 8 AU/mL for RSV-B. PP Set included FAS participants (all randomized participants who received any study injection, had baseline data for analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, 169, and 281

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                       | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed              | 18                                                                           | 19                                                                           | 19                                                                           | 19                                                                           |
| Units: ratio                             |                                                                              |                                                                              |                                                                              |                                                                              |
| geometric mean (confidence interval 95%) |                                                                              |                                                                              |                                                                              |                                                                              |
| RSV-A: Day 29 (n=18,19,19,18,15,4)       | 20.52 (13.62 to 30.91)                                                       | 22.25 (14.77 to 33.51)                                                       | 23.54 (16.14 to 34.33)                                                       | 19.96 (13.95 to 28.58)                                                       |

|                                     |                        |                        |                        |                       |
|-------------------------------------|------------------------|------------------------|------------------------|-----------------------|
| RSV-A: Day 57 (n=18,19,15,17,14,4)  | 17.51 (10.98 to 27.91) | 16.83 (10.09 to 28.08) | 15.33 (9.24 to 25.44)  | 13.93 (9.80 to 19.81) |
| RSV-A: Day 85 (n=18,19,13,17,13,3)  | 15.77 (10.67 to 23.33) | 11.78 (7.76 to 17.90)  | 21.19 (11.53 to 38.93) | 9.34 (5.99 to 14.56)  |
| RSV-A: Day 113 (n=18,17,12,16,13,3) | 14.25 (9.09 to 22.34)  | 8.70 (5.30 to 14.27)   | 17.22 (10.58 to 28.02) | 9.58 (6.65 to 13.82)  |
| RSV-A: Day 141 (n=18,19,13,16,14,3) | 9.74 (6.07 to 15.63)   | 7.44 (4.94 to 11.20)   | 15.56 (9.54 to 25.38)  | 9.22 (6.82 to 12.47)  |
| RSV-A: Day 169 (n=18,19,13,17,13,3) | 9.62 (6.27 to 14.77)   | 6.98 (4.64 to 10.49)   | 19.69 (12.79 to 30.30) | 8.42 (5.91 to 12.01)  |
| RSV-A: Day 281 (n=0,0,12,0,0,3)     | 9999 (9999 to 9999)    | 9999 (9999 to 9999)    | 12.55 (7.96 to 19.78)  | 9999 (9999 to 9999)   |
| RSV-B: Day 29 (n=18,19,19,18,15,4)  | 14.44 (9.57 to 21.80)  | 11.67 (6.72 to 20.28)  | 16.02 (9.92 to 25.87)  | 13.88 (8.06 to 23.92) |
| RSV-B: Day 57 (n=18,19,15,17,14,4)  | 15.28 (9.61 to 24.32)  | 13.03 (8.11 to 20.94)  | 19.28 (12.29 to 30.23) | 8.68 (5.18 to 14.56)  |
| RSV-B: Day 85 (n=18,19,13,17,13,3)  | 10.54 (6.78 to 16.36)  | 8.24 (5.23 to 12.97)   | 14.87 (8.66 to 25.54)  | 7.34 (4.36 to 12.36)  |
| RSV-B: Day 113 (n=18,17,12,16,13,3) | 10.38 (6.51 to 16.55)  | 8.52 (5.36 to 13.54)   | 16.54 (8.49 to 32.23)  | 6.38 (3.71 to 10.97)  |
| RSV-B: Day 141 (n=18,19,13,16,14,3) | 10.66 (6.45 to 17.62)  | 7.35 (4.52 to 11.95)   | 20.19 (12.20 to 33.40) | 5.23 (3.34 to 8.18)   |
| RSV-B: Day 169 (n=18,19,13,17,13,3) | 8.90 (5.69 to 13.93)   | 5.28 (3.54 to 7.90)    | 16.54 (9.40 to 29.08)  | 5.01 (3.17 to 7.93)   |
| RSV-B: Day 281 (n=0,0,12,0,0,3)     | 9999 (9999 to 9999)    | 9999 (9999 to 9999)    | 10.66 (5.82 to 19.54)  | 9999 (9999 to 9999)   |

| End point values                         | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) | Three Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |  |  |
|------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                                         | Reporting group                                                        |  |  |
| Number of subjects analysed              | 15                                                                      | 4                                                                      |  |  |
| Units: ratio                             |                                                                         |                                                                        |  |  |
| geometric mean (confidence interval 95%) |                                                                         |                                                                        |  |  |
| RSV-A: Day 29 (n=18,19,19,18,15,4)       | 0.92 (0.79 to 1.08)                                                     | 0.97 (0.69 to 1.35)                                                    |  |  |
| RSV-A: Day 57 (n=18,19,15,17,14,4)       | 0.91 (0.73 to 1.14)                                                     | 0.76 (0.31 to 1.90)                                                    |  |  |
| RSV-A: Day 85 (n=18,19,13,17,13,3)       | 0.95 (0.77 to 1.17)                                                     | 0.73 (0.35 to 1.54)                                                    |  |  |
| RSV-A: Day 113 (n=18,17,12,16,13,3)      | 0.87 (0.70 to 1.08)                                                     | 1.02 (0.20 to 5.28)                                                    |  |  |
| RSV-A: Day 141 (n=18,19,13,16,14,3)      | 0.95 (0.70 to 1.31)                                                     | 1.00 (0.13 to 7.46)                                                    |  |  |
| RSV-A: Day 169 (n=18,19,13,17,13,3)      | 0.95 (0.76 to 1.18)                                                     | 0.71 (0.15 to 3.36)                                                    |  |  |
| RSV-A: Day 281 (n=0,0,12,0,0,3)          | 9999 (9999 to 9999)                                                     | 0.58 (0.35 to 0.95)                                                    |  |  |
| RSV-B: Day 29 (n=18,19,19,18,15,4)       | 0.88 (0.69 to 1.13)                                                     | 1.19 (0.60 to 2.38)                                                    |  |  |
| RSV-B: Day 57 (n=18,19,15,17,14,4)       | 0.94 (0.67 to 1.33)                                                     | 1.58 (0.54 to 4.61)                                                    |  |  |
| RSV-B: Day 85 (n=18,19,13,17,13,3)       | 0.92 (0.63 to 1.35)                                                     | 1.21 (0.37 to 3.90)                                                    |  |  |

|                                     |                     |                     |  |  |
|-------------------------------------|---------------------|---------------------|--|--|
| RSV-B: Day 113 (n=18,17,12,16,13,3) | 0.80 (0.59 to 1.08) | 1.33 (0.71 to 2.48) |  |  |
| RSV-B: Day 141 (n=18,19,13,16,14,3) | 0.86 (0.65 to 1.13) | 1.35 (0.35 to 5.23) |  |  |
| RSV-B: Day 169 (n=18,19,13,17,13,3) | 0.67 (0.49 to 0.92) | 1.02 (0.26 to 3.97) |  |  |
| RSV-B: Day 281 (n=0,0,12,0,0,3)     | 9999 (9999 to 9999) | 0.75 (0.09 to 5.90) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Older Adults Cohorts

|                 |                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Older Adults Cohorts <sup>[33]</sup> |
|-----------------|----------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 11 AU/mL for RSV-A and 8 AU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 169, and 365

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                       | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed              | 46                                                                      | 43                                                                      | 47                                                                      | 45                                                                       |
| Units: ratio                             |                                                                         |                                                                         |                                                                         |                                                                          |
| geometric mean (confidence interval 95%) |                                                                         |                                                                         |                                                                         |                                                                          |
| RSV-A: Day 29 (n=44,43,47,45,44,56)      | 12.03 (8.78 to 16.47)                                                   | 14.14 (10.23 to 19.54)                                                  | 16.67 (12.34 to 22.53)                                                  | 12.17 (8.90 to 16.64)                                                    |
| RSV-A: Day 57 (n=46,39,44,42,45,58)      | 9.16 (6.73 to 12.47)                                                    | 9.31 (6.65 to 13.04)                                                    | 12.86 (9.62 to 17.19)                                                   | 10.03 (7.18 to 14.03)                                                    |
| RSV-A: Day 85 (n=44,42,46,45,43,55)      | 7.53 (5.54 to 10.24)                                                    | 7.73 (5.95 to 10.05)                                                    | 9.43 (6.80 to 13.06)                                                    | 7.54 (5.57 to 10.22)                                                     |
| RSV-A: Day 169 (n=43,42,44,44,44,55)     | 5.05 (3.77 to 6.67)                                                     | 4.05 (2.96 to 5.54)                                                     | 5.79 (4.56 to 7.35)                                                     | 4.10 (3.04 to 5.54)                                                      |
| RSV-A: Day 365 (n=38,33,36,41,40,49)     | 3.06 (2.20 to 4.24)                                                     | 2.66 (1.94 to 3.66)                                                     | 3.19 (2.37 to 4.30)                                                     | 2.96 (2.22 to 3.94)                                                      |

|                                      |                      |                      |                       |                     |
|--------------------------------------|----------------------|----------------------|-----------------------|---------------------|
| RSV-B: Day 29 (n=44,43,47,45,44,56)  | 8.96 (6.79 to 11.84) | 9.60 (7.31 to 12.61) | 12.50 (9.10 to 17.16) | 6.65 (4.86 to 8.87) |
| RSV-B: Day 57 (n=46,39,44,42,45,58)  | 7.08 (5.40 to 9.28)  | 8.87 (6.71 to 11.73) | 9.77 (7.34 to 13.00)  | 5.66 (4.35 to 7.36) |
| RSV-B: Day 85 (n=44,42,46,45,43,55)  | 5.62 (4.24 to 7.45)  | 7.02 (5.35 to 9.20)  | 7.99 (6.00 to 10.64)  | 4.57 (3.54 to 5.90) |
| RSV-B: Day 169 (n=43,42,44,44,44,55) | 4.38 (3.37 to 5.70)  | 4.60 (3.69 to 5.73)  | 5.50 (4.39 to 6.89)   | 3.20 (2.36 to 4.34) |
| RSV-B: Day 365 (n=38,33,36,41,40,49) | 2.37 (1.87 to 3.01)  | 2.78 (2.10 to 3.69)  | 2.89 (2.28 to 3.66)   | 1.61 (1.25 to 2.06) |

| End point values                         | Cohort 11: mRNA-1345 Dose F in Older Adults (65 to 79 Years) | Two Injection Placebo in Older Adults (65 to 79 Years) |  |  |
|------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                              | Reporting group                                        |  |  |
| Number of subjects analysed              | 45                                                           | 58                                                     |  |  |
| Units: ratio                             |                                                              |                                                        |  |  |
| geometric mean (confidence interval 95%) |                                                              |                                                        |  |  |
| RSV-A: Day 29 (n=44,43,47,45,44,56)      | 10.19 (7.17 to 14.48)                                        | 1.15 (0.99 to 1.34)                                    |  |  |
| RSV-A: Day 57 (n=46,39,44,42,45,58)      | 7.05 (5.14 to 9.69)                                          | 1.12 (0.95 to 1.33)                                    |  |  |
| RSV-A: Day 85 (n=44,42,46,45,43,55)      | 5.27 (3.82 to 7.29)                                          | 1.11 (0.98 to 1.26)                                    |  |  |
| RSV-A: Day 169 (n=43,42,44,44,44,55)     | 3.08 (2.33 to 4.08)                                          | 0.99 (0.86 to 1.15)                                    |  |  |
| RSV-A: Day 365 (n=38,33,36,41,40,49)     | 2.39 (1.84 to 3.10)                                          | 1.15 (0.96 to 3.38)                                    |  |  |
| RSV-B: Day 29 (n=44,43,47,45,44,56)      | 5.30 (3.74 to 7.49)                                          | 1.12 (0.98 to 1.29)                                    |  |  |
| RSV-B: Day 57 (n=46,39,44,42,45,58)      | 4.28 (3.21 to 5.72)                                          | 1.27 (1.12 to 1.44)                                    |  |  |
| RSV-B: Day 85 (n=44,42,46,45,43,55)      | 3.51 (2.58 to 4.78)                                          | 1.27 (1.12 to 1.44)                                    |  |  |
| RSV-B: Day 169 (n=43,42,44,44,44,55)     | 2.87 (2.24 to 3.70)                                          | 1.33 (1.14 to 1.55)                                    |  |  |
| RSV-B: Day 365 (n=38,33,36,41,40,49)     | 1.52 (1.23 to 1.88)                                          | 1.07 (0.89 to 1.29)                                    |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Japanese Adults Cohorts

|                 |                                                                                                                 |
|-----------------|-----------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Japanese Adults Cohorts<br>[34] |
|-----------------|-----------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-

baseline to baseline titer values. LLOQ was 11 AU/mL for RSV-A and 8 AU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, and 169

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) |  |  |
|---------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| Subject group type                          | Reporting group                                                  | Reporting group                                                            |  |  |
| Number of subjects analysed                 | 20                                                               | 4                                                                          |  |  |
| Units: ratio                                |                                                                  |                                                                            |  |  |
| geometric mean (confidence interval<br>95%) |                                                                  |                                                                            |  |  |
| RSV-A: Day 29 (n=20,4)                      | 11.15 (7.76 to<br>16.01)                                         | 0.82 (0.42 to<br>1.60)                                                     |  |  |
| RSV-A: Day 57 (n=20,4)                      | 9.75 (7.17 to<br>13.27)                                          | 0.84 (0.32 to<br>2.19)                                                     |  |  |
| RSV-A: Day 85 (n=19,4)                      | 7.77 (5.61 to<br>10.76)                                          | 0.81 (0.28 to<br>2.29)                                                     |  |  |
| RSV-A: Day 169 (n=20,4)                     | 4.16 (2.96 to<br>5.43)                                           | 0.72 (0.33 to<br>1.55)                                                     |  |  |
| RSV-B: Day 29 (n=20,4)                      | 6.60 (4.90 to<br>8.88)                                           | 0.81 (0.47 to<br>1.41)                                                     |  |  |
| RSV-B: Day 57 (n=20,4)                      | 4.72 (3.60 to<br>6.19)                                           | 0.85 (0.60 to<br>1.20)                                                     |  |  |
| RSV-B: Day 85 (n=19,4)                      | 3.82 (2.97 to<br>4.91)                                           | 0.81 (0.49 to<br>1.36)                                                     |  |  |
| RSV-B: Day 169 (n=20,4)                     | 2.67 (2.04 to<br>3.50)                                           | 0.69 (0.47 to<br>1.01)                                                     |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for WOCBP Cohorts

|                 |                                                                                                       |
|-----------------|-------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for WOCBP Cohorts<br>[35] |
|-----------------|-------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-

baseline to baseline titer values. LLOQ was 11 AU/mL for RSV-A and 8 AU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, and 169

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|---------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                          | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed                 | 49                                                                | 46                                                                | 41                                                                | 28                                                          |
| Units: ratio                                |                                                                   |                                                                   |                                                                   |                                                             |
| geometric mean (confidence interval<br>95%) |                                                                   |                                                                   |                                                                   |                                                             |
| RSV-A: Day 29 (n=49,46,41,28)               | 9.41 (7.29 to<br>12.15)                                           | 11.22 (8.43 to<br>14.94)                                          | 11.60 (8.71 to<br>15.46)                                          | 1.05 (0.88 to<br>1.26)                                      |
| RSV-A: Day 57 (n=45,45,42,28)               | 9.30 (6.99 to<br>12.36)                                           | 10.19 (7.80 to<br>13.31)                                          | 10.79 (8.53 to<br>13.64)                                          | 1.41 (1.11 to<br>1.78)                                      |
| RSV-A: Day 85 (n=43,41,37,24)               | 7.50 (5.60 to<br>10.05)                                           | 10.15 (7.60 to<br>13.57)                                          | 8.75 (6.59 to<br>11.61)                                           | 1.21 (0.94 to<br>1.56)                                      |
| RSV-A: Day 113 (n=44,43,37,25)              | 6.07 (4.48 to<br>8.22)                                            | 7.07 (5.39 to<br>9.27)                                            | 6.88 (5.30 to<br>8.94)                                            | 1.32 (0.99 to<br>1.75)                                      |
| RSV-A: Day 141 (n=40,42,36,25)              | 4.75 (3.49 to<br>6.46)                                            | 5.84 (4.58 to<br>7.43)                                            | 5.70 (4.30 to<br>7.56)                                            | 1.02 (0.79 to<br>1.33)                                      |
| RSV-A: Day 169 (n=41,43,34,23)              | 3.94 (2.94 to<br>5.29)                                            | 5.11 (3.86 to<br>6.77)                                            | 4.42 (3.60 to<br>5.43)                                            | 0.99 (0.81 to<br>1.21)                                      |
| RSV-B: Day 29 (n=49,46,41,28)               | 7.55 (5.36 to<br>10.64)                                           | 6.45 (4.68 to<br>8.89)                                            | 9.09 (6.04 to<br>13.68)                                           | 0.95 (0.75 to<br>1.21)                                      |
| RSV-B: Day 57 (n=45,45,42,28)               | 5.45 (3.90 to<br>7.62)                                            | 4.76 (3.49 to<br>6.49)                                            | 6.63 (4.71 to<br>9.34)                                            | 1.46 (1.19 to<br>1.80)                                      |
| RSV-B: Day 85 (n=43,41,37,24)               | 5.65 (4.14 to<br>7.72)                                            | 4.56 (3.29 to<br>6.31)                                            | 5.88 (4.27 to<br>8.10)                                            | 1.47 (1.11 to<br>1.97)                                      |
| RSV-B: Day 113 (n=44,43,37,25)              | 3.91 (2.83 to<br>5.41)                                            | 3.79 (2.78 to<br>5.16)                                            | 5.02 (3.80 to<br>6.64)                                            | 1.73 (1.20 to<br>2.49)                                      |
| RSV-B: Day 141 (n=40,42,36,25)              | 3.52 (2.55 to<br>4.87)                                            | 3.15 (2.39 to<br>4.16)                                            | 3.79 (2.69 to<br>5.33)                                            | 1.44 (1.09 to<br>1.92)                                      |
| RSV-B: Day 169 (n=41,43,34,23)              | 3.15 (2.27 to<br>4.36)                                            | 2.98 (2.21 to<br>4.02)                                            | 3.06 (2.24 to<br>4.17)                                            | 1.21 (0.96 to<br>1.52)                                      |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Children Cohorts

|                 |                                                                                                                  |
|-----------------|------------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline RSV Neutralizing Abs (RSV-A and RSV-B) Titers for Children Cohorts <sup>[36]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------|

### End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 11 AU/mL for RSV-A and 8 AU/mL for RSV-B. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Days 29, 85, and 141

### Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type                       | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed              | 14                                                                   | 12                                                                   | 11                                                             |  |
| Units: ratio                             |                                                                      |                                                                      |                                                                |  |
| geometric mean (confidence interval 95%) |                                                                      |                                                                      |                                                                |  |
| RSV-A: Day 29 (n=14,12,11)               | 34.88 (13.79 to 88.22)                                               | 18.94 (5.54 to 64.71)                                                | 1.44 (0.66 to 3.15)                                            |  |
| RSV-A: Day 85 (n=5,9,4)                  | 40.25 (15.23 to 106.35)                                              | 7.26 (1.75 to 30.14)                                                 | 0.65 (0.21 to 2.02)                                            |  |
| RSV-A: Day 141 (n=4,5,5)                 | 49.96 (9.01 to 276.88)                                               | 17.71 (1.69 to 185.65)                                               | 1.41 (0.32 to 6.12)                                            |  |
| RSV-B: Day 29 (n=14,12,11)               | 14.26 (7.05 to 28.87)                                                | 7.21 (2.36 to 22.02)                                                 | 1.24 (0.55 to 2.82)                                            |  |
| RSV-B: Day 85 (n=5,9,4)                  | 17.56 (5.59 to 55.13)                                                | 3.20 (0.94 to 10.89)                                                 | 0.64 (0.27 to 1.52)                                            |  |
| RSV-B: Day 141 (n=4,5,5)                 | 13.28 (3.35 to 52.64)                                                | 6.32 (3.30 to 12.08)                                                 | 1.93 (0.35 to 52.64)                                           |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Young Adults Cohorts

|                 |                                                                                                                  |
|-----------------|------------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Young Adults Cohorts <sup>[37]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------|

# End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included FAS participants (all randomized participants who received any study injection, had baseline data for analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with injection schedule, b) complied with timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

# End point timeframe:

Days 29, 57, 85, 113, 141, 169, and 281

# Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                       | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed              | 18                                                                           | 19                                                                           | 15                                                                           | 18                                                                           |
| Units: ratio                             |                                                                              |                                                                              |                                                                              |                                                                              |
| geometric mean (confidence interval 95%) |                                                                              |                                                                              |                                                                              |                                                                              |
| PreF-bAb: Day 29 (n=18,19,15,18,14,4)    | 16.14 (11.44 to 22.76)                                                       | 21.67 (15.42 to 30.45)                                                       | 21.76 (16.73 to 28.30)                                                       | 16.87 (12.41 to 22.94)                                                       |
| PreF-bAb: Day 57 (n=18,19,14,17,14,4)    | 13.24 (9.71 to 18.05)                                                        | 15.47 (10.80 to 22.15)                                                       | 16.02 (11.60 to 22.12)                                                       | 11.89 (8.46 to 16.72)                                                        |
| PreF-bAb: Day 85 (n=18,19,12,17,13,3)    | 9.32 (6.40 to 13.57)                                                         | 11.68 (7.93 to 17.22)                                                        | 17.08 (13.05 to 22.37)                                                       | 9.27 (6.85 to 12.54)                                                         |
| PreF-bAb: Day 113 (n=18,17,12,16,13,3)   | 8.19 (5.94 to 11.30)                                                         | 9.67 (6.52 to 14.35)                                                         | 15.27 (10.79 to 21.61)                                                       | 7.46 (5.27 to 10.57)                                                         |
| PreF-bAb: Day 141 (n=18,19,13,16,14,3)   | 7.67 (5.47 to 10.75)                                                         | 8.28 (6.02 to 11.38)                                                         | 16.07 (12.12 to 21.30)                                                       | 6.50 (4.73 to 8.95)                                                          |
| PreF-bAb: Day 169 (n=18,19,13,17,13,3)   | 6.48 (4.72 to 8.89)                                                          | 7.04 (5.14 to 9.65)                                                          | 13.48 (10.07 to 18.04)                                                       | 5.87 (4.44 to 7.75)                                                          |
| PreF-bAb: Day 281 (n=0,0,12,0,0,3)       | 9999 (9999 to 9999)                                                          | 9999 (9999 to 9999)                                                          | 8.42 (5.87 to 12.08)                                                         | 9999 (9999 to 9999)                                                          |
| PostF-bAb: Day 29 (n=18,19,15,18,14,4)   | 13.98 (8.69 to 22.49)                                                        | 17.70 (11.75 to 26.66)                                                       | 15.42 (10.99 to 21.64)                                                       | 14.64 (10.81 to 19.83)                                                       |
| PostF-bAb: Day 57 (n=18,19,14,17,14,4)   | 10.95 (7.07 to 16.95)                                                        | 11.87 (7.70 to 18.30)                                                        | 10.85 (7.39 to 15.94)                                                        | 9.08 (6.65 to 12.41)                                                         |
| PostF-bAb: Day 85 (n=18,19,12,17,13,3)   | 7.83 (4.79 to 12.81)                                                         | 9.28 (5.93 to 14.52)                                                         | 9.87 (6.48 to 15.02)                                                         | 6.90 (5.08 to 9.38)                                                          |
| PostF-bAb: Day 113 (n=18,17,12,16,13,3)  | 6.84 (4.46 to 10.49)                                                         | 7.56 (4.72 to 12.10)                                                         | 8.96 (5.79 to 13.88)                                                         | 5.60 (4.01 to 7.82)                                                          |
| PostF-bAb: Day 141 (n=18,19,13,16,14,3)  | 6.21 (4.06 to 9.49)                                                          | 6.59 (4.23 to 10.26)                                                         | 7.98 (5.47 to 11.63)                                                         | 4.54 (3.38 to 6.11)                                                          |
| PostF-bAb: Day 169 (n=18,19,13,17,13,3)  | 5.33 (3.53 to 8.04)                                                          | 5.35 (3.58 to 7.98)                                                          | 7.04 (4.87 to 10.17)                                                         | 4.20 (3.14 to 5.62)                                                          |
| PostF-bAb: Day 281 (n=0,0,12,0,0,3)      | 9999 (9999 to 9999)                                                          | 9999 (9999 to 9999)                                                          | 4.78 (3.25 to 7.04)                                                          | 9999 (9999 to 9999)                                                          |

| End point values                            | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) | Three Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |  |  |
|---------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| Subject group type                          | Reporting group                                                         | Reporting group                                                        |  |  |
| Number of subjects analysed                 | 14                                                                      | 4                                                                      |  |  |
| Units: ratio                                |                                                                         |                                                                        |  |  |
| geometric mean (confidence interval<br>95%) |                                                                         |                                                                        |  |  |
| PreF-bAb: Day 29 (n=18,19,15,18,14,4)       | 0.99 (0.88 to<br>1.12)                                                  | 1.11 (0.86 to<br>1.43)                                                 |  |  |
| PreF-bAb: Day 57 (n=18,19,14,17,14,4)       | 1.05 (0.97 to<br>1.14)                                                  | 0.98 (0.83 to<br>1.16)                                                 |  |  |
| PreF-bAb: Day 85 (n=18,19,12,17,13,3)       | 0.99 (0.89 to<br>1.11)                                                  | 1.02 (0.80 to<br>1.31)                                                 |  |  |
| PreF-bAb: Day 113<br>(n=18,17,12,16,13,3)   | 0.96 (0.85 to<br>1.08)                                                  | 0.99 (0.85 to<br>1.15)                                                 |  |  |
| PreF-bAb: Day 141<br>(n=18,19,13,16,14,3)   | 0.97 (0.86 to<br>1.10)                                                  | 0.96 (0.63 to<br>1.47)                                                 |  |  |
| PreF-bAb: Day 169<br>(n=18,19,13,17,13,3)   | 0.97 (0.85 to<br>1.11)                                                  | 0.96 (0.89 to<br>1.03)                                                 |  |  |
| PreF-bAb: Day 281 (n=0,0,12,0,0,3)          | 9999 (9999 to<br>9999)                                                  | 0.80 (0.34 to<br>1.90)                                                 |  |  |
| PostF-bAb: Day 29<br>(n=18,19,15,18,14,4)   | 1.03 (0.94 to<br>1.12)                                                  | 1.09 (0.96 to<br>1.25)                                                 |  |  |
| PostF-bAb: Day 57<br>(n=18,19,14,17,14,4)   | 1.03 (0.97 to<br>1.09)                                                  | 1.03 (0.86 to<br>1.24)                                                 |  |  |
| PostF-bAb: Day 85<br>(n=18,19,12,17,13,3)   | 1.02 (0.95 to<br>1.10)                                                  | 1.12 (0.94 to<br>1.33)                                                 |  |  |
| PostF-bAb: Day 113<br>(n=18,17,12,16,13,3)  | 1.05 (0.98 to<br>1.13)                                                  | 1.09 (0.98 to<br>1.20)                                                 |  |  |
| PostF-bAb: Day 141<br>(n=18,19,13,16,14,3)  | 1.03 (0.95 to<br>1.12)                                                  | 1.07 (0.90 to<br>1.27)                                                 |  |  |
| PostF-bAb: Day 169<br>(n=18,19,13,17,13,3)  | 1.06 (0.97 to<br>1.16)                                                  | 1.02 (0.72 to<br>1.46)                                                 |  |  |
| PostF-bAb: Day 281 (n=0,0,12,0,0,3)         | 9999 (9999 to<br>9999)                                                  | 0.85 (0.40 to<br>1.84)                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Older Adults Cohorts

|                 |                                                                                                                  |
|-----------------|------------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Older Adults Cohorts <sup>[38]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least

1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                               |           |
|-------------------------------|-----------|
| End point type                | Secondary |
| End point timeframe:          |           |
| Days 29, 57, 85, 169, and 365 |           |

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|---------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                          | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed                 | 44                                                                      | 43                                                                      | 47                                                                      | 45                                                                       |
| Units: ratio                                |                                                                         |                                                                         |                                                                         |                                                                          |
| geometric mean (confidence interval 95%)    |                                                                         |                                                                         |                                                                         |                                                                          |
| PreF-bAb: Day 29<br>(n=44,43,47,45,44,56)   | 8.46 (6.79 to 10.55)                                                    | 11.61 (9.24 to 14.58)                                                   | 12.12 (9.17 to 16.01)                                                   | 8.40 (6.77 to 10.41)                                                     |
| PreF-bAb: Day 57<br>(n=46,39,44,42,45,58)   | 7.03 (5.75 to 8.59)                                                     | 7.83 (6.32 to 9.69)                                                     | 9.25 (7.20 to 11.87)                                                    | 6.57 (5.26 to 8.22)                                                      |
| PreF-bAb: Day 85<br>(n=44,42,46,45,43,55)   | 5.44 (4.27 to 6.92)                                                     | 6.54 (5.26 to 8.11)                                                     | 6.96 (5.43 to 8.93)                                                     | 5.40 (4.40 to 6.63)                                                      |
| PreF-bAb: Day 169<br>(n=43,42,44,44,44,55)  | 4.05 (3.34 to 4.90)                                                     | 4.08 (3.25 to 5.14)                                                     | 4.72 (3.83 to 5.81)                                                     | 3.31 (2.71 to 4.06)                                                      |
| PreF-bAb: Day 365<br>(n=38,33,36,41,40,49)  | 2.90 (2.38 to 3.53)                                                     | 3.37 (2.62 to 4.33)                                                     | 3.22 (2.55 to 4.07)                                                     | 2.42 (1.98 to 2.95)                                                      |
| PostF-bAb: Day 29<br>(n=44,43,47,45,44,56)  | 5.91 (4.63 to 7.54)                                                     | 7.89 (6.20 to 10.04)                                                    | 9.20 (7.08 to 11.94)                                                    | 5.86 (4.54 to 7.56)                                                      |
| PostF-bAb: Day 57<br>(n=46,39,44,42,45,58)  | 4.85 (3.92 to 6.01)                                                     | 4.99 (4.00 to 6.22)                                                     | 7.40 (5.89 to 9.30)                                                     | 4.12 (3.08 to 5.51)                                                      |
| PostF-bAb: Day 85<br>(n=44,42,46,45,43,55)  | 3.75 (2.83 to 4.97)                                                     | 4.30 (3.41 to 5.41)                                                     | 5.66 (4.51 to 7.12)                                                     | 3.82 (3.00 to 4.87)                                                      |
| PostF-bAb: Day 169<br>(n=43,42,44,44,44,55) | 3.00 (2.47 to 3.64)                                                     | 2.69 (2.15 to 3.37)                                                     | 3.75 (3.05 to 4.62)                                                     | 2.58 (2.03 to 3.27)                                                      |
| PostF-bAb: Day 365<br>(n=38,33,36,41,40,49) | 2.27 (1.86 to 2.77)                                                     | 2.34 (1.87 to 2.93)                                                     | 2.62 (2.17 to 3.15)                                                     | 1.87 (1.47 to 2.37)                                                      |

| End point values                          | Cohort 11:<br>mRNA-1345<br>Dose F in Older<br>Adults (65 to<br>79 Years) | Two Injection<br>Placebo in<br>Older Adults<br>(65 to 79<br>Years) |  |  |
|-------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                                          | Reporting group                                                    |  |  |
| Number of subjects analysed               | 44                                                                       | 56                                                                 |  |  |
| Units: ratio                              |                                                                          |                                                                    |  |  |
| geometric mean (confidence interval 95%)  |                                                                          |                                                                    |  |  |
| PreF-bAb: Day 29<br>(n=44,43,47,45,44,56) | 7.21 (5.61 to 9.26)                                                      | 1.04 (0.92 to 1.17)                                                |  |  |

|                                             |                     |                     |  |  |
|---------------------------------------------|---------------------|---------------------|--|--|
| PreF-bAb: Day 57<br>(n=46,39,44,42,45,58)   | 5.11 (4.03 to 6.48) | 1.04 (0.92 to 1.16) |  |  |
| PreF-bAb: Day 85<br>(n=44,42,46,45,43,55)   | 4.32 (3.42 to 5.46) | 1.02 (0.91 to 1.14) |  |  |
| PreF-bAb: Day 169<br>(n=43,42,44,44,44,55)  | 2.82 (2.28 to 3.48) | 1.02 (0.89 to 1.16) |  |  |
| PreF-bAb: Day 365<br>(n=38,33,36,41,40,49)  | 2.10 (1.73 to 2.55) | 1.16 (0.96 to 1.39) |  |  |
| PostF-bAb: Day 29<br>(n=44,43,47,45,44,56)  | 4.35 (3.60 to 5.25) | 1.03 (0.92 to 1.17) |  |  |
| PostF-bAb: Day 57<br>(n=46,39,44,42,45,58)  | 3.42 (2.85 to 4.09) | 1.02 (0.92 to 1.13) |  |  |
| PostF-bAb: Day 85<br>(n=44,42,46,45,43,55)  | 2.86 (2.41 to 3.40) | 1.02 (0.91 to 1.14) |  |  |
| PostF-bAb: Day 169<br>(n=43,42,44,44,44,55) | 1.93 (1.66 to 2.25) | 1.00 (0.89 to 1.13) |  |  |
| PostF-bAb: Day 365<br>(n=38,33,36,41,40,49) | 1.56 (1.35 to 1.81) | 1.16 (0.97 to 1.39) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Japanese Adults Cohorts

|                 |                                                                                                                     |
|-----------------|---------------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Japanese Adults Cohorts <sup>[39]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, and 169

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

|                                          |                                                                  |                                                                            |  |  |
|------------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| <b>End point values</b>                  | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) |  |  |
| Subject group type                       | Reporting group                                                  | Reporting group                                                            |  |  |
| Number of subjects analysed              | 20                                                               | 4                                                                          |  |  |
| Units: ratio                             |                                                                  |                                                                            |  |  |
| geometric mean (confidence interval 95%) |                                                                  |                                                                            |  |  |

|                             |                      |                     |  |  |
|-----------------------------|----------------------|---------------------|--|--|
| PreF-bAb: Day 29 (n=20,4)   | 9.10 (6.46 to 12.83) | 1.07 (0.94 to 1.21) |  |  |
| PreF-bAb: Day 57 (n=20,4)   | 7.24 (5.26 to 9.97)  | 1.11 (0.96 to 1.29) |  |  |
| PreF-bAb: Day 85 (n=19,4)   | 6.04 (4.34 to 8.41)  | 1.05 (0.85 to 1.30) |  |  |
| PreF-bAb: Day 169 (n=20,4)  | 3.89 (2.87 to 5.26)  | 1.00 (0.85 to 1.17) |  |  |
| PostF-bAb: Day 29 (n=20,4)  | 7.57 (4.70 to 12.21) | 0.95 (0.79 to 1.14) |  |  |
| PostF-bAb: Day 57 (n=20,4)  | 5.79 (3.80 to 8.82)  | 1.01 (0.88 to 1.17) |  |  |
| PostF-bAb: Day 85 (n=19,4)  | 4.60 (3.11 to 6.80)  | 1.00 (0.90 to 1.11) |  |  |
| PostF-bAb: Day 169 (n=20,4) | 3.29 (2.36 to 4.60)  | 0.97 (0.78 to 1.20) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for WOCBP Cohorts

|                 |                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for WOCBP Cohorts <sup>[40]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, and 169

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                         | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                       | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed              | 49                                                                | 46                                                                | 42                                                                | 28                                                          |
| Units: ratio                             |                                                                   |                                                                   |                                                                   |                                                             |
| geometric mean (confidence interval 95%) |                                                                   |                                                                   |                                                                   |                                                             |
| PreF-bAb: Day 29 (n=49,46,41,28)         | 8.43 (6.86 to 10.37)                                              | 9.58 (7.74 to 11.86)                                              | 10.22 (7.80 to 13.39)                                             | 1.00 (0.88 to 1.13)                                         |

|                                    |                     |                     |                      |                     |
|------------------------------------|---------------------|---------------------|----------------------|---------------------|
| PreF-bAb: Day 57 (n=45,45,42,28)   | 6.65 (5.26 to 8.39) | 7.45 (6.10 to 9.10) | 8.09 (6.54 to 10.01) | 0.99 (0.87 to 1.14) |
| PreF-bAb: Day 85 (n=43,41,37,24)   | 5.65 (4.44 to 7.18) | 6.54 (5.30 to 8.08) | 6.17 (4.84 to 7.87)  | 0.99 (0.85 to 1.16) |
| PreF-bAb: Day 113 (n=44,43,37,25)  | 4.81 (3.82 to 6.06) | 5.43 (4.41 to 6.69) | 5.10 (3.96 to 6.56)  | 1.17 (0.94 to 1.47) |
| PreF-bAb: Day 141 (n=40,42,36,24)  | 4.08 (3.23 to 5.14) | 4.95 (4.17 to 5.88) | 4.32 (3.53 to 5.29)  | 1.14 (0.92 to 1.41) |
| PreF-bAb: Day 169 (n=41,43,34,23)  | 3.83 (3.04 to 4.82) | 4.43 (3.64 to 5.40) | 4.05 (3.30 to 4.98)  | 1.02 (0.91 to 1.16) |
| PostF-bAb: Day 29 (n=49,46,41,28)  | 7.64 (6.00 to 9.74) | 7.22 (5.74 to 9.09) | 8.11 (6.39 to 10.29) | 0.97 (0.89 to 1.07) |
| PostF-bAb: Day 57 (n=45,45,42,28)  | 5.90 (4.66 to 7.48) | 5.16 (4.13 to 6.43) | 5.86 (4.85 to 7.08)  | 0.99 (0.89 to 1.10) |
| PostF-bAb: Day 85 (n=43,41,37,24)  | 4.76 (3.74 to 6.05) | 4.39 (3.46 to 5.58) | 4.40 (3.52 to 5.50)  | 0.96 (0.85 to 1.10) |
| PostF-bAb: Day 113 (n=44,43,37,25) | 4.19 (3.37 to 5.21) | 3.94 (3.15 to 4.93) | 3.93 (3.18 to 4.86)  | 1.13 (0.95 to 1.35) |
| PostF-bAb: Day 141 (n=40,42,36,24) | 3.58 (2.83 to 4.53) | 3.41 (2.80 to 4.15) | 3.35 (2.76 to 4.08)  | 1.10 (0.92 to 1.32) |
| PostF-bAb: Day 169 (n=41,43,34,23) | 3.27 (2.62 to 4.08) | 3.19 (2.60 to 3.92) | 3.12 (2.54 to 3.83)  | 1.00 (0.87 to 1.15) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Children Cohorts

|                 |                                                                                                              |
|-----------------|--------------------------------------------------------------------------------------------------------------|
| End point title | GMFR of Postbaseline/Baseline Serum Binding Abs (PreF and PostF) Titers for Children Cohorts <sup>[41]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------|

End point description:

Antibody values reported as below LLOQ at baseline were replaced by LLOQ for GMFR comparing post-baseline to baseline titer values. LLOQ was 19 AU/mL for PreF-bAb and 16 AU/mL for PostF-bAb. PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 85, and 141

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                            | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|---------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type                          | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed                 | 14                                                                   | 11                                                                   | 11                                                             |  |
| Units: ratio                                |                                                                      |                                                                      |                                                                |  |
| geometric mean (confidence interval<br>95%) |                                                                      |                                                                      |                                                                |  |
| PreF-bAb: Day 29 (n=14,11,11)               | 26.51 (13.37<br>to 52.59)                                            | 13.92 (6.90 to<br>28.10)                                             | 1.73 (0.56 to<br>5.31)                                         |  |
| PreF-bAb: Day 85 (n=5,9,4)                  | 51.02 (5.41 to<br>481.44)                                            | 6.48 (3.02 to<br>13.87)                                              | 0.67 (0.48 to<br>0.93)                                         |  |
| PreF-bAb: Day 141 (n=4,5,5)                 | 62.82 (1.54 to<br>2556.22)                                           | 8.32 (5.75 to<br>12.03)                                              | 1.74 (0.35 to<br>8.61)                                         |  |
| PostF-bAb: Day 29 (n=14,11,11)              | 16.04 (9.19 to<br>28.00)                                             | 9.28 (4.42 to<br>19.48)                                              | 1.76 (0.47 to<br>6.61)                                         |  |
| PostF-bAb: Day 85 (n=5,9,4)                 | 12.13 (2.21 to<br>66.49)                                             | 4.68 (2.01 to<br>10.92)                                              | 0.68 (0.39 to<br>1.18)                                         |  |
| PostF-bAb: Day 141 (n=4,5,5)                | 10.62 (0.95 to<br>118.19)                                            | 4.47 (1.37 to<br>14.62)                                              | 1.01 (0.57 to<br>1.81)                                         |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Young Adult Cohorts

|                 |                                                                                                                                                                                   |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Young Adult Cohorts <sup>[42]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, 169, and 281

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                     | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                                   | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed                          | 18                                                                           | 19                                                                           | 19                                                                           | 18                                                                           |
| Units: percentage of participants                    |                                                                              |                                                                              |                                                                              |                                                                              |
| number (confidence interval 95%)                     |                                                                              |                                                                              |                                                                              |                                                                              |
| RSV-A: ≥2-fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 100.0 (81.5 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (81.5 to<br>100.0)                                                     |
| RSV-A: ≥4-fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 100.0 (81.5 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (81.5 to<br>100.0)                                                     |
| RSV-A: ≥2-fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 100.0 (81.5 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (78.2 to<br>100.0)                                                     | 100.0 (80.5 to<br>100.0)                                                     |
| RSV-A: ≥4-fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 94.4 (72.7 to<br>99.9)                                                       | 94.7 (74.0 to<br>99.9)                                                       | 86.7 (59.5 to<br>98.3)                                                       | 100.0 (80.5 to<br>100.0)                                                     |
| RSV-A: ≥2-fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 100.0 (81.5 to<br>100.0)                                                     | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (75.3 to<br>100.0)                                                     | 94.1 (71.3 to<br>99.9)                                                       |
| RSV-A: ≥4-fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 94.4 (72.7 to<br>99.9)                                                       | 94.7 (74.0 to<br>99.9)                                                       | 84.6 (54.6 to<br>98.1)                                                       | 94.1 (71.3 to<br>99.9)                                                       |
| RSV-A: ≥2-fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 100.0 (81.5 to<br>100.0)                                                     | 100.0 (80.5 to<br>100.0)                                                     | 100.0 (73.5 to<br>100.0)                                                     | 100.0 (79.4 to<br>100.0)                                                     |
| RSV-A: ≥4-fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 94.4 (72.7 to<br>99.9)                                                       | 70.6 (44.0 to<br>89.7)                                                       | 91.7 (61.5 to<br>99.8)                                                       | 93.8 (69.8 to<br>99.8)                                                       |
| RSV-A: ≥2-fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 94.4 (72.7 to<br>99.9)                                                       | 94.7 (74.0 to<br>99.9)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 100.0 (79.4 to<br>100.0)                                                     |
| RSV-A: ≥4-fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 77.8 (52.4 to<br>93.6)                                                       | 73.7 (48.8 to<br>90.9)                                                       | 92.3 (64.0 to<br>99.8)                                                       | 93.8 (69.8 to<br>99.8)                                                       |
| RSV-A: ≥2-fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 100.0 (81.5 to<br>100.0)                                                     | 94.7 (74.0 to<br>99.9)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 100.0 (80.5 to<br>100.0)                                                     |
| RSV-A: ≥4-fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 83.3 (58.6 to<br>96.4)                                                       | 73.7 (48.8 to<br>90.9)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 82.4 (56.6 to<br>96.2)                                                       |
| RSV-A: ≥2-fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to<br>9999)                                                       | 9999 (9999 to<br>9999)                                                       | 100.0 (73.5 to<br>100.0)                                                     | 9999 (9999 to<br>9999)                                                       |
| RSV-A: ≥4-fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to<br>9999)                                                       | 9999 (9999 to<br>9999)                                                       | 91.7 (61.5 to<br>99.8)                                                       | 9999 (9999 to<br>9999)                                                       |
| RSV-B: ≥2-fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 100.0 (81.5 to<br>100.0)                                                     | 94.7 (74.0 to<br>99.9)                                                       | 100.0 (82.4 to<br>100.0)                                                     | 100.0 (81.5 to<br>100.0)                                                     |
| RSV-B: ≥4-fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 94.4 (72.7 to<br>99.9)                                                       | 89.5 (66.9 to<br>98.7)                                                       | 89.5 (66.9 to<br>98.7)                                                       | 94.4 (72.7 to<br>99.9)                                                       |
| RSV-B: ≥2-fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 100.0 (81.5 to<br>100.0)                                                     | 94.7 (74.0 to<br>99.9)                                                       | 100.0 (78.2 to<br>100.0)                                                     | 94.1 (71.3 to<br>99.9)                                                       |
| RSV-B: ≥4-fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 94.4 (72.7 to<br>99.9)                                                       | 89.5 (72.7 to<br>99.9)                                                       | 100.0 (78.2 to<br>100.0)                                                     | 76.5 (50.1 to<br>93.2)                                                       |
| RSV-B: ≥2-fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 100.0 (81.5 to<br>100.0)                                                     | 94.7 (74.0 to<br>99.9)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 94.1 (71.3 to<br>99.9)                                                       |
| RSV-B: ≥4-fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 88.9 (65.3 to<br>98.6)                                                       | 78.9 (54.4 to<br>93.9)                                                       | 92.3 (64.0 to<br>99.8)                                                       | 76.5 (50.1 to<br>93.2)                                                       |
| RSV-B: ≥2-fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 94.4 (72.7 to<br>99.9)                                                       | 94.1 (71.3 to<br>99.9)                                                       | 100.0 (73.5 to<br>100.0)                                                     | 93.8 (69.8 to<br>99.8)                                                       |
| RSV-B: ≥4-fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 88.9 (65.3 to<br>98.6)                                                       | 76.5 (50.1 to<br>93.2)                                                       | 83.3 (51.6 to<br>97.9)                                                       | 62.5 (35.4 to<br>84.8)                                                       |
| RSV-B: ≥2-fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 94.4 (72.7 to<br>99.9)                                                       | 89.5 (66.9 to<br>98.7)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 81.3 (54.4 to<br>96.0)                                                       |
| RSV-B: ≥4-fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 83.3 (58.6 to<br>96.4)                                                       | 68.4 (43.4 to<br>87.4)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 62.5 (35.4 to<br>84.8)                                                       |
| RSV-B: ≥2-fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 94.4 (72.7 to<br>99.9)                                                       | 84.2 (60.4 to<br>96.6)                                                       | 100.0 (75.3 to<br>100.0)                                                     | 88.2 (63.6 to<br>98.5)                                                       |
| RSV-B: ≥4-fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 88.9 (65.3 to<br>98.6)                                                       | 73.7 (48.8 to<br>90.9)                                                       | 92.3 (64.0 to<br>99.8)                                                       | 52.9 (27.8 to<br>77.0)                                                       |

|                                                         |                     |                     |                     |                     |
|---------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| RSV-B: $\geq 2$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3) | 9999 (9999 to 9999) | 9999 (9999 to 9999) | 91.7 (61.5 to 99.8) | 9999 (9999 to 9999) |
| RSV-B: $\geq 4$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3) | 9999 (9999 to 9999) | 9999 (9999 to 9999) | 91.7 (61.5 to 99.8) | 9999 (9999 to 9999) |

| End point values                                            | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) | Three Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |  |  |
|-------------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| Subject group type                                          | Reporting group                                                         | Reporting group                                                        |  |  |
| Number of subjects analysed                                 | 15                                                                      | 4                                                                      |  |  |
| Units: percentage of participants                           |                                                                         |                                                                        |  |  |
| number (confidence interval 95%)                            |                                                                         |                                                                        |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 0.0 (0.0 to 21.8)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 0.0 (0.0 to 21.8)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 0.0 (0.0 to 23.2)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 0.0 (0.0 to 23.2)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 0.0 (0.0 to 24.7)                                                       | 33.3 (0.8 to 90.6)                                                     |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 7.1 (0.2 to 33.9)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 7.1 (0.2 to 33.9)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to 9999)                                                     | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to 9999)                                                     | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 0.0 (0.0 to 21.8)                                                       | 25.0 (0.6 to 80.6)                                                     |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 29<br>(n=18,19,19,18,15,4)  | 0.0 (0.0 to 21.8)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 7.1 (0.2 to 33.9)                                                       | 50.0 (6.8 to 93.2)                                                     |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 57<br>(n=18,19,15,17,14,4)  | 0.0 (0.0 to 23.2)                                                       | 0.0 (0.0 to 60.2)                                                      |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 15.4 (1.9 to 45.4)                                                      | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 85<br>(n=18,19,13,17,13,3)  | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 113<br>(n=18,17,12,16,13,3) | 0.0 (0.0 to 24.7)                                                       | 0.0 (0.0 to 70.8)                                                      |  |  |

|                                                             |                     |                    |  |  |
|-------------------------------------------------------------|---------------------|--------------------|--|--|
| RSV-B: $\geq 2$ -fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 0.0 (0.0 to 23.2)   | 33.3 (0.8 to 90.6) |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 141<br>(n=18,19,13,16,14,3) | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 70.8)  |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8)  |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 169<br>(n=18,19,13,17,13,3) | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8)  |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8)  |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 281<br>(n=0,0,12,0,0,3)     | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8)  |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Older Adults Cohorts

|                 |                                                                                                                                                                                    |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Older Adults Cohorts <sup>[43]</sup> |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 169, and 365

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                            | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|-------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                                          | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed                                 | 47                                                                      | 46                                                                      | 47                                                                      | 46                                                                       |
| Units: percentage of participants                           |                                                                         |                                                                         |                                                                         |                                                                          |
| number (confidence interval 95%)                            |                                                                         |                                                                         |                                                                         |                                                                          |
| RSV-A: $\geq 2$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 100.0 (92.0 to 100.0)                                                   | 97.7 (87.7 to 99.9)                                                     | 97.9 (87.7 to 99.9)                                                     | 97.8 (88.2 to 99.9)                                                      |
| RSV-A: $\geq 4$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 84.1 (69.9 to 93.4)                                                     | 93.0 (80.9 to 98.5)                                                     | 93.6 (82.5 to 98.7)                                                     | 88.9 (75.9 to 96.3)                                                      |
| RSV-A: $\geq 2$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 93.5 (82.1 to 98.6)                                                     | 94.9 (82.7 to 99.4)                                                     | 95.5 (84.5 to 99.4)                                                     | 92.9 (80.5 to 98.5)                                                      |
| RSV-A: $\geq 4$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 78.3 (63.6 to 89.1)                                                     | 74.4 (57.9 to 87.0)                                                     | 90.9 (78.3 to 97.5)                                                     | 85.7 (71.5 to 94.6)                                                      |

|                                                             |                     |                       |                       |                     |
|-------------------------------------------------------------|---------------------|-----------------------|-----------------------|---------------------|
| RSV-A: $\geq 2$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 90.9 (78.3 to 97.5) | 97.6 (97.4 to 99.9)   | 95.7 (85.2 to 99.5)   | 95.6 (84.9 to 99.5) |
| RSV-A: $\geq 4$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 75.0 (59.7 to 86.8) | 83.3 (68.6 to 93.0)   | 82.6 (68.6 to 92.2)   | 73.3 (58.1 to 85.4) |
| RSV-A: $\geq 2$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 83.7 (69.3 to 93.2) | 85.7 (71.5 to 94.6)   | 93.2 (81.3 to 98.6)   | 77.3 (62.2 to 88.5) |
| RSV-A: $\geq 4$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 51.2 (35.5 to 66.7) | 47.6 (32.0 to 63.6)   | 65.9 (50.1 to 79.5)   | 45.5 (30.4 to 61.2) |
| RSV-A: $\geq 2$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 60.5 (43.4 to 76.0) | 63.6 (45.1 to 79.6)   | 66.7 (49.0 to 81.4)   | 65.9 (49.4 to 79.9) |
| RSV-A: $\geq 4$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 42.1 (26.3 to 59.2) | 24.2 (11.1 to 42.3)   | 41.7 (25.5 to 59.2)   | 36.6 (22.1 to 53.1) |
| RSV-B: $\geq 2$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 97.7 (88.0 to 99.9) | 97.7 (87.7 to 99.9)   | 100.0 (92.5 to 100.0) | 91.1 (78.8 to 97.5) |
| RSV-B: $\geq 4$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 79.5 (64.7 to 90.2) | 79.1 (64.0 to 90.0)   | 80.9 (66.7 to 90.9)   | 66.7 (51.0 to 80.0) |
| RSV-B: $\geq 2$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 89.1 (76.4 to 96.4) | 100.0 (91.0 to 100.0) | 95.5 (84.5 to 99.4)   | 90.5 (77.4 to 97.3) |
| RSV-B: $\geq 4$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 73.9 (58.9 to 85.7) | 92.3 (79.1 to 98.4)   | 81.8 (67.3 to 91.8)   | 71.4 (55.4 to 84.3) |
| RSV-B: $\geq 2$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 86.4 (72.6 to 94.8) | 97.6 (87.4 to 99.9)   | 91.3 (79.2 to 97.6)   | 84.4 (70.5 to 93.5) |
| RSV-B: $\geq 4$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 65.9 (50.1 to 79.5) | 78.6 (63.2 to 89.7)   | 73.9 (58.9 to 85.7)   | 55.6 (40.0 to 70.4) |
| RSV-B: $\geq 2$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 83.7 (69.3 to 93.2) | 95.2 (83.8 to 99.4)   | 90.9 (78.3 to 97.5)   | 68.2 (52.4 to 81.4) |
| RSV-B: $\geq 4$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 46.5 (31.2 to 62.3) | 45.2 (29.8 to 61.3)   | 65.9 (50.1 to 79.5)   | 36.4 (22.4 to 52.2) |
| RSV-B: $\geq 2$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 52.6 (35.8 to 69.0) | 60.6 (42.1 to 77.1)   | 77.8 (60.8 to 89.9)   | 29.3 (16.1 to 45.5) |
| RSV-B: $\geq 4$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 15.8 (6.0 to 31.3)  | 30.3 (15.6 to 48.7)   | 16.7 (6.4 to 32.8)    | 14.6 (5.6 to 29.2)  |

| End point values                                            | Cohort 11:<br>mRNA-1345<br>Dose F in Older<br>Adults (65 to<br>79 Years) | Two Injection<br>Placebo in<br>Older Adults<br>(65 to 79<br>Years) |  |  |
|-------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|--|
| Subject group type                                          | Reporting group                                                          | Reporting group                                                    |  |  |
| Number of subjects analysed                                 | 46                                                                       | 58                                                                 |  |  |
| Units: percentage of participants                           |                                                                          |                                                                    |  |  |
| number (confidence interval 95%)                            |                                                                          |                                                                    |  |  |
| RSV-A: $\geq 2$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 93.2 (81.3 to 98.6)                                                      | 7.1 (2.0 to 17.3)                                                  |  |  |
| RSV-A: $\geq 4$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 75.0 (59.7 to 86.8)                                                      | 5.4 (1.1 to 14.9)                                                  |  |  |
| RSV-A: $\geq 2$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 93.3 (81.7 to 98.6)                                                      | 6.9 (1.9 to 16.7)                                                  |  |  |
| RSV-A: $\geq 4$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 68.9 (53.4 to 81.8)                                                      | 1.7 (0.0 to 9.2)                                                   |  |  |
| RSV-A: $\geq 2$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 83.7 (69.3 to 93.2)                                                      | 3.6 (0.4 to 12.5)                                                  |  |  |
| RSV-A: $\geq 4$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 51.2 (35.5 to 66.7)                                                      | 1.8 (0.0 to 9.7)                                                   |  |  |
| RSV-A: $\geq 2$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 59.1 (43.2 to 73.7)                                                      | 3.6 (0.4 to 12.5)                                                  |  |  |
| RSV-A: $\geq 4$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 34.1 (20.5 to 49.9)                                                      | 3.6 (0.4 to 12.5)                                                  |  |  |

|                                                             |                     |                    |  |  |
|-------------------------------------------------------------|---------------------|--------------------|--|--|
| RSV-A: $\geq 2$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 47.5 (31.5 to 63.9) | 16.3 (7.3 to 29.7) |  |  |
| RSV-A: $\geq 4$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 27.5 (14.6 to 43.9) | 6.1 (1.3 to 16.9)  |  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 77.3 (62.2 to 88.5) | 7.1 (2.0 to 17.3)  |  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 29<br>(n=44,43,47,45,44,56) | 54.5 (38.8 to 69.6) | 1.8 (0.0 to 9.6)   |  |  |
| RSV-B: $\geq 2$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 73.3 (58.1 to 85.4) | 13.8 (6.1 to 25.4) |  |  |
| RSV-B: $\geq 4$ -fold Rise-Day 57<br>(n=46,39,44,42,45,58)  | 51.1 (35.8 to 66.3) | 1.7 (.0 to 9.2)    |  |  |
| RSV-B: $\geq 2$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 72.1 (56.3 to 84.7) | 9.1 (3.0 to 20.0)  |  |  |
| RSV-B: $\geq 4$ -fold Rise-Day 85<br>(n=44,42,46,45,43,55)  | 41.9 (27.0 to 57.9) | 1.8 (0.0 to 9.7)   |  |  |
| RSV-B: $\geq 2$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 63.6 (47.8 to 77.6) | 16.4 (7.8 to 28.8) |  |  |
| RSV-B: $\geq 4$ -fold Rise-Day 169<br>(n=43,42,44,44,44,55) | 27.3 (15.0 to 42.8) | 7.3 (2.0 to 17.6)  |  |  |
| RSV-B: $\geq 2$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 25.0 (12.7 to 41.2) | 10.2 (3.4 to 22.2) |  |  |
| RSV-B: $\geq 4$ -fold Rise-Day 365<br>(n=38,33,36,41,40,49) | 12.5 (4.2 to 26.8)  | 6.1 (1.3 to 16.9)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Japanese Adult Cohorts

|                 |                                                                                                                                                                                      |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Japanese Adult Cohorts <sup>[44]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, and 169

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                      | Cohort 15:<br>mRNA-1345<br>Dose B in<br>Japanese Older<br>Adults | Single Injection<br>Placebo in<br>Japanese Older<br>Adults (≥ 60<br>Years) |  |  |
|---------------------------------------|------------------------------------------------------------------|----------------------------------------------------------------------------|--|--|
| Subject group type                    | Reporting group                                                  | Reporting group                                                            |  |  |
| Number of subjects analysed           | 20                                                               | 4                                                                          |  |  |
| Units: percentage of participants     |                                                                  |                                                                            |  |  |
| number (confidence interval 95%)      |                                                                  |                                                                            |  |  |
| RSV-A: ≥2-fold Rise- Day 29 (n=20,4)  | 100.0 (83.2 to 100.0)                                            | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥4-fold Rise- Day 29 (n=20,4)  | 90.0 (68.3 to 98.8)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥2-fold Rise- Day 57 (n=20,4)  | 100.0 (83.2 to 100.0)                                            | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥4-fold Rise- Day 57 (n=20,4)  | 85.0 (62.1 to 96.8)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥2-fold Rise- Day 85 (n=19,4)  | 94.7 (74.0 to 99.9)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥4-fold Rise- Day 85 (n=19,4)  | 89.5 (66.9 to 98.7)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥2-fold Rise- Day 169 (n=20,4) | 90.0 (68.3 to 98.8)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-A: ≥4-fold Rise- Day 169 (n=20,4) | 45.0 (23.1 to 68.5)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥2-fold Rise- Day 29 (n=20,4)  | 100.0 (83.2 to 100.0)                                            | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥4-fold Rise- Day 29 (n=20,4)  | 75.0 (50.9 to 91.3)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥2-fold Rise- Day 57 (n=20,4)  | 85.0 (62.1 to 96.8)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥4-fold Rise- Day 57 (n=20,4)  | 65.0 (40.8 to 84.6)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥2-fold Rise- Day 85 (n=19,4)  | 94.7 (74.0 to 99.9)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥4-fold Rise- Day 85 (n=19,4)  | 47.4 (24.4 to 71.1)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥2-fold Rise- Day 169 (n=20,4) | 65.0 (40.8 to 84.6)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |
| RSV-B: ≥4-fold Rise- Day 169 (n=20,4) | 30.0 (11.9 to 54.3)                                              | 0.0 (0.0 to 60.2)                                                          |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with ≥2-fold and ≥4-fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in WOCBP Cohorts

|                 |                                                                                                                                                               |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with ≥2-fold and ≥4-fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in WOCBP Cohorts <sup>[45]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the

immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, and 169

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                      | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|-------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                                    | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed                           | 49                                                                | 48                                                                | 44                                                                | 29                                                          |
| Units: percentage of participants                     |                                                                   |                                                                   |                                                                   |                                                             |
| number (confidence interval 95%)                      |                                                                   |                                                                   |                                                                   |                                                             |
| RSV-A: $\geq 2$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 95.9 (86.0 to 99.5)                                               | 97.8 (88.5 to 99.9)                                               | 95.1 (83.5 to 99.4)                                               | 7.1 (0.9 to 23.5)                                           |
| RSV-A: $\geq 4$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 83.7 (70.3 to 92.7)                                               | 84.8 (71.1 to 93.7)                                               | 92.7 (80.1 to 98.5)                                               | 3.6 (0.1 to 18.3)                                           |
| RSV-A: $\geq 2$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 95.6 (84.9 to 99.5)                                               | 95.6 (84.9 to 99.5)                                               | 97.6 (87.4 to 99.9)                                               | 21.4 (8.3 to 41.0)                                          |
| RSV-A: $\geq 4$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 82.2 (67.9 to 92.0)                                               | 80.0 (65.4 to 90.4)                                               | 88.1 (74.4 to 96.0)                                               | 10.7 (2.3 to 28.2)                                          |
| RSV-A: $\geq 2$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 90.7 (77.9 to 97.4)                                               | 95.1 (83.5 to 99.4)                                               | 97.3 (85.8 to 99.9)                                               | 25.0 (9.8 to 46.7)                                          |
| RSV-A: $\geq 4$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 67.4 (51.5 to 80.9)                                               | 85.4 (70.8 to 94.4)                                               | 83.8 (68.0 to 93.8)                                               | 4.2 (0.1 to 21.1)                                           |
| RSV-A: $\geq 2$ -fold Rise-Day 113<br>(n=44,43,37,25) | 86.4 (72.6 to 94.8)                                               | 90.7 (77.9 to 97.4)                                               | 97.3 (77.9 to 97.4)                                               | 20.0 (6.8 to 40.7)                                          |
| RSV-A: $\geq 4$ -fold Rise-Day 113<br>(n=44,43,37,25) | 61.4 (45.5 to 75.6)                                               | 76.7 (61.4 to 88.2)                                               | 75.7 (58.8 to 88.2)                                               | 8.0 (1.0 to 26.0)                                           |
| RSV-A: $\geq 2$ -fold Rise-Day 141<br>(n=40,42,36,25) | 80.0 (64.4 to 90.9)                                               | 90.5 (77.4 to 97.3)                                               | 94.4 (81.3 to 99.3)                                               | 16.0 (4.5 to 36.1)                                          |
| RSV-A: $\geq 4$ -fold Rise-Day 141<br>(n=40,42,36,25) | 47.5 (31.5 to 63.9)                                               | 69.0 (52.9 to 82.4)                                               | 66.7 (49.0 to 81.4)                                               | 4.0 (0.1 to 20.4)                                           |
| RSV-A: $\geq 2$ -fold Rise-Day 169<br>(n=41,43,34,23) | 75.6 (59.7 to 87.6)                                               | 79.1 (64.0 to 90.0)                                               | 91.2 (76.3 to 98.1)                                               | 13.0 (2.8 to 33.6)                                          |
| RSV-A: $\geq 4$ -fold Rise-Day 169<br>(n=41,43,34,23) | 43.9 (28.5 to 60.3)                                               | 67.4 (51.5 to 80.9)                                               | 61.8 (43.6 to 77.8)                                               | 0.0 (0.0 to 14.8)                                           |
| RSV-B: $\geq 2$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 87.8 (75.2 to 95.4)                                               | 87.0 (73.7 to 95.1)                                               | 85.4 (70.8 to 94.4)                                               | 10.7 (2.3 to 28.2)                                          |
| RSV-B: $\geq 4$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 73.5 (58.9 to 85.1)                                               | 63.0 (47.5 to 76.8)                                               | 73.2 (57.1 to 85.8)                                               | 3.6 (0.1 to 18.3)                                           |
| RSV-B: $\geq 2$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 84.4 (70.5 to 93.5)                                               | 82.2 (67.9 to 92.0)                                               | 88.1 (74.4 to 96.0)                                               | 14.3 (4.0 to 32.7)                                          |
| RSV-B: $\geq 4$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 55.6 (40.0 to 70.4)                                               | 57.8 (42.2 to 72.3)                                               | 66.7 (50.5 to 80.4)                                               | 7.1 (0.9 to 23.5)                                           |
| RSV-B: $\geq 2$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 86.0 (72.1 to 94.7)                                               | 78.0 (62.4 to 89.4)                                               | 89.2 (74.6 to 97.0)                                               | 20.8 (7.1 to 42.2)                                          |
| RSV-B: $\geq 4$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 67.4 (51.5 to 80.9)                                               | 53.7 (37.4 to 69.3)                                               | 62.2 (44.8 to 77.5)                                               | 8.3 (1.0 to 27.0)                                           |
| RSV-B: $\geq 2$ -fold Rise-Day 113<br>(n=44,43,37,25) | 75.0 (59.7 to 86.8)                                               | 74.4 (58.8 to 86.5)                                               | 89.2 (74.6 to 97.0)                                               | 24.0 (9.4 to 45.1)                                          |
| RSV-B: $\geq 4$ -fold Rise-Day 113<br>(n=44,43,37,25) | 47.7 (32.5 to 63.3)                                               | 48.8 (33.3 to 64.5)                                               | 56.8 (39.5 to 72.9)                                               | 16.0 (4.5 to 36.1)                                          |

|                                                       |                     |                     |                     |                     |
|-------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| RSV-B: $\geq 2$ -fold Rise-Day 141<br>(n=40,42,36,25) | 72.5 (56.1 to 85.4) | 66.7 (50.5 to 80.4) | 83.3 (67.2 to 93.6) | 28.0 (12.1 to 49.4) |
| RSV-B: $\geq 4$ -fold Rise-Day 141<br>(n=40,42,36,25) | 32.5 (18.6 to 49.1) | 45.2 (29.8 to 61.3) | 44.4 (27.9 to 61.9) | 8.0 (1.0 to 26.0)   |
| RSV-B: $\geq 2$ -fold Rise-Day 169<br>(n=41,43,34,23) | 65.9 (49.4 to 79.9) | 67.4 (51.5 to 80.9) | 76.5 (58.8 to 89.3) | 8.7 (1.1 to 28.0)   |
| RSV-B: $\geq 4$ -fold Rise-Day 169<br>(n=41,43,34,23) | 41.5 (26.3 to 57.9) | 39.5 (25.0 to 55.6) | 38.2 (22.2 to 56.4) | 0.0 (0.0 to 14.8)   |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Children Cohorts

|                 |                                                                                                                                                                                |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in RSV Neutralizing Abs (RSV-A and RSV-B) Titers from Baseline in Children Cohorts <sup>[46]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 85, and 141

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                   | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|----------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type                                 | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed                        | 14                                                                   | 13                                                                   | 11                                                             |  |
| Units: percentage of participants                  |                                                                      |                                                                      |                                                                |  |
| number (confidence interval 95%)                   |                                                                      |                                                                      |                                                                |  |
| RSV-A: $\geq 2$ -fold Rise- Day 29<br>(n=14,12,11) | 100.0 (76.8 to 100.0)                                                | 75.0 (42.8 to 94.5)                                                  | 27.3 (6.0 to 61.0)                                             |  |
| RSV-A: $\geq 4$ -fold Rise- Day 29<br>(n=14,12,11) | 92.9 (66.1 to 99.8)                                                  | 75.0 (42.8 to 94.5)                                                  | 18.2 (2.3 to 51.8)                                             |  |
| RSV-A: $\geq 2$ -fold Rise- Day 85 (n=5,9,4)       | 100.0 (47.8 to 100.0)                                                | 77.8 (40.0 to 97.5)                                                  | 0.0 (0.0 to 60.2)                                              |  |
| RSV-A: $\geq 4$ -fold Rise- Day 85 (n=5,9,4)       | 100.0 (47.8 to 100.0)                                                | 77.8 (40.0 to 97.5)                                                  | 0.0 (0.0 to 60.2)                                              |  |
| RSV-A: $\geq 2$ -fold Rise- Day 141<br>(n=4,5,5)   | 100.0 (39.8 to 100)                                                  | 80.0 (28.4 to 99.5)                                                  | 40.0 (5.3 to 85.3)                                             |  |
| RSV-A: $\geq 4$ -fold Rise- Day 141<br>(n=4,5,5)   | 100 (39.8 to 100.0)                                                  | 80.0 (28.4 to 99.5)                                                  | 20.0 (0.5 to 71.6)                                             |  |

|                                                    |                       |                       |                    |  |
|----------------------------------------------------|-----------------------|-----------------------|--------------------|--|
| RSV-B: $\geq 2$ -fold Rise- Day 29<br>(n=14,12,11) | 100.0 (76.8 to 100.0) | 83.3 (51.6 to 97.9)   | 18.2 (2.3 to 51.8) |  |
| RSV-B: $\geq 4$ -fold Rise- Day 29<br>(n=14,12,11) | 71.4 (41.9 to 91.6)   | 83.3 (51.6 to 97.9)   | 18.2 (2.3 to 51.8) |  |
| RSV-B: $\geq 2$ -fold Rise- Day 85 (n=5,9,4)       | 100.0 (47.8 to 100.0) | 88.9 (51.8 to 99.7)   | 0.0 (0.0 to 60.2)  |  |
| RSV-B: $\geq 4$ -fold Rise- Day 85 (n=5,9,4)       | 100.0 (47.8 to 100.0) | 44.4 (13.7 to 78.8)   | 0.0 (0.0 to 60.2)  |  |
| RSV-B: $\geq 2$ -fold Rise- Day 141<br>(n=4,5,5)   | 100.0 (39.8 to 100.0) | 100.0 (47.8 to 100.0) | 40.0 (5.3 to 85.3) |  |
| RSV-B: $\geq 4$ -fold Rise- Day 141<br>(n=4,5,5)   | 100.0 (39.8 to 100.0) | 60.0 (14.7 to 94.7)   | 40.0 (5.3 to 85.3) |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Young Adults Cohorts

|                 |                                                                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Young Adults Cohorts <sup>[47]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories. '9999' represents data not collected for specified cohorts.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, 169, and 281

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                             | Cohort 1:<br>mRNA-1345<br>Dose A in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 2:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 3:<br>mRNA-1345<br>Dose B in<br>Younger Adults<br>(18 to 49<br>Years) | Cohort 4:<br>mRNA-1345<br>Dose C in<br>Younger Adults<br>(18 to 49<br>Years) |
|--------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Subject group type                                           | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              | Reporting group                                                              |
| Number of subjects analysed                                  | 18                                                                           | 19                                                                           | 15                                                                           | 18                                                                           |
| Units: percentage of participants                            |                                                                              |                                                                              |                                                                              |                                                                              |
| number (confidence interval 95%)                             |                                                                              |                                                                              |                                                                              |                                                                              |
| PreF-bAb: $\geq 2$ -fold Rise-Day 29<br>(n=18,19,15,18,14,4) | 100.0 (81.5 to 100.0)                                                        | 100.0 (82.4 to 100.0)                                                        | 100.0 (78.2 to 100.0)                                                        | 100.0 (81.5 to 100.0)                                                        |
| PreF-bAb: $\geq 4$ -fold Rise-Day 29<br>(n=18,19,15,18,14,4) | 100.0 (81.5 to 100.0)                                                        | 100.0 (82.4 to 100.0)                                                        | 100.0 (78.2 to 100.0)                                                        | 100.0 (81.5 to 100.0)                                                        |
| PreF-bAb: $\geq 2$ -fold Rise-Day 57<br>(n=18,19,14,17,14,4) | 100.0 (81.5 to 100.0)                                                        | 100.0 (82.4 to 100.0)                                                        | 100.0 (76.8 to 100.0)                                                        | 100.0 (80.5 to 100.0)                                                        |

|                                                              |                       |                       |                       |                       |
|--------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| PreF-bAb: $\geq 4$ -fold Rise-Day 57<br>(n=18,19,14,17,14,4) | 100.0 (81.5 to 100.0) | 100.0 (82.4 to 100.0) | 100.0 (76.8 to 100.0) | 94.1 (71.3 to 99.9)   |
| PreF-bAb: $\geq 2$ -fold Rise-Day 85<br>(n=18,19,12,17,13,3) | 94.4 (72.7 to 99.9)   | 100.0 (82.4 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (80.5 to 100.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 85<br>(n=18,19,12,17,13,3) | 88.9 (65.3 to 98.6)   | 94.7 (74.0 to 99.9)   | 100.0 (73.5 to 100.0) | 94.1 (71.3 to 99.9)   |
| PreF-bAb: $\geq 2$ -fold Rise-Day 113(n=18,17,12,16,13,3)    | 100.0 (81.5 to 100.0) | 100.0 (80.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (79.4 to 100.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 113(n=18,17,12,16,13,3)    | 88.9 (65.3 to 98.6)   | 88.2 (63.6 to 98.5)   | 100.0 (73.5 to 100.0) | 87.5 (61.7 to 98.4)   |
| PreF-bAb: $\geq 2$ -fold Rise-Day 141(n=18,19,13,16,14,3)    | 100.0 (81.5 to 100.0) | 100.0 (82.4 to 100.0) | 100.0 (75.3 to 100.0) | 100.0 (79.4 to 100.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 141(n=18,19,13,16,14,3)    | 83.3 (58.6 to 96.4)   | 84.2 (60.4 to 96.6)   | 100.0 (75.3 to 100.0) | 87.5 (61.7 to 98.4)   |
| PreF-bAb: $\geq 2$ -fold Rise-Day 169(n=18,19,13,17,13,3)    | 100.0 (81.5 to 100.0) | 100.0 (82.4 to 100.0) | 100.0 (75.3 to 100.0) | 100.0 (80.5 to 100.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 169(n=18,19,13,17,13,3)    | 66.7 (41.0 to 86.7)   | 68.4 (43.4 to 87.4)   | 100.0 (75.3 to 100.0) | 82.4 (56.6 to 96.2)   |
| PreF-bAb: $\geq 2$ -fold Rise-Day 281<br>(n=0,0,12,0,0,3)    | 9999 (9999 to 9999)   | 9999 (9999 to 9999)   | 100.0 (73.5 to 100.0) | 9999 (9999 to 9999)   |
| PreF-bAb: $\geq 4$ -fold Rise-Day 281<br>(n=0,0,12,0,0,3)    | 9999 (9999 to 9999)   | 9999 (9999 to 9999)   | 91.7 (61.5 to 99.8)   | 9999 (9999 to 9999)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 29(n=18,19,15,18,14,4)    | 100.0 (81.5 to 100.0) | 100.0 (82.4 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (81.5 to 100.0) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 29(n=18,19,15,18,14,4)    | 88.9 (65.3 to 98.6)   | 100.0 (82.4 to 100.0) | 93.3 (68.1 to 99.8)   | 100.0 (81.5 to 100.0) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 57(n=18,19,14,17,14,4)    | 100.0 (81.5 to 100.0) | 100.0 (82.4 to 100.0) | 92.9 (66.1 to 99.8)   | 100.0 (80.5 to 100.0) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 57(n=18,19,14,17,14,4)    | 83.3 (58.6 to 96.4)   | 94.7 (74.0 to 99.9)   | 92.9 (66.1 to 99.8)   | 94.1 (71.3 to 99.9)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 85(n=18,19,12,17,13,3)    | 94.4 (72.7 to 99.9)   | 100.0 (82.4 to 100.0) | 91.7 (61.5 to 99.8)   | 100.0 (80.5 to 100.0) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 85(n=18,19,12,17,13,3)    | 83.3 (58.6 to 96.4)   | 78.9 (54.4 to 93.9)   | 91.7 (61.5 to 99.8)   | 76.5 (66.5 to 89.4)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 113(n=18,17,12,16,13,3)   | 94.4 (72.7 to 99.9)   | 100.0 (80.5 to 100.0) | 91.7 (61.5 to 99.8)   | 100.0 (79.4 to 100.0) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 113(n=18,17,12,16,13,3)   | 72.2 (46.5 to 90.3)   | 64.7 (38.3 to 85.8)   | 91.7 (61.5 to 99.8)   | 68.8 (41.3 to 89.0)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 141(n=18,19,13,16,14,3)   | 94.4 (72.7 to 99.9)   | 94.7 (74.0 to 99.9)   | 92.3 (64.0 to 99.8)   | 93.8 (69.8 to 99.8)   |
| PostF-bAb: $\geq 4$ -fold Rise-Day 141(n=18,19,13,16,14,3)   | 72.2 (46.5 to 90.3)   | 57.9 (33.5 to 79.7)   | 92.3 (64.0 to 99.8)   | 62.5 (35.4 to 84.8)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 169(n=18,19,13,17,13,3)   | 94.4 (72.7 to 99.9)   | 94.7 (74.0 to 99.9)   | 92.3 (64.0 to 99.8)   | 88.2 (63.6 to 98.5)   |
| PostF-bAb: $\geq 4$ -fold Rise-Day 169(n=18,19,13,17,13,3)   | 55.6 (30.8 to 78.5)   | 52.6 (28.9 to 75.6)   | 92.3 (64.0 to 99.8)   | 52.9 (27.8 to 77.0)   |
| PostF-bAb: $\geq 2$ -fold Rise-Day 281<br>(n=0,0,12,0,0,3)   | 9999 (9999 to 9999)   | 9999 (9999 to 9999)   | 91.7 (61.5 to 99.8)   | 9999 (9999 to 9999)   |
| PostF-bAb: $\geq 4$ -fold Rise-Day 281<br>(n=0,0,12,0,0,3)   | 9999 (9999 to 9999)   | 9999 (9999 to 9999)   | 66.7 (34.9 to 90.1)   | 9999 (9999 to 9999)   |

| End point values                  | Single Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) | Three Injection<br>Placebo in<br>Younger Adults<br>(18 to 49<br>Years) |  |  |
|-----------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|--|--|
| Subject group type                | Reporting group                                                         | Reporting group                                                        |  |  |
| Number of subjects analysed       | 14                                                                      | 4                                                                      |  |  |
| Units: percentage of participants |                                                                         |                                                                        |  |  |

| number (confidence interval 95%)                      |                     |                   |  |  |
|-------------------------------------------------------|---------------------|-------------------|--|--|
| PreF-bAb: ≥2-fold Rise-Day 29<br>(n=18,19,15,18,14,4) | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 29<br>(n=18,19,15,18,14,4) | 0.0 (0.0 to 23.0)   | 0.0 (0.0 to 60.2) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 57<br>(n=18,19,14,17,14,4) | 0.0 (0.0 to 23.0)   | 0.0 (0.0 to 60.2) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 57<br>(n=18,19,14,17,14,4) | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 85<br>(n=18,19,12,17,13,3) | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 85<br>(n=18,19,12,17,13,3) | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 113(n=18,17,12,16,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 113(n=18,17,12,16,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 141(n=18,19,13,16,14,3)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 141(n=18,19,13,16,14,3)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 169(n=18,19,13,17,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 169(n=18,19,13,17,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥2-fold Rise-Day 281<br>(n=0,0,12,0,0,3)    | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8) |  |  |
| PreF-bAb: ≥4-fold Rise-Day 281<br>(n=0,0,12,0,0,3)    | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 29(n=18,19,15,18,14,4)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 29(n=18,19,15,18,14,4)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 57(n=18,19,14,17,14,4)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 57(n=18,19,14,17,14,4)    | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 85(n=18,19,12,17,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 85(n=18,19,12,17,13,3)    | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 113(n=18,17,12,16,13,3)   | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 113(n=18,17,12,16,13,3)   | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 141(n=18,19,13,16,14,3)   | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 141(n=18,19,13,16,14,3)   | 0.0 (0.0 to 23.2)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 169(n=18,19,13,17,13,3)   | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 169(n=18,19,13,17,13,3)   | 0.0 (0.0 to 24.7)   | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥2-fold Rise-Day 281<br>(n=0,0,12,0,0,3)   | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 281<br>(n=0,0,12,0,0,3)   | 9999 (9999 to 9999) | 0.0 (0.0 to 70.8) |  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Older Adult Cohorts

|                 |                                                                                                                                                                                |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Older Adult Cohorts <sup>[48]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 169, and 365

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                           | Cohort 7:<br>mRNA-1345<br>Dose A in Older<br>Adults (65 to<br>79 Years) | Cohort 8:<br>mRNA-1345<br>Dose B in Older<br>Adults (65 to<br>79 Years) | Cohort 9:<br>mRNA-1345<br>Dose C in Older<br>Adults (65 to<br>79 Years) | Cohort 10:<br>mRNA-1345<br>Dose E in Older<br>Adults (65 to<br>79 Years) |
|------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Subject group type                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                         | Reporting group                                                          |
| Number of subjects analysed                                | 46                                                                      | 43                                                                      | 47                                                                      | 45                                                                       |
| Units: percentage of participants                          |                                                                         |                                                                         |                                                                         |                                                                          |
| number (confidence interval 95%)                           |                                                                         |                                                                         |                                                                         |                                                                          |
| PreF-bAb: $\geq 2$ -fold Rise-Day 29(n=44,43,47,45,44,56)  | 100.0 (92.0 to 100.0)                                                   | 100.0 (91.8 to 100.0)                                                   | 100.0 (92.5 to 100.0)                                                   | 97.8 (88.2 to 99.9)                                                      |
| PreF-bAb: $\geq 4$ -fold Rise-Day 29(n=44,43,47,45,44,56)  | 86.4 (72.6 to 94.8)                                                     | 88.4 (74.9 to 96.1)                                                     | 80.9 (66.7 to 90.9)                                                     | 88.9 (75.9 to 96.3)                                                      |
| PreF-bAb: $\geq 2$ -fold Rise-Day 57(n=46,39,44,42,45,58)  | 97.8 (88.5 to 99.9)                                                     | 100.0 (91.0 to 100.0)                                                   | 100.0 (92.0 to 100.0)                                                   | 95.2 (83.8 to 99.4)                                                      |
| PreF-bAb: $\geq 4$ -fold Rise-Day 57(n=46,39,44,42,45,58)  | 76.1 (61.2 to 87.4)                                                     | 84.6 (69.5 to 94.1)                                                     | 81.8 (67.3 to 91.8)                                                     | 78.6 (63.2 to 89.7)                                                      |
| PreF-bAb: $\geq 2$ -fold Rise-Day 85(n=44,42,46,45,43,55)  | 90.9 (78.3 to 97.5)                                                     | 95.2 (83.8 to 99.4)                                                     | 95.7 (85.2 to 99.5)                                                     | 97.8 (88.2 to 99.9)                                                      |
| PreF-bAb: $\geq 4$ -fold Rise-Day 85(n=44,42,46,45,43,55)  | 65.9 (50.1 to 79.5)                                                     | 73.8 (58.0 to 86.1)                                                     | 76.1 (61.2 to 87.4)                                                     | 64.4 (48.8 to 78.1)                                                      |
| PreF-bAb: $\geq 2$ -fold Rise-Day 169(n=43,42,44,44,44,55) | 90.7 (77.9 to 97.4)                                                     | 85.7 (71.5 to 94.6)                                                     | 88.6 (75.4 to 96.2)                                                     | 77.3 (62.2 to 88.5)                                                      |
| PreF-bAb: $\geq 4$ -fold Rise-Day 169(n=43,42,44,44,44,55) | 46.5 (31.2 to 62.3)                                                     | 50.0 (34.2 to 65.8)                                                     | 56.8 (41.0 to 71.7)                                                     | 43.2 (28.3 to 59.0)                                                      |
| PreF-bAb: $\geq 2$ -fold Rise-Day 365(n=38,33,36,41,40,49) | 68.4 (51.3 to 82.5)                                                     | 81.8 (64.5 to 93.0)                                                     | 69.4 (51.9 to 83.7)                                                     | 58.5 (42.1 to 73.7)                                                      |
| PreF-bAb: $\geq 4$ -fold Rise-Day 365(n=38,33,36,41,40,49) | 28.9 (15.4 to 45.9)                                                     | 30.3 (15.6 to 48.7)                                                     | 33.3 (18.6 to 51.0)                                                     | 17.1 (7.2 to 32.1)                                                       |
| PostF-bAb: $\geq 2$ -fold Rise-Day 29(n=44,43,47,45,44,56) | 95.5 (84.5 to 99.4)                                                     | 100.0 (91.8 to 100.0)                                                   | 95.7 (85.5 to 99.5)                                                     | 93.3 (81.7 to 98.6)                                                      |
| PostF-bAb: $\geq 4$ -fold Rise-Day 29(n=44,43,47,45,44,56) | 65.9 (50.1 to 79.5)                                                     | 79.1 (64.0 to 90.0)                                                     | 83.0 (69.2 to 92.4)                                                     | 66.7 (51.0 to 80.0)                                                      |

|                                                      |                     |                     |                     |                     |
|------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| PostF-bAb: ≥2-fold Rise-Day 57(n=46,39,44,42,45,58)  | 93.5 (82.1 to 98.6) | 92.3 (79.1 to 98.4) | 95.5 (84.5 to 99.4) | 78.6 (63.2 to 89.7) |
| PostF-bAb: ≥4-fold Rise-Day 57(n=46,39,44,42,45,58)  | 52.2 (36.9 to 67.1) | 61.5 (44.6 to 76.6) | 81.8 (67.3 to 91.8) | 57.1 (41.0 to 72.3) |
| PostF-bAb: ≥2-fold Rise-Day 85(n=44,42,46,45,43,55)  | 79.5 (64.7 to 90.2) | 88.1 (74.4 to 96.0) | 87.0 (73.7 to 95.1) | 80.0 (65.4 to 90.4) |
| PostF-bAb: ≥4-fold Rise-Day 85(n=44,42,46,45,43,55)  | 54.5 (38.8 to 69.6) | 54.8 (38.7 to 70.2) | 71.7 (56.5 to 84.0) | 51.1 (35.8 to 66.3) |
| PostF-bAb: ≥2-fold Rise-Day 169(n=43,42,44,44,44,55) | 67.4 (51.5 to 80.9) | 61.9 (45.6 to 76.4) | 84.1 (69.9 to 93.4) | 63.6 (47.8 to 77.6) |
| PostF-bAb: ≥4-fold Rise-Day 169(n=43,42,44,44,44,55) | 37.2 (23.0 to 53.3) | 26.2 (13.9 to 42.0) | 50.0 (34.6 to 65.4) | 29.5 (16.8 to 45.2) |
| PostF-bAb: ≥2-fold Rise-Day 365(n=38,33,36,41,40,49) | 50.0 (33.4 to 66.6) | 51.5 (33.5 to 69.2) | 66.7 (49.0 to 81.4) | 43.9 (28.5 to 60.3) |
| PostF-bAb: ≥4-fold Rise-Day 365(n=38,33,36,41,40,49) | 13.2 (4.4 to 28.1)  | 18.2 (7.0 to 35.5)  | 19.4 (8.2 to 36.0)  | 9.8 (2.7 to 23.1)   |

| End point values                                    | Cohort 11:<br>mRNA-1345<br>Dose F in Older<br>Adults (65 to<br>79 Years) | Two Injection<br>Placebo in<br>Older Adults<br>(65 to 79<br>Years) |  |  |
|-----------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|--|--|
| Subject group type                                  | Reporting group                                                          | Reporting group                                                    |  |  |
| Number of subjects analysed                         | 45                                                                       | 58                                                                 |  |  |
| Units: percentage of participants                   |                                                                          |                                                                    |  |  |
| number (confidence interval 95%)                    |                                                                          |                                                                    |  |  |
| PreF-bAb: ≥2-fold Rise-Day 29(n=44,43,47,45,44,56)  | 93.2 (81.3 to 98.6)                                                      | 1.8 (0.0 to 9.6)                                                   |  |  |
| PreF-bAb: ≥4-fold Rise-Day 29(n=44,43,47,45,44,56)  | 75.0 (59.7 to 86.8)                                                      | 1.8 (0.0 to 9.6)                                                   |  |  |
| PreF-bAb: ≥2-fold Rise-Day 57(n=46,39,44,42,45,58)  | 84.4 (70.5 to 93.5)                                                      | 1.7 (0.0 to 9.2)                                                   |  |  |
| PreF-bAb: ≥4-fold Rise-Day 57(n=46,39,44,42,45,58)  | 57.8 (42.2 to 72.3)                                                      | 1.7 (0.0 to 9.2)                                                   |  |  |
| PreF-bAb: ≥2-fold Rise-Day 85(n=44,42,46,45,43,55)  | 86.0 (72.1 to 94.7)                                                      | 1.8 (0.0 to 9.7)                                                   |  |  |
| PreF-bAb: ≥4-fold Rise-Day 85(n=44,42,46,45,43,55)  | 58.1 (42.1 to 73.0)                                                      | 1.8 (0.0 to 9.7)                                                   |  |  |
| PreF-bAb: ≥2-fold Rise-Day 169(n=43,42,44,44,44,55) | 63.6 (47.8 to 77.6)                                                      | 3.6 (0.4 to 12.5)                                                  |  |  |
| PreF-bAb: ≥4-fold Rise-Day 169(n=43,42,44,44,44,55) | 29.5 (16.8 to 45.2)                                                      | 3.6 (0.4 to 12.5)                                                  |  |  |
| PreF-bAb: ≥2-fold Rise-Day 365(n=38,33,36,41,40,49) | 55.0 (38.5 to 70.7)                                                      | 14.3 (5.9 to 27.2)                                                 |  |  |
| PreF-bAb: ≥4-fold Rise-Day 365(n=38,33,36,41,40,49) | 17.5 (7.3 to 32.8)                                                       | 10.2 (3.4 to 22.2)                                                 |  |  |
| PostF-bAb: ≥2-fold Rise-Day 29(n=44,43,47,45,44,56) | 93.2 (81.3 to 98.6)                                                      | 1.8 (0.0 to 9.6)                                                   |  |  |
| PostF-bAb: ≥4-fold Rise-Day 29(n=44,43,47,45,44,56) | 54.5 (38.8 to 69.6)                                                      | 1.8 (0.0 to 9.6)                                                   |  |  |
| PostF-bAb: ≥2-fold Rise-Day 57(n=46,39,44,42,45,58) | 82.2 (67.9 to 92.0)                                                      | 1.7 (0.0 to 9.2)                                                   |  |  |
| PostF-bAb: ≥4-fold Rise-Day 57(n=46,39,44,42,45,58) | 40.0 (25.7 to 55.7)                                                      | 1.7 (0.0 to 9.2)                                                   |  |  |
| PostF-bAb: ≥2-fold Rise-Day 85(n=44,42,46,45,43,55) | 74.4 (58.8 to 86.5)                                                      | 1.8 (0.0 to 9.7)                                                   |  |  |
| PostF-bAb: ≥4-fold Rise-Day 85(n=44,42,46,45,43,55) | 25.6 (13.5 to 41.2)                                                      | 1.8 (0.0 to 9.7)                                                   |  |  |

|                                                     |                     |                    |  |  |
|-----------------------------------------------------|---------------------|--------------------|--|--|
| PostF-bAb: ≥2-fold Rise-Day 169(n=43,42,44,44,44,55 | 45.5 (30.4 to 61.2) | 3.6 (0.4 to 12.5)  |  |  |
| PostF-bAb: ≥4-fold Rise-Day 169(n=43,42,44,44,44,55 | 9.1 (2.5 to 21.7)   | 1.8 (0.0 to 9.7)   |  |  |
| PostF-bAb: ≥2-fold Rise-Day 365(n=38,33,36,41,40,49 | 22.5 (10.8 to 38.5) | 14.3 (5.9 to 27.2) |  |  |
| PostF-bAb: ≥4-fold Rise-Day 365(n=38,33,36,41,40,49 | 5.0 (0.6 to 16.9)   | 6.1 (1.3 to 16.9)  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with ≥2-fold and ≥4-fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Japanese Adults Cohorts

|                 |                                                                                                                                                                      |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with ≥2-fold and ≥4-fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Japanese Adults Cohorts <sup>[49]</sup> |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, and 169

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                        | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |  |  |
|-----------------------------------------|------------------------------------------------------|----------------------------------------------------------------|--|--|
| Subject group type                      | Reporting group                                      | Reporting group                                                |  |  |
| Number of subjects analysed             | 20                                                   | 4                                                              |  |  |
| Units: percentage of participants       |                                                      |                                                                |  |  |
| number (confidence interval 95%)        |                                                      |                                                                |  |  |
| PreF-bAb: ≥2-fold Rise- Day 29 (n=20,4) | 100.0 (83.2 to 100.0)                                | 0.0 (0.0 to 60.2)                                              |  |  |
| PreF-bAb: ≥4-fold Rise- Day 29 (n=20,4) | 90.0 (68.3 to 98.8)                                  | 0.0 (0.0 to 60.2)                                              |  |  |
| PreF-bAb: ≥2-fold Rise- Day 57 (n=20,4) | 100.0 (83.2 to 100.0)                                | 0.0 (0.0 to 60.2)                                              |  |  |
| PreF-bAb: ≥4-fold Rise- Day 57 (n=20,4) | 85.0 (62.1 to 96.8)                                  | 0.0 (0.0 to 60.2)                                              |  |  |
| PreF-bAb: ≥2-fold Rise- Day 85 (n=19,4) | 94.7 (74.0 to 99.9)                                  | 0.0 (0.0 to 60.2)                                              |  |  |
| PreF-bAb: ≥4-fold Rise- Day 85 (n=19,4) | 68.4 (43.4 to 87.4)                                  | 0.0 (0.0 to 60.2)                                              |  |  |

|                                                     |                     |                   |  |  |
|-----------------------------------------------------|---------------------|-------------------|--|--|
| PreF-bAb: $\geq 2$ -fold Rise- Day 169<br>(n=20,4)  | 85.0 (62.1 to 96.8) | 0.0 (0.0 to 60.2) |  |  |
| PreF-bAb: $\geq 4$ -fold Rise- Day 169<br>(n=20,4)  | 40.0 (19.1 to 63.9) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 2$ -fold Rise- Day 29<br>(n=20,4)  | 95.0 (75.1 to 99.9) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 4$ -fold Rise- Day 29<br>(n=20,4)  | 80.0 (56.3 to 94.3) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 2$ -fold Rise- Day 57<br>(n=20,4)  | 95.0 (75.1 to 99.9) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 4$ -fold Rise- Day 57<br>(n=20,4)  | 70.0 (45.7 to 88.1) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 2$ -fold Rise- Day 85<br>(n=19,4)  | 89.5 (66.9 to 98.7) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 4$ -fold Rise- Day 85<br>(n=19,4)  | 42.1 (20.3 to 66.5) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 2$ -fold Rise- Day 169<br>(n=20,4) | 75.0 (50.9 to 91.3) | 0.0 (0.0 to 60.2) |  |  |
| PostF-bAb: $\geq 4$ -fold Rise- Day 169<br>(n=20,4) | 30.0 (11.9 to 54.3) | 0.0 (0.0 to 60.2) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for WOCBP Cohorts

|                 |                                                                                                                                                                          |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for WOCBP Cohorts <sup>[50]</sup> |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Days 29, 57, 85, 113, 141, and 169

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                  | Cohort 12:<br>mRNA-1345<br>Dose F in<br>WOCBP (18 to<br>40 Years) | Cohort 13:<br>mRNA-1345<br>Dose E in<br>WOCBP (18 to<br>40 Years) | Cohort 14:<br>mRNA-1345<br>Dose A in<br>WOCBP (18 to<br>40 Years) | Single Injection<br>Placebo in<br>WOCBP (18 to<br>40 Years) |
|-----------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| Subject group type                | Reporting group                                                   | Reporting group                                                   | Reporting group                                                   | Reporting group                                             |
| Number of subjects analysed       | 49                                                                | 46                                                                | 42                                                                | 28                                                          |
| Units: percentage of participants |                                                                   |                                                                   |                                                                   |                                                             |
| number (confidence interval 95%)  |                                                                   |                                                                   |                                                                   |                                                             |

|                                                           |                     |                     |                       |                   |
|-----------------------------------------------------------|---------------------|---------------------|-----------------------|-------------------|
| PreF-bAb: $\geq 2$ -fold Rise-Day 29<br>(n=49,46,41,28)   | 98.0 (89.1 to 99.9) | 97.8 (88.5 to 99.9) | 97.6 (87.1 to 99.9)   | 3.6 (0.1 to 18.3) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 29<br>(n=49,46,41,28)   | 83.7 (70.3 to 92.7) | 89.1 (76.4 to 96.4) | 85.4 (70.8 to 94.4)   | 0.0 (0.0 to 12.3) |
| PreF-bAb: $\geq 2$ -fold Rise-Day 57<br>(n=45,45,42,28)   | 93.3 (81.7 to 98.6) | 97.8 (88.2 to 99.9) | 100.0 (91.6 to 100.0) | 3.6 (0.1 to 18.3) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 57<br>(n=45,45,42,28)   | 80.0 (65.4 to 90.4) | 82.2 (67.9 to 92.0) | 85.7 (71.5 to 94.6)   | 0.0 (0.0 to 12.3) |
| PreF-bAb: $\geq 2$ -fold Rise-Day 85<br>(n=43,41,37,24)   | 88.4 (74.9 to 96.1) | 97.6 (87.1 to 99.9) | 97.3 (85.8 to 99.9)   | 8.3 (1.0 to 27.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 85<br>(n=43,41,37,24)   | 65.1 (49.1 to 79.0) | 82.9 (67.9 to 92.8) | 73.0 (55.9 to 86.2)   | 0.0 (0.0 to 14.2) |
| PreF-bAb: $\geq 2$ -fold Rise-Day 113<br>(n=44,43,37,25)  | 90.9 (78.3 to 97.5) | 93.0 (80.9 to 98.5) | 91.9 (78.1 to 98.3)   | 8.0 (1.0 to 26.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 113<br>(n=44,43,37,25)  | 52.3 (36.7 to 67.5) | 69.8 (53.9 to 82.8) | 62.2 (44.8 to 77.5)   | 4.0 (0.1 to 20.4) |
| PreF-bAb: $\geq 2$ -fold Rise-Day 141<br>(n=40,42,36,24)  | 82.5 (67.2 to 92.7) | 97.6 (87.4 to 99.9) | 94.4 (81.3 to 99.3)   | 8.3 (1.0 to 27.0) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 141<br>(n=40,42,36,24)  | 45.0 (29.3 to 61.5) | 66.7 (50.5 to 80.4) | 55.6 (38.1 to 72.1)   | 4.2 (0.1 to 21.1) |
| PreF-bAb: $\geq 2$ -fold Rise-Day 169<br>(n=41,43,34,23)  | 78.0 (62.4 to 89.4) | 93.0 (80.9 to 98.5) | 91.2 (76.3 to 98.1)   | 4.3 (0.1 to 21.9) |
| PreF-bAb: $\geq 4$ -fold Rise-Day 169<br>(n=41,43,34,23)  | 41.5 (26.3 to 57.9) | 55.8 (39.9 to 70.9) | 55.9 (37.9 to 72.8)   | 0.0 (0.0 to 14.8) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 98.0 (89.1 to 99.9) | 95.7 (85.2 to 99.5) | 95.1 (83.5 to 99.4)   | 0.0 (0.0 to 12.3) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 29<br>(n=49,46,41,28)  | 73.5 (58.9 to 85.1) | 82.6 (68.6 to 92.2) | 82.9 (67.9 to 92.8)   | 0.0 (0.0 to 12.3) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 93.3 (81.7 to 98.6) | 88.9 (75.9 to 96.3) | 95.2 (83.8 to 99.4)   | 3.6 (0.1 to 18.3) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 57<br>(n=45,45,42,28)  | 66.7 (51.0 to 80.0) | 66.7 (51.0 to 80.0) | 76.2 (60.5 to 87.9)   | 0.0 (0.0 to 12.3) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 86.0 (72.1 to 94.7) | 87.8 (73.8 to 95.9) | 91.9 (78.1 to 98.3)   | 0.0 (0.0 to 14.2) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 85<br>(n=43,41,37,24)  | 51.2 (35.5 to 66.7) | 53.7 (37.4 to 69.3) | 54.1 (36.9 to 70.5)   | 0.0 (0.0 to 14.2) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 113<br>(n=44,43,37,25) | 90.9 (78.3 to 97.5) | 83.7 (69.3 to 93.2) | 86.5 (71.2 to 95.5)   | 8.0 (1.0 to 26.0) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 113<br>(n=44,43,37,25) | 43.2 (28.3 to 59.0) | 55.8 (39.9 to 70.9) | 48.6 (31.9 to 65.6)   | 4.0 (0.1 to 20.4) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 141<br>(n=40,42,36,24) | 80.0 (64.4 to 90.9) | 85.7 (71.5 to 94.6) | 80.6 (64.0 to 91.8)   | 4.2 (0.1 to 21.1) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 141<br>(n=40,42,36,24) | 32.5 (18.6 to 49.1) | 38.1 (23.6 to 54.4) | 36.1 (20.8 to 53.8)   | 0.0 (0.0 to 14.2) |
| PostF-bAb: $\geq 2$ -fold Rise-Day 169<br>(n=41,43,34,23) | 73.2 (57.1 to 85.2) | 79.1 (64.0 to 90.0) | 79.4 (62.1 to 91.3)   | 0.0 (0.0 to 14.8) |
| PostF-bAb: $\geq 4$ -fold Rise-Day 169<br>(n=41,43,34,23) | 31.7 (18.1 to 48.1) | 27.9 (15.3 to 43.7) | 26.5 (12.9 to 44.4)   | 0.0 (0.0 to 14.8) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Children Cohorts

|                 |                                                                                                                                                                             |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with $\geq 2$ -fold and $\geq 4$ -fold Increases in Serum Binding Abs (PreF and PostF) Titers from Baseline for Children Cohorts <sup>[51]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**End point description:**

PP Set included all FAS participants (all randomized participants who received any study injection, had baseline data for those analyses that require baseline data, and had at least 1 postinjection assessment for the analysis endpoint) who a) complied with the injection schedule, b) complied with the timing of immunogenicity blood sampling in order to have baseline and postinjection results available for at least 1 assay component corresponding to the immunogenicity analysis objective, and c) had no major protocol violations that impacted immune response during the period corresponding to the immunogenicity analysis objective. Participants were included in the treatment arm to which they were randomized. 'n' = participants evaluable for specified categories.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

**End point timeframe:**

Days 29, 85, and 141

**Notes:**

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is descriptive in nature.

| End point values                                      | Cohort 5:<br>mRNA-1345<br>Dose D in<br>Children (12 to<br>59 Months) | Cohort 6:<br>mRNA-1345<br>Dose G in<br>Children (12 to<br>59 Months) | Three Injection<br>Placebo in<br>Children (12 to<br>59 Months) |  |
|-------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------|--|
| Subject group type                                    | Reporting group                                                      | Reporting group                                                      | Reporting group                                                |  |
| Number of subjects analysed                           | 14                                                                   | 11                                                                   | 11                                                             |  |
| Units: percentage of participants                     |                                                                      |                                                                      |                                                                |  |
| number (confidence interval 95%)                      |                                                                      |                                                                      |                                                                |  |
| PreF-bAb: $\geq 2$ -fold Rise-Day 29<br>(n=14,11,11)  | 100.0 (76.8 to<br>100.0)                                             | 90.9 (58.7 to<br>99.8)                                               | 27.3 (6.0 to<br>61.0)                                          |  |
| PreF-bAb: $\geq 4$ -fold Rise-Day 29<br>(n=14,11,11)  | 92.9 (66.1 to<br>99.8)                                               | 90.9 (58.7 to<br>99.8)                                               | 18.2 (2.3 to<br>51.8)                                          |  |
| PreF-bAb: $\geq 2$ -fold Rise-Day 85<br>(n=5,9,4)     | 100.0 (47.8 to<br>100.0)                                             | 88.9 (51.8 to<br>99.7)                                               | 0.0 (0.0 to<br>60.2)                                           |  |
| PreF-bAb: $\geq 4$ -fold Rise-Day 85<br>(n=5,9,4)     | 100.0 (47.8 to<br>100.0)                                             | 77.8 (40.0 to<br>97.2)                                               | 0.0 (0.0 to<br>60.2)                                           |  |
| PreF-bAb: $\geq 2$ -fold Rise-Day 141<br>(n=4,5,5)    | 100.0 (39.8 to<br>100.0)                                             | 100.0 (47.8 to<br>100.0)                                             | 40.0 (5.3 to<br>85.3)                                          |  |
| PreF-bAb: $\geq 4$ -fold Rise-Day 141<br>(n=4,5,5)    | 100.0 (39.8 to<br>100.0)                                             | 100.0 (47.8 to<br>100.0)                                             | 40.0 (5.3 to<br>85.3)                                          |  |
| PostF-bAb: $\geq 2$ -fold Rise-Day 29<br>(n=14,11,11) | 100.0 (76.8 to<br>100.0)                                             | 90.9 (58.7 to<br>99.8)                                               | 27.3 (6.0 to<br>61.0)                                          |  |
| PostF-bAb: $\geq 4$ -fold Rise-Day 29<br>(n=14,11,11) | 92.9 (66.1 to<br>99.8)                                               | 72.7 (39.0 to<br>94.0)                                               | 18.2 (2.3 to<br>51.8)                                          |  |
| PostF-bAb: $\geq 2$ -fold Rise-Day 85<br>(n=5,9,4)    | 100.0 (47.8 to<br>100.0)                                             | 88.9 (51.8 to<br>99.7)                                               | 0.0 (0.0 to<br>60.2)                                           |  |
| PostF-bAb: $\geq 4$ -fold Rise-Day 85<br>(n=5,9,4)    | 80.0 (28.4 to<br>99.5)                                               | 66.7 (29.9 to<br>92.5)                                               | 0.0 (0.0 to<br>60.2)                                           |  |
| PostF-bAb: $\geq 2$ -fold Rise-Day 141<br>(n=4,5,5)   | 100.0 (39.8 to<br>100.0)                                             | 80.0 (28.4 to<br>99.5)                                               | 20.0 (0.5 to<br>71.6)                                          |  |
| PostF-bAb: $\geq 4$ -fold Rise-Day 141<br>(n=4,5,5)   | 75.0 (19.4 to<br>99.4)                                               | 40.0 (5.3 to<br>85.3)                                                | 0.0 (0.0 to<br>52.2)                                           |  |

**Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 1 through Day 1095 (end of study)

Adverse event reporting additional description:

Safety Set included all randomized participants who received any study injection. Participants were included in the treatment arm corresponding to the study drug they actually received. Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were not considered AEs unless they were serious.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 25.0 |
|--------------------|------|

### Reporting groups

|                       |                                                    |
|-----------------------|----------------------------------------------------|
| Reporting group title | Single Injection Placebo in WOCBP (18 to 40 Years) |
|-----------------------|----------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                      |
|-----------------------|------------------------------------------------------|
| Reporting group title | Cohort 15: mRNA-1345 Dose B in Japanese Older Adults |
|-----------------------|------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                       |                                                               |
|-----------------------|---------------------------------------------------------------|
| Reporting group title | Cohort 2: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|-----------------------|---------------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose B of mRNA-1345 on Day 1.

|                       |                                                               |
|-----------------------|---------------------------------------------------------------|
| Reporting group title | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) |
|-----------------------|---------------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose C of mRNA-1345 on Day 1.

|                       |                                                        |
|-----------------------|--------------------------------------------------------|
| Reporting group title | Two Injection Placebo in Older Adults (After 1st Dose) |
|-----------------------|--------------------------------------------------------|

Reporting group description:

Participants received 1 injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                                      |
|-----------------------|----------------------------------------------------------------------|
| Reporting group title | Single Injection Placebo in Japanese Older Adults ( $\geq 60$ Years) |
|-----------------------|----------------------------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Single Injection Placebo in Younger Adults (18 to 49 Years) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received a single injection of mRNA-1345 matching-placebo on Day 1.

|                       |                                                               |
|-----------------------|---------------------------------------------------------------|
| Reporting group title | Cohort 1: mRNA-1345 Dose A in Younger Adults (18 to 49 Years) |
|-----------------------|---------------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose A of mRNA-1345 on Day 1.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 8: mRNA-1345 Dose B in Older Adults (After 1st Dose) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose B of mRNA-1345 on Day 1.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 9: mRNA-1345 Dose C in Older Adults (After 1st Dose) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose C of mRNA-1345 on Day 1.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 11: mRNA-1345 Dose F in Older Adults (After 1st Dose) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose F of mRNA-1345 on Day 1.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 7: mRNA-1345 Dose A in Older Adults (After 1st Dose) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose A of mRNA-1345 on Day 1.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 10: mRNA-1345 Dose E in Older Adults (After 1st Dose) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose E of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose F of mRNA-1345 on Day 1.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 9: mRNA-1345 Dose C in Older Adults (After Month 12) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose C of mRNA-1345 approximately 12 months later.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 8: mRNA-1345 Dose B in Older Adults (After Month 12) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose B of mRNA-1345 approximately 12 months later.

|                       |                                                             |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Cohort 7: mRNA-1345 Dose A in Older Adults (After Month 12) |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose A of mRNA-1345 approximately 12 months later.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose E of mRNA-1345 on Day 1.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a single injection of Dose A of mRNA-1345 on Day 1.

|                       |                                                            |
|-----------------------|------------------------------------------------------------|
| Reporting group title | Three Injection Placebo in Younger Adults (18 to 49 Years) |
|-----------------------|------------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections, 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.

|                       |                                                               |
|-----------------------|---------------------------------------------------------------|
| Reporting group title | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|-----------------------|---------------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections, 1 injection of Dose B of mRNA-1345 per day on Day 1, Day 57, and Day 113.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Three Injection Placebo in Children (12 to 59 Months) |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections, 1 injection of mRNA-1345 matching-placebo per day on Day 1, Day 57, and Day 113.

|                       |                                                          |
|-----------------------|----------------------------------------------------------|
| Reporting group title | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months) |
|-----------------------|----------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections, 1 injection of Dose G of mRNA-1345 per day on Day 1, Day 57, and Day 113.

|                       |                                                          |
|-----------------------|----------------------------------------------------------|
| Reporting group title | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months) |
|-----------------------|----------------------------------------------------------|

Reporting group description:

Participants received a total of 3 injections, 1 injection of Dose D of mRNA-1345 per day on Day 1, Day 57, and Day 113.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 11: mRNA-1345 Dose F in Older Adults (After Month 12) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose F of mRNA-1345 approximately 12 months later.

|                       |                                                        |
|-----------------------|--------------------------------------------------------|
| Reporting group title | Two Injection Placebo in Older Adults (After Month 12) |
|-----------------------|--------------------------------------------------------|

Reporting group description:

Participants received 1 injection of mRNA-1345 matching-placebo approximately 12 months later.

|                       |                                                              |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Cohort 10: mRNA-1345 Dose E in Older Adults (After Month 12) |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

Participants received 1 injection of Dose E of mRNA-1345 approximately 12 months later.

|                       |                                                       |
|-----------------------|-------------------------------------------------------|
| Reporting group title | Older Adult Cohorts: After Month 24: mRNA-1345 Dose A |
|-----------------------|-------------------------------------------------------|

Reporting group description:

Participants received second booster injection of Dose A of mRNA-1345 at Month 24.

| Serious adverse events                                                 | Single Injection<br>Placebo in WOCBP<br>(18 to 40 Years) | Cohort 15: mRNA-<br>1345 Dose B in<br>Japanese Older<br>Adults | Cohort 2: mRNA-<br>1345 Dose B in<br>Younger Adults (18<br>to 49 Years) |
|------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|
| Total subjects affected by serious<br>adverse events                   |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| number of deaths (all causes)                                          | 0                                                        | 0                                                              | 0                                                                       |
| number of deaths resulting from<br>adverse events                      |                                                          |                                                                |                                                                         |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps) |                                                          |                                                                |                                                                         |
| Bone sarcoma                                                           |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| Squamous cell carcinoma                                                |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| Injury, poisoning and procedural<br>complications                      |                                                          |                                                                |                                                                         |
| Concussion                                                             |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| Clavicle fracture                                                      |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| Gun shot wound                                                         |                                                          |                                                                |                                                                         |
| subjects affected / exposed                                            | 0 / 30 (0.00%)                                           | 0 / 21 (0.00%)                                                 | 0 / 20 (0.00%)                                                          |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                    | 0 / 0                                                          | 0 / 0                                                                   |
| Periprosthetic fracture                                                |                                                          |                                                                |                                                                         |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                    |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                 |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|                               |                 |               |                  |
|-------------------------------|-----------------|---------------|------------------|
| <b>Serious adverse events</b> | Cohort 4: mRNA- | Two Injection | Single Injection |
|-------------------------------|-----------------|---------------|------------------|

|                                                                        | 1345 Dose C in<br>Younger Adults (18<br>to 49 Years) | Placebo in Older<br>Adults (After 1st<br>Dose) | Placebo in Japanese<br>Older Adults (≥ 60<br>Years) |
|------------------------------------------------------------------------|------------------------------------------------------|------------------------------------------------|-----------------------------------------------------|
| Total subjects affected by serious<br>adverse events                   |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 1 / 59 (1.69%)                                 | 0 / 4 (0.00%)                                       |
| number of deaths (all causes)                                          | 0                                                    | 0                                              | 0                                                   |
| number of deaths resulting from<br>adverse events                      |                                                      |                                                |                                                     |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps) |                                                      |                                                |                                                     |
| Bone sarcoma                                                           |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Squamous cell carcinoma                                                |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Injury, poisoning and procedural<br>complications                      |                                                      |                                                |                                                     |
| Concussion                                                             |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Clavicle fracture                                                      |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Gun shot wound                                                         |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Periprosthetic fracture                                                |                                                      |                                                |                                                     |
| subjects affected / exposed                                            | 0 / 20 (0.00%)                                       | 0 / 59 (0.00%)                                 | 0 / 4 (0.00%)                                       |
| occurrences causally related to<br>treatment / all                     | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| deaths causally related to<br>treatment / all                          | 0 / 0                                                | 0 / 0                                          | 0 / 0                                               |
| Rib fracture                                                           |                                                      |                                                |                                                     |

|                                                 |                |                |               |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Pelvic fracture                                 |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Road traffic accident                           |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Tibia fracture                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Cardiac disorders                               |                |                |               |
| Bradycardia                                     |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Coronary artery disease                         |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Cardiac arrest                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Sinus bradycardia                               |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Ventricular tachycardia                         |                |                |               |

|                                                 |                |                |               |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Surgical and medical procedures                 |                |                |               |
| Hospitalisation                                 |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Nervous system disorders                        |                |                |               |
| Headache                                        |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Cerebrovascular accident                        |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Subarachnoid haemorrhage                        |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Vertebral artery occlusion                      |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Transient ischaemic attack                      |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Eye disorders                                   |                |                |               |
| Papilloedema                                    |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |

|                                                 |                |                |               |
|-------------------------------------------------|----------------|----------------|---------------|
| Gastrointestinal disorders                      |                |                |               |
| Pancreatitis acute                              |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Upper gastrointestinal haemorrhage              |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Reproductive system and breast disorders        |                |                |               |
| Pelvic organ prolapse                           |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Musculoskeletal and connective tissue disorders |                |                |               |
| Arthropathy                                     |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Osteoarthritis                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Spinal stenosis                                 |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Infections and infestations                     |                |                |               |
| Appendicitis                                    |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| COVID-19                                        |                |                |               |

|                                                 |                |                |               |
|-------------------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Appendicitis perforated                         |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Intervertebral discitis                         |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Diverticulitis                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Localised infection                             |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Pneumonia                                       |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |
| Metabolism and nutrition disorders              |                |                |               |
| Type 2 diabetes mellitus                        |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0         |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0         |

| Serious adverse events                            | Single Injection<br>Placebo in Younger<br>Adults (18 to 49<br>Years) | Cohort 1: mRNA-<br>1345 Dose A in<br>Younger Adults (18<br>to 49 Years) | Cohort 8: mRNA-<br>1345 Dose B in<br>Older Adults (After<br>1st Dose) |
|---------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                                      |                                                                         |                                                                       |
| subjects affected / exposed                       | 0 / 15 (0.00%)                                                       | 0 / 19 (0.00%)                                                          | 0 / 48 (0.00%)                                                        |
| number of deaths (all causes)                     | 0                                                                    | 0                                                                       | 0                                                                     |

|                                                                     |                |                |                |
|---------------------------------------------------------------------|----------------|----------------|----------------|
| number of deaths resulting from adverse events                      |                |                |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Bone sarcoma                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Concussion                                                          |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Clavicle fracture                                                   |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Gun shot wound                                                      |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Periprosthetic fracture                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                                     |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Cohort 9: mRNA-1345 Dose C in Older Adults (After 1st Dose) | Cohort 11: mRNA-1345 Dose F in Older Adults (After 1st Dose) | Cohort 7: mRNA-1345 Dose A in Older Adults (After 1st Dose) |
|---------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                             |                                                              |                                                             |
| subjects affected / exposed                       | 1 / 48 (2.08%)                                              | 5 / 48 (10.42%)                                              | 4 / 47 (8.51%)                                              |
| number of deaths (all causes)                     | 0                                                           | 0                                                            | 0                                                           |

|                                                                     |                |                |                |
|---------------------------------------------------------------------|----------------|----------------|----------------|
| number of deaths resulting from adverse events                      |                |                |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Bone sarcoma                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Concussion                                                          |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Clavicle fracture                                                   |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Gun shot wound                                                      |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Periprosthetic fracture                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                                     |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 48 (2.08%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Cohort 10: mRNA-1345 Dose E in Older Adults (After 1st Dose) | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) | Cohort 9: mRNA-1345 Dose C in Older Adults (After Month 12) |
|---------------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                              |                                                       |                                                             |
| subjects affected / exposed                       | 3 / 48 (6.25%)                                               | 1 / 51 (1.96%)                                        | 0 / 19 (0.00%)                                              |
| number of deaths (all causes)                     | 0                                                            | 0                                                     | 0                                                           |

|                                                                     |                |                |                |
|---------------------------------------------------------------------|----------------|----------------|----------------|
| number of deaths resulting from adverse events                      |                |                |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Bone sarcoma                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Concussion                                                          |                |                |                |
| subjects affected / exposed                                         | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Clavicle fracture                                                   |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Gun shot wound                                                      |                |                |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Periprosthetic fracture                                             |                |                |                |
| subjects affected / exposed                                         | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                                        |                |                |                |
| subjects affected / exposed                                         | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                                     |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 1 / 51 (1.96%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Cohort 8: mRNA-1345 Dose B in Older Adults (After Month 12) | Cohort 7: mRNA-1345 Dose A in Older Adults (After Month 12) | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
|---------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                             |                                                             |                                                       |
| subjects affected / exposed                       | 1 / 18 (5.56%)                                              | 1 / 18 (5.56%)                                              | 0 / 49 (0.00%)                                        |
| number of deaths (all causes)                     | 0                                                           | 0                                                           | 0                                                     |

|                                                                     |                |                |                |
|---------------------------------------------------------------------|----------------|----------------|----------------|
| number of deaths resulting from adverse events                      |                |                |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Bone sarcoma                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Concussion                                                          |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Clavicle fracture                                                   |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Gun shot wound                                                      |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Periprosthetic fracture                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                                     |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 1 / 18 (5.56%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 1 / 18 (5.56%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) | Three Injection Placebo in Younger Adults (18 to 49 Years) | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|---------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                       |                                                            |                                                               |
| subjects affected / exposed                       | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 0 / 20 (0.00%)                                                |
| number of deaths (all causes)                     | 0                                                     | 0                                                          | 0                                                             |

|                                                                     |                |               |                |
|---------------------------------------------------------------------|----------------|---------------|----------------|
| number of deaths resulting from adverse events                      |                |               |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |               |                |
| Bone sarcoma                                                        |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Squamous cell carcinoma                                             |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |               |                |
| Concussion                                                          |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Clavicle fracture                                                   |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Gun shot wound                                                      |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Periprosthetic fracture                                             |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Rib fracture                                                        |                |               |                |
| subjects affected / exposed                                         | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0         | 0 / 0          |
| Pelvic fracture                                                     |                |               |                |

|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Road traffic accident                           |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Tibia fracture                                  |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Cardiac disorders                               |                |               |                |
| Bradycardia                                     |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Coronary artery disease                         |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Cardiac arrest                                  |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Sinus bradycardia                               |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Ventricular tachycardia                         |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Surgical and medical procedures                 |                |               |                |

|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| Hospitalisation                                 |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Nervous system disorders                        |                |               |                |
| Headache                                        |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Cerebrovascular accident                        |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Subarachnoid haemorrhage                        |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Vertebral artery occlusion                      |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Transient ischaemic attack                      |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Eye disorders                                   |                |               |                |
| Papilloedema                                    |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Gastrointestinal disorders                      |                |               |                |
| Pancreatitis acute                              |                |               |                |

|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Reproductive system and breast disorders        |                |               |                |
| Pelvic organ prolapse                           |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |               |                |
| Arthropathy                                     |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Osteoarthritis                                  |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Spinal stenosis                                 |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Infections and infestations                     |                |               |                |
| Appendicitis                                    |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| COVID-19                                        |                |               |                |

|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Appendicitis perforated                         |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Intervertebral discitis                         |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Diverticulitis                                  |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Localised infection                             |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Pneumonia                                       |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |
| Metabolism and nutrition disorders              |                |               |                |
| Type 2 diabetes mellitus                        |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0         | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0          |

| Serious adverse events                            | Three Injection Placebo in Children (12 to 59 Months) | Cohort 6: mRNA-1345 Dose G in Children (12 to 59 Months) | Cohort 5: mRNA-1345 Dose D in Children (12 to 59 Months) |
|---------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                       |                                                          |                                                          |
| subjects affected / exposed                       | 0 / 15 (0.00%)                                        | 0 / 15 (0.00%)                                           | 0 / 15 (0.00%)                                           |
| number of deaths (all causes)                     | 0                                                     | 0                                                        | 0                                                        |

|                                                                     |                |                |                |
|---------------------------------------------------------------------|----------------|----------------|----------------|
| number of deaths resulting from adverse events                      |                |                |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                |                |
| Bone sarcoma                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Squamous cell carcinoma                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                |                |
| Concussion                                                          |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Clavicle fracture                                                   |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Gun shot wound                                                      |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Periprosthetic fracture                                             |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Rib fracture                                                        |                |                |                |
| subjects affected / exposed                                         | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0          | 0 / 0          |
| Pelvic fracture                                                     |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tibia fracture                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Bradycardia                                     |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Coronary artery disease                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Sinus bradycardia                               |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Ventricular tachycardia                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Surgical and medical procedures                 |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Hospitalisation                                 |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Headache                                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cerebrovascular accident                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vertebral artery occlusion                      |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transient ischaemic attack                      |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                |                |                |
| Papilloedema                                    |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Pancreatitis acute                              |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Reproductive system and breast disorders        |                |                |                |
| Pelvic organ prolapse                           |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthropathy                                     |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Spinal stenosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| COVID-19                                        |                |                |                |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Appendicitis perforated                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intervertebral discitis                         |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Diverticulitis                                  |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Localised infection                             |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia                                       |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Type 2 diabetes mellitus                        |                |                |                |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

| Serious adverse events                            | Cohort 11: mRNA-1345 Dose F in Older Adults (After Month 12) | Two Injection Placebo in Older Adults (After Month 12) | Cohort 10: mRNA-1345 Dose E in Older Adults (After Month 12) |
|---------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------|
| Total subjects affected by serious adverse events |                                                              |                                                        |                                                              |
| subjects affected / exposed                       | 1 / 22 (4.55%)                                               | 7 / 148 (4.73%)                                        | 2 / 22 (9.09%)                                               |
| number of deaths (all causes)                     | 0                                                            | 3                                                      | 0                                                            |

|                                                                     |                |                 |                |
|---------------------------------------------------------------------|----------------|-----------------|----------------|
| number of deaths resulting from adverse events                      |                |                 |                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                 |                |
| Bone sarcoma                                                        |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 1           | 0 / 0          |
| Squamous cell carcinoma                                             |                |                 |                |
| subjects affected / exposed                                         | 1 / 22 (4.55%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications                      |                |                 |                |
| Concussion                                                          |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Clavicle fracture                                                   |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Gun shot wound                                                      |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Periprosthetic fracture                                             |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Rib fracture                                                        |                |                 |                |
| subjects affected / exposed                                         | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0           | 0 / 0          |
| Pelvic fracture                                                     |                |                 |                |

|                                                 |                |                 |                |
|-------------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Road traffic accident                           |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1           | 0 / 0          |
| Tibia fracture                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                |                 |                |
| Bradycardia                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Coronary artery disease                         |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cardiac arrest                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1           | 0 / 0          |
| Sinus bradycardia                               |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Ventricular tachycardia                         |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Surgical and medical procedures                 |                |                 |                |

|                                                 |                |                 |                |
|-------------------------------------------------|----------------|-----------------|----------------|
| Hospitalisation                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                |                 |                |
| Headache                                        |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cerebrovascular accident                        |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Subarachnoid haemorrhage                        |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Vertebral artery occlusion                      |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Transient ischaemic attack                      |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                |                 |                |
| Papilloedema                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                |                 |                |
| Pancreatitis acute                              |                |                 |                |

|                                                 |                |                 |                |
|-------------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Upper gastrointestinal haemorrhage              |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Reproductive system and breast disorders        |                |                 |                |
| Pelvic organ prolapse                           |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                 |                |
| Arthropathy                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Osteoarthritis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Spinal stenosis                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                |                 |                |
| Appendicitis                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| COVID-19                                        |                |                 |                |

|                                                 |                |                 |                |
|-------------------------------------------------|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Appendicitis perforated                         |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Intervertebral discitis                         |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Diverticulitis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Localised infection                             |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pneumonia                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Metabolism and nutrition disorders              |                |                 |                |
| Type 2 diabetes mellitus                        |                |                 |                |
| subjects affected / exposed                     | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

|                                                   |                                                             |  |  |
|---------------------------------------------------|-------------------------------------------------------------|--|--|
| <b>Serious adverse events</b>                     | Older Adult Cohorts:<br>After Month 24:<br>mRNA-1345 Dose A |  |  |
| Total subjects affected by serious adverse events |                                                             |  |  |
| subjects affected / exposed                       | 5 / 109 (4.59%)                                             |  |  |
| number of deaths (all causes)                     | 1                                                           |  |  |
| number of deaths resulting from                   |                                                             |  |  |

|                                                                     |                 |  |  |
|---------------------------------------------------------------------|-----------------|--|--|
| adverse events                                                      |                 |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |  |  |
| Bone sarcoma                                                        |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Squamous cell carcinoma                                             |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Injury, poisoning and procedural complications                      |                 |  |  |
| Concussion                                                          |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Clavicle fracture                                                   |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Gun shot wound                                                      |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Periprosthetic fracture                                             |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Rib fracture                                                        |                 |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all                     | 0 / 0           |  |  |
| deaths causally related to treatment / all                          | 0 / 0           |  |  |
| Pelvic fracture                                                     |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Road traffic accident                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Tibia fracture                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac disorders                               |                 |  |  |
| Bradycardia                                     |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Coronary artery disease                         |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cardiac arrest                                  |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 1           |  |  |
| Sinus bradycardia                               |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Ventricular tachycardia                         |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Surgical and medical procedures                 |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Hospitalisation                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Nervous system disorders                        |                 |  |  |
| Headache                                        |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Cerebrovascular accident                        |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Subarachnoid haemorrhage                        |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Vertebral artery occlusion                      |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Transient ischaemic attack                      |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Eye disorders                                   |                 |  |  |
| Papilloedema                                    |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Gastrointestinal disorders                      |                 |  |  |
| Pancreatitis acute                              |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Upper gastrointestinal haemorrhage              |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Reproductive system and breast disorders        |                 |  |  |
| Pelvic organ prolapse                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Arthropathy                                     |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Osteoarthritis                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Spinal stenosis                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Infections and infestations                     |                 |  |  |
| Appendicitis                                    |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| COVID-19                                        |                 |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Appendicitis perforated                         |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Intervertebral discitis                         |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Diverticulitis                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Localised infection                             |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Pneumonia                                       |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |
| Metabolism and nutrition disorders              |                 |  |  |
| Type 2 diabetes mellitus                        |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences causally related to treatment / all | 0 / 1           |  |  |
| deaths causally related to treatment / all      | 0 / 0           |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Single Injection<br>Placebo in WOCBP<br>(18 to 40 Years)                                                                                                                              | Cohort 15: mRNA-<br>1345 Dose B in<br>Japanese Older<br>Adults                                                                                             | Cohort 2: mRNA-<br>1345 Dose B in<br>Younger Adults (18<br>to 49 Years)                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed                                                                                                                                                                                                                                                                                                                                                                                                                                             | 7 / 30 (23.33%)                                                                                                                                                                       | 1 / 21 (4.76%)                                                                                                                                             | 0 / 20 (0.00%)                                                                                                                  |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                    | 0 / 30 (0.00%)<br>0                                                                                                                                                                   | 0 / 21 (0.00%)<br>0                                                                                                                                        | 0 / 20 (0.00%)<br>0                                                                                                             |
| General disorders and administration<br>site conditions<br>Fatigue<br>subjects affected / exposed<br>occurrences (all)<br><br>Injection site erythema<br>subjects affected / exposed<br>occurrences (all)<br><br>Injection site pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Pyrexia<br>subjects affected / exposed<br>occurrences (all)<br><br>Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all) | 1 / 30 (3.33%)<br>1<br><br>0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0<br><br>0 / 20 (0.00%)<br>0<br><br>0 / 20 (0.00%)<br>0<br><br>0 / 20 (0.00%)<br>0<br><br>0 / 20 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)<br><br>Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                    | 0 / 30 (0.00%)<br>0<br><br>0 / 30 (0.00%)<br>0                                                                                                                                        | 0 / 21 (0.00%)<br>0<br><br>0 / 21 (0.00%)<br>0                                                                                                             | 0 / 20 (0.00%)<br>0<br><br>0 / 20 (0.00%)<br>0                                                                                  |
| Respiratory, thoracic and mediastinal<br>disorders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                       |                                                                                                                                                            |                                                                                                                                 |

|                                                                                                                                                                                                                                                                                                                                                                                                                                        |                |                |                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|----------------|
| Asthma<br>subjects affected / exposed<br>occurrences (all)<br><br>Bronchospasm<br>subjects affected / exposed<br>occurrences (all)<br><br>Cough<br>subjects affected / exposed<br>occurrences (all)<br><br>Dyspnoea<br>subjects affected / exposed<br>occurrences (all)<br><br>Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)<br><br>Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all) | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1              | 0              | 0              |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)<br><br>Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)<br><br>Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                            | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)<br><br>Attention deficit hyperactivity disorder<br>subjects affected / exposed<br>occurrences (all)<br><br>Oppositional defiant disorder<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                      | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
| Investigations<br>Blood pressure increased<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                         | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |
| Injury, poisoning and procedural complications<br>Concussion<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                       | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0              | 0              | 0              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Arthropod bite              |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Meniscus injury             |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Limb injury                 |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Radial head dislocation     |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Skin abrasion               |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Skin laceration             |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Upper limb fracture         |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Cardiac disorders           |                |                |                |
| Palpitations                |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Nervous system disorders    |                |                |                |
| Headache                    |                |                |                |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Migraine                    |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Morton's neuralgia          |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Sensory disturbance         |                |                |                |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Ear and labyrinth disorders                      |                     |                     |                     |
| Ear pain                                         |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Tympanic membrane perforation                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Vertigo                                          |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Gastrointestinal disorders                       |                     |                     |                     |
| Aphthous ulcer                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Gastrooesophageal reflux disease                 |                     |                     |                     |
| subjects affected / exposed                      | 1 / 30 (3.33%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Diarrhoea                                        |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Large intestine polyp                            |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Nausea                                           |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Teething                                         |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Tooth disorder                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Toothache                                        |                     |                     |                     |

|                                        |                |                |                |
|----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Vomiting                               |                |                |                |
| subjects affected / exposed            | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 1              | 0              | 0              |
| Skin and subcutaneous tissue disorders |                |                |                |
| Actinic keratosis                      |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Angioedema                             |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Dermatitis atopic                      |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Dermatitis contact                     |                |                |                |
| subjects affected / exposed            | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 1              | 0              | 0              |
| Ecchymosis                             |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Nail dystrophy                         |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Rash                                   |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Skin lesion                            |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Solar lentigo                          |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Splinter haemorrhages                  |                |                |                |
| subjects affected / exposed            | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Urticaria                                       |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Urticaria papular                               |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Endocrine disorders                             |                |                |                |
| Basedow's disease                               |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Hyperthyroidism                                 |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Hypothyroidism                                  |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Arthralgia                                      |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Arthritis                                       |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Musculoskeletal stiffness                       |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Back pain                                       |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Osteoarthritis                                  |                |                |                |
| subjects affected / exposed                     | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 1              | 0              | 0              |
| Osteoporosis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Trigger finger                                  |                |                |                |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Infections and infestations                      |                     |                     |                     |
| Acute sinusitis                                  |                     |                     |                     |
| subjects affected / exposed                      | 1 / 30 (3.33%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Adenovirus infection                             |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Appendicitis                                     |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Asymptomatic COVID-19                            |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Bordetella infection                             |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Bronchiolitis                                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Bronchitis                                       |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Coronavirus infection                            |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| COVID-19                                         |                     |                     |                     |
| subjects affected / exposed                      | 1 / 30 (3.33%)      | 1 / 21 (4.76%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 1                   | 1                   | 0                   |
| Ear infection                                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Croup infectious                                 |                     |                     |                     |
| subjects affected / exposed                      | 0 / 30 (0.00%)      | 0 / 21 (0.00%)      | 0 / 20 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Eye infection               |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Folliculitis                |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastroenteritis             |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Impetigo                    |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| HCoV-OC43 infection         |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Influenza                   |                |                |                |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Metapneumovirus infection   |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Nasopharyngitis             |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Onychomycosis               |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Oral fungal infection       |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Oral herpes                 |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Otitis media                |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                                                                             |                     |                     |                     |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Parainfluenzae virus infection<br>subjects affected / exposed<br>occurrences (all)          | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Otitis media acute<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Pharyngitis<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Pharyngitis streptococcal<br>subjects affected / exposed<br>occurrences (all)               | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Respiratory tract infection viral<br>subjects affected / exposed<br>occurrences (all)       | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Rhinovirus infection<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Sinusitis<br>subjects affected / exposed<br>occurrences (all)                               | 1 / 30 (3.33%)<br>1 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Tonsillitis<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)       | 1 / 30 (3.33%)<br>1 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 30 (0.00%)<br>0 | 0 / 21 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Metabolism and nutrition disorders<br>Dehydration                                           |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hypercholesterolaemia       |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Hyperlipidaemia             |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Type 2 diabetes mellitus    |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Vitamin B12 deficiency      |                |                |                |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 21 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

| <b>Non-serious adverse events</b>                                   | Cohort 4: mRNA-1345 Dose C in Younger Adults (18 to 49 Years) | Two Injection Placebo in Older Adults (After 1st Dose) | Single Injection Placebo in Japanese Older Adults (≥ 60 Years) |
|---------------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------|
| Total subjects affected by non-serious adverse events               |                                                               |                                                        |                                                                |
| subjects affected / exposed                                         | 13 / 20 (65.00%)                                              | 14 / 59 (23.73%)                                       | 2 / 4 (50.00%)                                                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                               |                                                        |                                                                |
| Melanocytic naevus                                                  |                                                               |                                                        |                                                                |
| subjects affected / exposed                                         | 0 / 20 (0.00%)                                                | 0 / 59 (0.00%)                                         | 0 / 4 (0.00%)                                                  |
| occurrences (all)                                                   | 0                                                             | 0                                                      | 0                                                              |
| General disorders and administration site conditions                |                                                               |                                                        |                                                                |
| Fatigue                                                             |                                                               |                                                        |                                                                |
| subjects affected / exposed                                         | 1 / 20 (5.00%)                                                | 1 / 59 (1.69%)                                         | 0 / 4 (0.00%)                                                  |
| occurrences (all)                                                   | 1                                                             | 1                                                      | 0                                                              |
| Injection site erythema                                             |                                                               |                                                        |                                                                |
| subjects affected / exposed                                         | 0 / 20 (0.00%)                                                | 0 / 59 (0.00%)                                         | 0 / 4 (0.00%)                                                  |
| occurrences (all)                                                   | 0                                                             | 0                                                      | 0                                                              |
| Injection site pain                                                 |                                                               |                                                        |                                                                |
| subjects affected / exposed                                         | 1 / 20 (5.00%)                                                | 0 / 59 (0.00%)                                         | 0 / 4 (0.00%)                                                  |
| occurrences (all)                                                   | 1                                                             | 0                                                      | 0                                                              |
| Pyrexia                                                             |                                                               |                                                        |                                                                |

|                                                                                                               |                      |                     |                    |
|---------------------------------------------------------------------------------------------------------------|----------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all)                                                              | 1 / 20 (5.00%)<br>1  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)               | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all) | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                                  | 2 / 20 (10.00%)<br>2 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 20 (0.00%)<br>0  | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 20 (0.00%)<br>0  | 1 / 59 (1.69%)<br>1 | 0 / 4 (0.00%)<br>0 |
| Psychiatric disorders                                                                                         |                      |                     |                    |

|                                                |                |                |               |
|------------------------------------------------|----------------|----------------|---------------|
| Anxiety                                        |                |                |               |
| subjects affected / exposed                    | 1 / 20 (5.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 1              | 0              | 0             |
| Attention deficit hyperactivity disorder       |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Oppositional defiant disorder                  |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Investigations                                 |                |                |               |
| Blood pressure increased                       |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Injury, poisoning and procedural complications |                |                |               |
| Concussion                                     |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Arthropod bite                                 |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Meniscus injury                                |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Limb injury                                    |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Radial head dislocation                        |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Skin abrasion                                  |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Skin laceration                                |                |                |               |
| subjects affected / exposed                    | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0             |
| Upper limb fracture                            |                |                |               |

|                                                  |                     |                     |                    |
|--------------------------------------------------|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Cardiac disorders                                |                     |                     |                    |
| Palpitations                                     |                     |                     |                    |
| subjects affected / exposed                      | 1 / 20 (5.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Nervous system disorders                         |                     |                     |                    |
| Headache                                         |                     |                     |                    |
| subjects affected / exposed                      | 2 / 20 (10.00%)     | 0 / 59 (0.00%)      | 1 / 4 (25.00%)     |
| occurrences (all)                                | 3                   | 0                   | 1                  |
| Migraine                                         |                     |                     |                    |
| subjects affected / exposed                      | 1 / 20 (5.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Morton's neuralgia                               |                     |                     |                    |
| subjects affected / exposed                      | 0 / 20 (0.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Sensory disturbance                              |                     |                     |                    |
| subjects affected / exposed                      | 0 / 20 (0.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Ear and labyrinth disorders                      |                     |                     |                    |
| Ear pain                                         |                     |                     |                    |
| subjects affected / exposed                      | 1 / 20 (5.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Tympanic membrane perforation                    |                     |                     |                    |
| subjects affected / exposed                      | 0 / 20 (0.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Vertigo                                          |                     |                     |                    |
| subjects affected / exposed                      | 0 / 20 (0.00%)      | 0 / 59 (0.00%)      | 1 / 4 (25.00%)     |
| occurrences (all)                                | 0                   | 0                   | 1                  |
| Gastrointestinal disorders                       |                     |                     |                    |
| Aphthous ulcer                                   |                     |                     |                    |
| subjects affected / exposed                      | 2 / 20 (10.00%)     | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 2                   | 0                   | 0                  |
| Gastrooesophageal reflux disease                 |                     |                     |                    |
| subjects affected / exposed                      | 0 / 20 (0.00%)      | 0 / 59 (0.00%)      | 0 / 4 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Diarrhoea                                        |                     |                     |                    |

|                                        |                |                |               |
|----------------------------------------|----------------|----------------|---------------|
| subjects affected / exposed            | 1 / 20 (5.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 1              | 0              | 0             |
| Large intestine polyp                  |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Nausea                                 |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Teething                               |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Tooth disorder                         |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Toothache                              |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Vomiting                               |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Skin and subcutaneous tissue disorders |                |                |               |
| Actinic keratosis                      |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 1              | 0             |
| Angioedema                             |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Dermatitis atopic                      |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |
| Dermatitis contact                     |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 1              | 0             |
| Ecchymosis                             |                |                |               |
| subjects affected / exposed            | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0             |

|                                                 |                |                |               |
|-------------------------------------------------|----------------|----------------|---------------|
| Nail dystrophy                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Rash                                            |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Skin lesion                                     |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Solar lentigo                                   |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Splinter haemorrhages                           |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Urticaria                                       |                |                |               |
| subjects affected / exposed                     | 1 / 20 (5.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 1              | 0              | 0             |
| Urticaria papular                               |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Endocrine disorders                             |                |                |               |
| Basedow's disease                               |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Hyperthyroidism                                 |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Hypothyroidism                                  |                |                |               |
| subjects affected / exposed                     | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0             |
| Musculoskeletal and connective tissue disorders |                |                |               |
| Arthralgia                                      |                |                |               |
| subjects affected / exposed                     | 1 / 20 (5.00%) | 3 / 59 (5.08%) | 0 / 4 (0.00%) |
| occurrences (all)                               | 1              | 3              | 0             |
| Arthritis                                       |                |                |               |

|                             |                |                |               |
|-----------------------------|----------------|----------------|---------------|
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Musculoskeletal stiffness   |                |                |               |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 1              | 0              | 0             |
| Back pain                   |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 1              | 0             |
| Osteoarthritis              |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 2 / 59 (3.39%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 2              | 0             |
| Osteoporosis                |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 1              | 0             |
| Trigger finger              |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Infections and infestations |                |                |               |
| Acute sinusitis             |                |                |               |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 1              | 0              | 0             |
| Adenovirus infection        |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Appendicitis                |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Asymptomatic COVID-19       |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Bordetella infection        |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Bronchiolitis               |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |

|                             |                |                |               |
|-----------------------------|----------------|----------------|---------------|
| Bronchitis                  |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 1              | 0             |
| Coronavirus infection       |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| COVID-19                    |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 2 / 59 (3.39%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 2              | 0             |
| Ear infection               |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Croup infectious            |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Eye infection               |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Folliculitis                |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Gastroenteritis             |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Impetigo                    |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| HCoV-OC43 infection         |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Influenza                   |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |
| Metapneumovirus infection   |                |                |               |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)           | 0              | 0              | 0             |

|                                   |                 |                |               |
|-----------------------------------|-----------------|----------------|---------------|
| Nasopharyngitis                   |                 |                |               |
| subjects affected / exposed       | 2 / 20 (10.00%) | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 3               | 1              | 0             |
| Onychomycosis                     |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Oral fungal infection             |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Oral herpes                       |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Otitis media                      |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Parainfluenzae virus infection    |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Otitis media acute                |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Pharyngitis                       |                 |                |               |
| subjects affected / exposed       | 1 / 20 (5.00%)  | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 1               | 1              | 0             |
| Pharyngitis streptococcal         |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Respiratory tract infection viral |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Rhinovirus infection              |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 0 / 59 (0.00%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 0              | 0             |
| Sinusitis                         |                 |                |               |
| subjects affected / exposed       | 0 / 20 (0.00%)  | 1 / 59 (1.69%) | 0 / 4 (0.00%) |
| occurrences (all)                 | 0               | 1              | 0             |

|                                                                                             |                     |                     |                    |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|--------------------|
| Tonsillitis<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)       | 0 / 20 (0.00%)<br>0 | 1 / 59 (1.69%)<br>1 | 0 / 4 (0.00%)<br>0 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 20 (0.00%)<br>0 | 1 / 59 (1.69%)<br>1 | 0 / 4 (0.00%)<br>0 |
| Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                                          |                     |                     |                    |
| Dehydration<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Hypercholesterolaemia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Type 2 diabetes mellitus<br>subjects affected / exposed<br>occurrences (all)                | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 20 (0.00%)<br>0 | 0 / 59 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 |

| <b>Non-serious adverse events</b>                                                            | Single Injection<br>Placebo in Younger<br>Adults (18 to 49<br>Years) | Cohort 1: mRNA-<br>1345 Dose A in<br>Younger Adults (18<br>to 49 Years) | Cohort 8: mRNA-<br>1345 Dose B in<br>Older Adults (After<br>1st Dose) |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed      | 5 / 15 (33.33%)                                                      | 2 / 19 (10.53%)                                                         | 15 / 48 (31.25%)                                                      |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps)<br>Melanocytic naevus |                                                                      |                                                                         |                                                                       |

|                                                         |                     |                     |                     |
|---------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)        | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| General disorders and administration<br>site conditions |                     |                     |                     |
| Fatigue                                                 |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 4 / 48 (8.33%)      |
| occurrences (all)                                       | 0                   | 0                   | 4                   |
| Injection site erythema                                 |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Injection site pain                                     |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 2 / 19 (10.53%)     | 1 / 48 (2.08%)      |
| occurrences (all)                                       | 0                   | 2                   | 1                   |
| Pyrexia                                                 |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Vaccination site pain                                   |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Vessel puncture site bruise                             |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Immune system disorders                                 |                     |                     |                     |
| Seasonal allergy                                        |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Drug hypersensitivity                                   |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Respiratory, thoracic and mediastinal<br>disorders      |                     |                     |                     |
| Asthma                                                  |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Bronchospasm                                            |                     |                     |                     |
| subjects affected / exposed                             | 0 / 15 (0.00%)      | 0 / 19 (0.00%)      | 0 / 48 (0.00%)      |
| occurrences (all)                                       | 0                   | 0                   | 0                   |
| Cough                                                   |                     |                     |                     |

|                                                |                |                |                |
|------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)                              | 0              | 0              | 1              |
| Dyspnoea                                       |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Respiratory tract congestion                   |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Rhinorrhoea                                    |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Psychiatric disorders                          |                |                |                |
| Anxiety                                        |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Attention deficit hyperactivity disorder       |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Oppositional defiant disorder                  |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Investigations                                 |                |                |                |
| Blood pressure increased                       |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)                              | 0              | 0              | 1              |
| Injury, poisoning and procedural complications |                |                |                |
| Concussion                                     |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Arthropod bite                                 |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Meniscus injury                                |                |                |                |
| subjects affected / exposed                    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                              | 0              | 0              | 0              |
| Limb injury                                    |                |                |                |

|                               |                 |                |                |
|-------------------------------|-----------------|----------------|----------------|
| subjects affected / exposed   | 1 / 15 (6.67%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 1               | 0              | 0              |
| Radial head dislocation       |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Skin abrasion                 |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Skin laceration               |                 |                |                |
| subjects affected / exposed   | 1 / 15 (6.67%)  | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)             | 1               | 0              | 1              |
| Upper limb fracture           |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Cardiac disorders             |                 |                |                |
| Palpitations                  |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Nervous system disorders      |                 |                |                |
| Headache                      |                 |                |                |
| subjects affected / exposed   | 4 / 15 (26.67%) | 0 / 19 (0.00%) | 3 / 48 (6.25%) |
| occurrences (all)             | 6               | 0              | 3              |
| Migraine                      |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Morton's neuralgia            |                 |                |                |
| subjects affected / exposed   | 1 / 15 (6.67%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 1               | 0              | 0              |
| Sensory disturbance           |                 |                |                |
| subjects affected / exposed   | 1 / 15 (6.67%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 1               | 0              | 0              |
| Ear and labyrinth disorders   |                 |                |                |
| Ear pain                      |                 |                |                |
| subjects affected / exposed   | 0 / 15 (0.00%)  | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)             | 0               | 0              | 0              |
| Tympanic membrane perforation |                 |                |                |

|                                                                                                 |                     |                     |                     |
|-------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Gastrointestinal disorders<br>Apthous ulcer<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Gastrooesophageal reflux disease<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Large intestine polyp<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                                      | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Teething<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Tooth disorder<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Toothache<br>subjects affected / exposed<br>occurrences (all)                                   | 1 / 15 (6.67%)<br>1 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders<br>Actinic keratosis                                     |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 2 / 48 (4.17%) |
| occurrences (all)           | 0              | 0              | 2              |
| Angioedema                  |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Dermatitis atopic           |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Dermatitis contact          |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Ecchymosis                  |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Nail dystrophy              |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rash                        |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Skin lesion                 |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Solar lentigo               |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Splinter haemorrhages       |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Urticaria                   |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Urticaria papular           |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Endocrine disorders         |                |                |                |

|                                                                               |                     |                     |                     |
|-------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Basedow's disease<br>subjects affected / exposed<br>occurrences (all)         | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)           | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                               |                     |                     |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 1 / 48 (2.08%)<br>1 |
| Arthritis<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Musculoskeletal stiffness<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 3 / 48 (6.25%)<br>4 |
| Osteoarthritis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 2 / 48 (4.17%)<br>2 |
| Osteoporosis<br>subjects affected / exposed<br>occurrences (all)              | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Trigger finger<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Infections and infestations                                                   |                     |                     |                     |
| Acute sinusitis<br>subjects affected / exposed<br>occurrences (all)           | 1 / 15 (6.67%)<br>1 | 0 / 19 (0.00%)<br>0 | 1 / 48 (2.08%)<br>1 |
| Adenovirus infection                                                          |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Appendicitis                |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Asymptomatic COVID-19       |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bordetella infection        |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchiolitis               |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchitis                  |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Coronavirus infection       |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| COVID-19                    |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)           | 0              | 0              | 1              |
| Ear infection               |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Croup infectious            |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Eye infection               |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Folliculitis                |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastroenteritis             |                |                |                |

|                                |                |                |                |
|--------------------------------|----------------|----------------|----------------|
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Impetigo                       |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| HCoV-OC43 infection            |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Influenza                      |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Metapneumovirus infection      |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Nasopharyngitis                |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)              | 0              | 0              | 1              |
| Onychomycosis                  |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Oral fungal infection          |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Oral herpes                    |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Otitis media                   |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Parainfluenzae virus infection |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Otitis media acute             |                |                |                |
| subjects affected / exposed    | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Pharyngitis                    |                |                |                |

|                                         |                |                |                |
|-----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Pharyngitis streptococcal               |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Respiratory tract infection viral       |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Rhinovirus infection                    |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Sinusitis                               |                |                |                |
| subjects affected / exposed             | 1 / 15 (6.67%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 1              | 0              | 0              |
| Tonsillitis                             |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Upper respiratory tract infection       |                |                |                |
| subjects affected / exposed             | 1 / 15 (6.67%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 1              | 0              | 0              |
| Urinary tract infection                 |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 1 / 48 (2.08%) |
| occurrences (all)                       | 0              | 0              | 2              |
| Viral upper respiratory tract infection |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Metabolism and nutrition disorders      |                |                |                |
| Dehydration                             |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Hypercholesterolaemia                   |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Hyperlipidaemia                         |                |                |                |
| subjects affected / exposed             | 0 / 15 (0.00%) | 0 / 19 (0.00%) | 0 / 48 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |

|                                                                              |                     |                     |                     |
|------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Type 2 diabetes mellitus<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all)   | 0 / 15 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 |

| <b>Non-serious adverse events</b>                                                                                                             | Cohort 9: mRNA-1345 Dose C in Older Adults (After 1st Dose) | Cohort 11: mRNA-1345 Dose F in Older Adults (After 1st Dose) | Cohort 7: mRNA-1345 Dose A in Older Adults (After 1st Dose) |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                          | 23 / 48 (47.92%)                                            | 19 / 48 (39.58%)                                             | 17 / 47 (36.17%)                                            |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0                                         | 0 / 48 (0.00%)<br>0                                          | 0 / 47 (0.00%)<br>0                                         |
| General disorders and administration site conditions<br>Fatigue<br>subjects affected / exposed<br>occurrences (all)                           | 2 / 48 (4.17%)<br>2                                         | 2 / 48 (4.17%)<br>2                                          | 0 / 47 (0.00%)<br>0                                         |
| Injection site erythema<br>subjects affected / exposed<br>occurrences (all)                                                                   | 1 / 48 (2.08%)<br>1                                         | 1 / 48 (2.08%)<br>1                                          | 0 / 47 (0.00%)<br>0                                         |
| Injection site pain<br>subjects affected / exposed<br>occurrences (all)                                                                       | 1 / 48 (2.08%)<br>1                                         | 0 / 48 (0.00%)<br>0                                          | 0 / 47 (0.00%)<br>0                                         |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                                                   | 0 / 48 (0.00%)<br>0                                         | 0 / 48 (0.00%)<br>0                                          | 0 / 47 (0.00%)<br>0                                         |
| Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)                                                                     | 0 / 48 (0.00%)<br>0                                         | 0 / 48 (0.00%)<br>0                                          | 0 / 47 (0.00%)<br>0                                         |
| Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all)                                                               | 0 / 48 (0.00%)<br>0                                         | 0 / 48 (0.00%)<br>0                                          | 0 / 47 (0.00%)<br>0                                         |
| Immune system disorders                                                                                                                       |                                                             |                                                              |                                                             |

|                                                                                              |                     |                     |                     |
|----------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)                         | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders                                              |                     |                     |                     |
| Asthma<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                    | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)             | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 48 (0.00%)<br>0 | 1 / 48 (2.08%)<br>1 | 1 / 47 (2.13%)<br>1 |
| Psychiatric disorders                                                                        |                     |                     |                     |
| Anxiety<br>subjects affected / exposed<br>occurrences (all)                                  | 2 / 48 (4.17%)<br>2 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Attention deficit hyperactivity disorder<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Oppositional defiant disorder<br>subjects affected / exposed<br>occurrences (all)            | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Investigations                                                                               |                     |                     |                     |

|                                                                              |                     |                     |                     |
|------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Blood pressure increased<br>subjects affected / exposed<br>occurrences (all) | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Injury, poisoning and procedural complications                               |                     |                     |                     |
| Concussion<br>subjects affected / exposed<br>occurrences (all)               | 0 / 48 (0.00%)<br>0 | 1 / 48 (2.08%)<br>1 | 0 / 47 (0.00%)<br>0 |
| Arthropod bite<br>subjects affected / exposed<br>occurrences (all)           | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Meniscus injury<br>subjects affected / exposed<br>occurrences (all)          | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Limb injury<br>subjects affected / exposed<br>occurrences (all)              | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Radial head dislocation<br>subjects affected / exposed<br>occurrences (all)  | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Skin abrasion<br>subjects affected / exposed<br>occurrences (all)            | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)          | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 2 / 47 (4.26%)<br>2 |
| Upper limb fracture<br>subjects affected / exposed<br>occurrences (all)      | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Cardiac disorders                                                            |                     |                     |                     |
| Palpitations<br>subjects affected / exposed<br>occurrences (all)             | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 2 / 47 (4.26%)<br>2 |
| Nervous system disorders                                                     |                     |                     |                     |
| Headache<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 48 (0.00%)<br>0 | 2 / 48 (4.17%)<br>2 | 0 / 47 (0.00%)<br>0 |

|                                  |                |                |                |
|----------------------------------|----------------|----------------|----------------|
| Migraine                         |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Morton's neuralgia               |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Sensory disturbance              |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Ear and labyrinth disorders      |                |                |                |
| Ear pain                         |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 1              | 0              |
| Tympanic membrane perforation    |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Vertigo                          |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 1              | 0              |
| Gastrointestinal disorders       |                |                |                |
| Aphthous ulcer                   |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Gastrooesophageal reflux disease |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Diarrhoea                        |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)                | 0              | 0              | 1              |
| Large intestine polyp            |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Nausea                           |                |                |                |
| subjects affected / exposed      | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Teething                         |                |                |                |

|                                                                        |                     |                     |                     |
|------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                       | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Tooth disorder<br>subjects affected / exposed<br>occurrences (all)     | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Toothache<br>subjects affected / exposed<br>occurrences (all)          | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)           | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders                                 |                     |                     |                     |
| Actinic keratosis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Angioedema<br>subjects affected / exposed<br>occurrences (all)         | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Dermatitis atopic<br>subjects affected / exposed<br>occurrences (all)  | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Dermatitis contact<br>subjects affected / exposed<br>occurrences (all) | 1 / 48 (2.08%)<br>1 | 2 / 48 (4.17%)<br>2 | 0 / 47 (0.00%)<br>0 |
| Ecchymosis<br>subjects affected / exposed<br>occurrences (all)         | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Nail dystrophy<br>subjects affected / exposed<br>occurrences (all)     | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Rash<br>subjects affected / exposed<br>occurrences (all)               | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Skin lesion<br>subjects affected / exposed<br>occurrences (all)        | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |

|                                                                                                                   |                     |                     |                     |
|-------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Solar lentigo<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Splinter haemorrhages<br>subjects affected / exposed<br>occurrences (all)                                         | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Urticaria papular<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Endocrine disorders<br>Basedow's disease<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)                                                | 2 / 48 (4.17%)<br>2 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all) | 4 / 48 (8.33%)<br>4 | 3 / 48 (6.25%)<br>4 | 2 / 47 (4.26%)<br>2 |
| Arthritis<br>subjects affected / exposed<br>occurrences (all)                                                     | 2 / 48 (4.17%)<br>2 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>1 |
| Musculoskeletal stiffness<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                                                     | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 1 / 47 (2.13%)<br>2 |
| Osteoarthritis                                                                                                    |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 48 (4.17%) | 1 / 48 (2.08%) | 1 / 47 (2.13%) |
| occurrences (all)           | 2              | 1              | 1              |
| Osteoporosis                |                |                |                |
| subjects affected / exposed | 1 / 48 (2.08%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Trigger finger              |                |                |                |
| subjects affected / exposed | 3 / 48 (6.25%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)           | 3              | 0              | 1              |
| Infections and infestations |                |                |                |
| Acute sinusitis             |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)           | 0              | 0              | 1              |
| Adenovirus infection        |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Appendicitis                |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Asymptomatic COVID-19       |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Bordetella infection        |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchiolitis               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchitis                  |                |                |                |
| subjects affected / exposed | 3 / 48 (6.25%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)           | 3              | 1              | 0              |
| Coronavirus infection       |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| COVID-19                    |                |                |                |
| subjects affected / exposed | 3 / 48 (6.25%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)           | 3              | 0              | 1              |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Ear infection               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)           | 0              | 0              | 1              |
| Croup infectious            |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Eye infection               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Folliculitis                |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastroenteritis             |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Impetigo                    |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| HCoV-OC43 infection         |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Influenza                   |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Metapneumovirus infection   |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Nasopharyngitis             |                |                |                |
| subjects affected / exposed | 1 / 48 (2.08%) | 2 / 48 (4.17%) | 0 / 47 (0.00%) |
| occurrences (all)           | 2              | 2              | 0              |
| Onychomycosis               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)           | 0              | 0              | 1              |
| Oral fungal infection       |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                   |                |                |                |
|-----------------------------------|----------------|----------------|----------------|
| Oral herpes                       |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Otitis media                      |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Parainfluenzae virus infection    |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Otitis media acute                |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Pharyngitis                       |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Pharyngitis streptococcal         |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Respiratory tract infection viral |                |                |                |
| subjects affected / exposed       | 1 / 48 (2.08%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 1              | 0              | 0              |
| Rhinovirus infection              |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Sinusitis                         |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 1 / 48 (2.08%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Tonsillitis                       |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 48 (0.00%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Upper respiratory tract infection |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 2 / 48 (4.17%) | 0 / 47 (0.00%) |
| occurrences (all)                 | 0              | 2              | 0              |
| Urinary tract infection           |                |                |                |
| subjects affected / exposed       | 2 / 48 (4.17%) | 0 / 48 (0.00%) | 1 / 47 (2.13%) |
| occurrences (all)                 | 2              | 0              | 1              |

|                                                                                             |                     |                     |                     |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 1 / 48 (2.08%)<br>1 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                                          |                     |                     |                     |
| Dehydration<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Hypercholesterolaemia<br>subjects affected / exposed<br>occurrences (all)                   | 1 / 48 (2.08%)<br>1 | 1 / 48 (2.08%)<br>1 | 0 / 47 (0.00%)<br>0 |
| Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |
| Type 2 diabetes mellitus<br>subjects affected / exposed<br>occurrences (all)                | 0 / 48 (0.00%)<br>0 | 2 / 48 (4.17%)<br>2 | 0 / 47 (0.00%)<br>0 |
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 48 (0.00%)<br>0 | 0 / 48 (0.00%)<br>0 | 0 / 47 (0.00%)<br>0 |

| Non-serious adverse events                                                                                                                    | Cohort 10: mRNA-1345 Dose E in Older Adults (After 1st Dose) | Cohort 12: mRNA-1345 Dose F in WOCBP (18 to 40 Years) | Cohort 9: mRNA-1345 Dose C in Older Adults (After Month 12) |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                          | 15 / 48 (31.25%)                                             | 8 / 51 (15.69%)                                       | 10 / 19 (52.63%)                                            |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0                                          | 1 / 51 (1.96%)<br>1                                   | 0 / 19 (0.00%)<br>0                                         |
| General disorders and administration site conditions                                                                                          |                                                              |                                                       |                                                             |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                                                                                   | 0 / 48 (0.00%)<br>0                                          | 1 / 51 (1.96%)<br>2                                   | 0 / 19 (0.00%)<br>0                                         |
| Injection site erythema<br>subjects affected / exposed<br>occurrences (all)                                                                   | 0 / 48 (0.00%)<br>0                                          | 0 / 51 (0.00%)<br>0                                   | 1 / 19 (5.26%)<br>1                                         |
| Injection site pain                                                                                                                           |                                                              |                                                       |                                                             |

|                                                                                                               |                     |                     |                     |
|---------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                              | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                   | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)               | 1 / 48 (2.08%)<br>1 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                                  | 1 / 48 (2.08%)<br>1 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Rhinorrhoea                                                                                                   |                     |                     |                     |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Psychiatric disorders                            |                     |                     |                     |
| Anxiety                                          |                     |                     |                     |
| subjects affected / exposed                      | 1 / 48 (2.08%)      | 2 / 51 (3.92%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 1                   | 2                   | 0                   |
| Attention deficit hyperactivity disorder         |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 1 / 19 (5.26%)      |
| occurrences (all)                                | 0                   | 0                   | 1                   |
| Oppositional defiant disorder                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Investigations                                   |                     |                     |                     |
| Blood pressure increased                         |                     |                     |                     |
| subjects affected / exposed                      | 1 / 48 (2.08%)      | 0 / 51 (0.00%)      | 1 / 19 (5.26%)      |
| occurrences (all)                                | 1                   | 0                   | 1                   |
| Injury, poisoning and procedural complications   |                     |                     |                     |
| Concussion                                       |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Arthropod bite                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 1 / 19 (5.26%)      |
| occurrences (all)                                | 0                   | 0                   | 1                   |
| Meniscus injury                                  |                     |                     |                     |
| subjects affected / exposed                      | 1 / 48 (2.08%)      | 0 / 51 (0.00%)      | 1 / 19 (5.26%)      |
| occurrences (all)                                | 1                   | 0                   | 1                   |
| Limb injury                                      |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Radial head dislocation                          |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 0 / 51 (0.00%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Skin abrasion                                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 48 (0.00%)      | 1 / 51 (1.96%)      | 0 / 19 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Skin laceration                                  |                     |                     |                     |

|                                                                                                  |                     |                     |                     |
|--------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                 | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Upper limb fracture<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Cardiac disorders<br>Palpitations<br>subjects affected / exposed<br>occurrences (all)            | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)         | 1 / 48 (2.08%)<br>1 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Morton's neuralgia<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Sensory disturbance<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Ear and labyrinth disorders<br>Ear pain<br>subjects affected / exposed<br>occurrences (all)      | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Tympanic membrane perforation<br>subjects affected / exposed<br>occurrences (all)                | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                                      | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Gastrointestinal disorders<br>Aphthous ulcer<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 51 (0.00%)<br>0 | 0 / 19 (0.00%)<br>0 |
| Gastrooesophageal reflux disease                                                                 |                     |                     |                     |

|                                        |                |                |                |
|----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                      | 0              | 0              | 1              |
| Diarrhoea                              |                |                |                |
| subjects affected / exposed            | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 1              | 0              | 0              |
| Large intestine polyp                  |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Nausea                                 |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Teething                               |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Tooth disorder                         |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                      | 0              | 0              | 1              |
| Toothache                              |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Vomiting                               |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Skin and subcutaneous tissue disorders |                |                |                |
| Actinic keratosis                      |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                      | 0              | 0              | 1              |
| Angioedema                             |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Dermatitis atopic                      |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |
| Dermatitis contact                     |                |                |                |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                      | 0              | 0              | 0              |

|                                                 |                |                |                |
|-------------------------------------------------|----------------|----------------|----------------|
| Ecchymosis                                      |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Nail dystrophy                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Rash                                            |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Skin lesion                                     |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Solar lentigo                                   |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Splinter haemorrhages                           |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Urticaria                                       |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Urticaria papular                               |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Endocrine disorders                             |                |                |                |
| Basedow's disease                               |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                               | 0              | 0              | 1              |
| Hyperthyroidism                                 |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                               | 0              | 0              | 1              |
| Hypothyroidism                                  |                |                |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                               | 0              | 0              | 0              |
| Musculoskeletal and connective tissue disorders |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| Arthralgia                  |                |                |                |
| subjects affected / exposed | 3 / 48 (6.25%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 3              | 0              | 0              |
| Arthritis                   |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Musculoskeletal stiffness   |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Back pain                   |                |                |                |
| subjects affected / exposed | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 2              | 0              | 0              |
| Osteoarthritis              |                |                |                |
| subjects affected / exposed | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Osteoporosis                |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Trigger finger              |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Infections and infestations |                |                |                |
| Acute sinusitis             |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Adenovirus infection        |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Appendicitis                |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Asymptomatic COVID-19       |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bordetella infection        |                |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchiolitis               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Bronchitis                  |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Coronavirus infection       |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| COVID-19                    |                |                |                |
| subjects affected / exposed | 3 / 48 (6.25%) | 2 / 51 (3.92%) | 1 / 19 (5.26%) |
| occurrences (all)           | 3              | 2              | 1              |
| Ear infection               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Croup infectious            |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Eye infection               |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Folliculitis                |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Gastroenteritis             |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Impetigo                    |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| HCoV-OC43 infection         |                |                |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Influenza                   |                |                |                |

|                                   |                |                |                |
|-----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Metapneumovirus infection         |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Nasopharyngitis                   |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Onychomycosis                     |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Oral fungal infection             |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Oral herpes                       |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                 | 0              | 0              | 1              |
| Otitis media                      |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Parainfluenzae virus infection    |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Otitis media acute                |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Pharyngitis                       |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Pharyngitis streptococcal         |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 1 / 51 (1.96%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 1              | 0              |
| Respiratory tract infection viral |                |                |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                 | 0              | 0              | 0              |
| Rhinovirus infection              |                |                |                |

|                                         |                |                |                |
|-----------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Sinusitis                               |                |                |                |
| subjects affected / exposed             | 2 / 48 (4.17%) | 2 / 51 (3.92%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 2              | 2              | 0              |
| Tonsillitis                             |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Upper respiratory tract infection       |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Urinary tract infection                 |                |                |                |
| subjects affected / exposed             | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                       | 1              | 0              | 1              |
| Viral upper respiratory tract infection |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Metabolism and nutrition disorders      |                |                |                |
| Dehydration                             |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 1 / 19 (5.26%) |
| occurrences (all)                       | 0              | 0              | 1              |
| Hypercholesterolaemia                   |                |                |                |
| subjects affected / exposed             | 1 / 48 (2.08%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 1              | 0              | 0              |
| Hyperlipidaemia                         |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 1 / 51 (1.96%) | 1 / 19 (5.26%) |
| occurrences (all)                       | 0              | 1              | 1              |
| Type 2 diabetes mellitus                |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |
| Vitamin B12 deficiency                  |                |                |                |
| subjects affected / exposed             | 0 / 48 (0.00%) | 0 / 51 (0.00%) | 0 / 19 (0.00%) |
| occurrences (all)                       | 0              | 0              | 0              |

|                                   |                                                             |                                                             |                                                       |
|-----------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------|
| <b>Non-serious adverse events</b> | Cohort 8: mRNA-1345 Dose B in Older Adults (After Month 12) | Cohort 7: mRNA-1345 Dose A in Older Adults (After Month 12) | Cohort 13: mRNA-1345 Dose E in WOCBP (18 to 40 Years) |
|-----------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                       |                                                                                                                                                            |                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                                                                                                                                                                                                                                                                                                                                                                                                             | 8 / 18 (44.44%)                                                                                                                                                                       | 7 / 18 (38.89%)                                                                                                                                            | 13 / 49 (26.53%)                                                                                                                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                    | 0 / 18 (0.00%)<br>0                                                                                                                                                                   | 1 / 18 (5.56%)<br>1                                                                                                                                        | 0 / 49 (0.00%)<br>0                                                                                                             |
| General disorders and administration site conditions<br>Fatigue<br>subjects affected / exposed<br>occurrences (all)<br><br>Injection site erythema<br>subjects affected / exposed<br>occurrences (all)<br><br>Injection site pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Pyrexia<br>subjects affected / exposed<br>occurrences (all)<br><br>Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0<br><br>1 / 18 (5.56%)<br>1<br><br>0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0<br><br>1 / 18 (5.56%)<br>1<br><br>0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0<br><br>1 / 18 (5.56%)<br>1 | 0 / 49 (0.00%)<br>0<br><br>0 / 49 (0.00%)<br>0<br><br>0 / 49 (0.00%)<br>0<br><br>0 / 49 (0.00%)<br>0<br><br>0 / 49 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)<br><br>Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                 | 1 / 18 (5.56%)<br>1<br><br>0 / 18 (0.00%)<br>0                                                                                                                                        | 0 / 18 (0.00%)<br>0<br><br>0 / 18 (0.00%)<br>0                                                                                                             | 0 / 49 (0.00%)<br>0<br><br>0 / 49 (0.00%)<br>0                                                                                  |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                                                                                                                                                                    | 0 / 18 (0.00%)<br>0                                                                                                                                                                   | 0 / 18 (0.00%)<br>0                                                                                                                                        | 0 / 49 (0.00%)<br>0                                                                                                             |

|                                                                                                                  |                     |                     |                     |
|------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                        | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 1 / 49 (2.04%)<br>1 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)                                 | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 | 0 / 49 (0.00%)<br>0 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 18 (0.00%)<br>0 | 1 / 18 (5.56%)<br>1 | 1 / 49 (2.04%)<br>1 |
| Attention deficit hyperactivity disorder<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 1 / 49 (2.04%)<br>1 |
| Oppositional defiant disorder<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Investigations<br>Blood pressure increased<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Concussion<br>subjects affected / exposed<br>occurrences (all) | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Arthropod bite<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |

|                                                                                          |                     |                     |                     |
|------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Meniscus injury<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Limb injury<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Radial head dislocation<br>subjects affected / exposed<br>occurrences (all)              | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Skin abrasion<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Upper limb fracture<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Cardiac disorders<br>Palpitations<br>subjects affected / exposed<br>occurrences (all)    | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 1 / 49 (2.04%)<br>1 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                             | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Morton's neuralgia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Sensory disturbance<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Ear and labyrinth disorders                                                              |                     |                     |                     |

|                                  |                |                |                |
|----------------------------------|----------------|----------------|----------------|
| Ear pain                         |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Tympanic membrane perforation    |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Vertigo                          |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Gastrointestinal disorders       |                |                |                |
| Aphthous ulcer                   |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Gastrooesophageal reflux disease |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Diarrhoea                        |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Large intestine polyp            |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 1 / 18 (5.56%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 1              | 0              |
| Nausea                           |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Teething                         |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Tooth disorder                   |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Toothache                        |                |                |                |
| subjects affected / exposed      | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                | 0              | 0              | 0              |
| Vomiting                         |                |                |                |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders           |                     |                     |                     |
| Actinic keratosis                                |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 18 (0.00%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Angioedema                                       |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 18 (0.00%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Dermatitis atopic                                |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 18 (0.00%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Dermatitis contact                               |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 18 (0.00%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Ecchymosis                                       |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 18 (5.56%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Nail dystrophy                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 18 (5.56%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Rash                                             |                     |                     |                     |
| subjects affected / exposed                      | 1 / 18 (5.56%)      | 0 / 18 (0.00%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Skin lesion                                      |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 18 (5.56%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Solar lentigo                                    |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 18 (5.56%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Splinter haemorrhages                            |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 1 / 18 (5.56%)      | 0 / 49 (0.00%)      |
| occurrences (all)                                | 0                   | 1                   | 0                   |
| Urticaria                                        |                     |                     |                     |
| subjects affected / exposed                      | 0 / 18 (0.00%)      | 0 / 18 (0.00%)      | 1 / 49 (2.04%)      |
| occurrences (all)                                | 0                   | 0                   | 1                   |

|                                                                               |                     |                     |                     |
|-------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Urticaria papular<br>subjects affected / exposed<br>occurrences (all)         | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Endocrine disorders                                                           |                     |                     |                     |
| Basedow's disease<br>subjects affected / exposed<br>occurrences (all)         | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)           | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)            | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                               |                     |                     |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Arthritis<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Musculoskeletal stiffness<br>subjects affected / exposed<br>occurrences (all) | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 2 / 49 (4.08%)<br>2 |
| Osteoarthritis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Osteoporosis<br>subjects affected / exposed<br>occurrences (all)              | 1 / 18 (5.56%)<br>1 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Trigger finger<br>subjects affected / exposed<br>occurrences (all)            | 0 / 18 (0.00%)<br>0 | 0 / 18 (0.00%)<br>0 | 0 / 49 (0.00%)<br>0 |
| Infections and infestations                                                   |                     |                     |                     |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| Acute sinusitis             |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 1 / 49 (2.04%) |
| occurrences (all)           | 0              | 0               | 1              |
| Adenovirus infection        |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Appendicitis                |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Asymptomatic COVID-19       |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Bordetella infection        |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Bronchiolitis               |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Bronchitis                  |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Coronavirus infection       |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| COVID-19                    |                |                 |                |
| subjects affected / exposed | 1 / 18 (5.56%) | 2 / 18 (11.11%) | 4 / 49 (8.16%) |
| occurrences (all)           | 1              | 2               | 4              |
| Ear infection               |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Croup infectious            |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Eye infection               |                |                 |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%)  | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |

|                                |                |                |                |
|--------------------------------|----------------|----------------|----------------|
| Folliculitis                   |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 1 / 49 (2.04%) |
| occurrences (all)              | 0              | 0              | 1              |
| Gastroenteritis                |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Impetigo                       |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| HCoV-OC43 infection            |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Influenza                      |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Metapneumovirus infection      |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Nasopharyngitis                |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Onychomycosis                  |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Oral fungal infection          |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Oral herpes                    |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Otitis media                   |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |
| Parainfluenzae virus infection |                |                |                |
| subjects affected / exposed    | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)              | 0              | 0              | 0              |

|                                         |                 |                |                |
|-----------------------------------------|-----------------|----------------|----------------|
| Otitis media acute                      |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Pharyngitis                             |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 1 / 18 (5.56%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 1              | 0              |
| Pharyngitis streptococcal               |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 1 / 49 (2.04%) |
| occurrences (all)                       | 0               | 0              | 1              |
| Respiratory tract infection viral       |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Rhinovirus infection                    |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Sinusitis                               |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 2 / 49 (4.08%) |
| occurrences (all)                       | 0               | 0              | 2              |
| Tonsillitis                             |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Upper respiratory tract infection       |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Urinary tract infection                 |                 |                |                |
| subjects affected / exposed             | 2 / 18 (11.11%) | 0 / 18 (0.00%) | 1 / 49 (2.04%) |
| occurrences (all)                       | 2               | 0              | 1              |
| Viral upper respiratory tract infection |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Metabolism and nutrition disorders      |                 |                |                |
| Dehydration                             |                 |                |                |
| subjects affected / exposed             | 0 / 18 (0.00%)  | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)                       | 0               | 0              | 0              |
| Hypercholesterolaemia                   |                 |                |                |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 18 (5.56%) | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Hyperlipidaemia             |                |                |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Type 2 diabetes mellitus    |                |                |                |
| subjects affected / exposed | 0 / 18 (0.00%) | 1 / 18 (5.56%) | 0 / 49 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Vitamin B12 deficiency      |                |                |                |
| subjects affected / exposed | 1 / 18 (5.56%) | 0 / 18 (0.00%) | 0 / 49 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |

| <b>Non-serious adverse events</b>                                   | Cohort 14: mRNA-1345 Dose A in WOCBP (18 to 40 Years) | Three Injection Placebo in Younger Adults (18 to 49 Years) | Cohort 3: mRNA-1345 Dose B in Younger Adults (18 to 49 Years) |
|---------------------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------|
| Total subjects affected by non-serious adverse events               |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 7 / 48 (14.58%)                                       | 0 / 5 (0.00%)                                              | 5 / 20 (25.00%)                                               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                       |                                                            |                                                               |
| Melanocytic naevus                                                  |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 0 / 20 (0.00%)                                                |
| occurrences (all)                                                   | 0                                                     | 0                                                          | 0                                                             |
| General disorders and administration site conditions                |                                                       |                                                            |                                                               |
| Fatigue                                                             |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 1 / 20 (5.00%)                                                |
| occurrences (all)                                                   | 0                                                     | 0                                                          | 1                                                             |
| Injection site erythema                                             |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 1 / 20 (5.00%)                                                |
| occurrences (all)                                                   | 0                                                     | 0                                                          | 1                                                             |
| Injection site pain                                                 |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 0 / 20 (0.00%)                                                |
| occurrences (all)                                                   | 0                                                     | 0                                                          | 0                                                             |
| Pyrexia                                                             |                                                       |                                                            |                                                               |
| subjects affected / exposed                                         | 0 / 48 (0.00%)                                        | 0 / 5 (0.00%)                                              | 0 / 20 (0.00%)                                                |
| occurrences (all)                                                   | 0                                                     | 0                                                          | 0                                                             |
| Vaccination site pain                                               |                                                       |                                                            |                                                               |

|                                                                                                               |                     |                    |                     |
|---------------------------------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)               | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Attention deficit hyperactivity disorder                                                                      |                     |                    |                     |

|                                                                                                                  |                     |                    |                     |
|------------------------------------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                                 | 1 / 48 (2.08%)<br>1 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Oppositional defiant disorder<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Investigations<br>Blood pressure increased<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Concussion<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Arthropod bite<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Meniscus injury<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Limb injury<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Radial head dislocation<br>subjects affected / exposed<br>occurrences (all)                                      | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Skin abrasion<br>subjects affected / exposed<br>occurrences (all)                                                | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)                                              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 1 / 20 (5.00%)<br>1 |
| Upper limb fracture<br>subjects affected / exposed<br>occurrences (all)                                          | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Cardiac disorders                                                                                                |                     |                    |                     |

|                                                                                      |                     |                    |                      |
|--------------------------------------------------------------------------------------|---------------------|--------------------|----------------------|
| Palpitations<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 2 / 20 (10.00%)<br>2 |
| Nervous system disorders                                                             |                     |                    |                      |
| Headache<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 3 / 20 (15.00%)<br>3 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Morton's neuralgia<br>subjects affected / exposed<br>occurrences (all)               | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Sensory disturbance<br>subjects affected / exposed<br>occurrences (all)              | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Ear and labyrinth disorders                                                          |                     |                    |                      |
| Ear pain<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Tympanic membrane perforation<br>subjects affected / exposed<br>occurrences (all)    | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)                          | 1 / 48 (2.08%)<br>1 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Gastrointestinal disorders                                                           |                     |                    |                      |
| Aphthous ulcer<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Gastrooesophageal reflux disease<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0  |
| Large intestine polyp                                                                |                     |                    |                      |

|                                        |                |               |                 |
|----------------------------------------|----------------|---------------|-----------------|
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Nausea                                 |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 2 / 20 (10.00%) |
| occurrences (all)                      | 0              | 0             | 2               |
| Teething                               |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Tooth disorder                         |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Toothache                              |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Vomiting                               |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Skin and subcutaneous tissue disorders |                |               |                 |
| Actinic keratosis                      |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Angioedema                             |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Dermatitis atopic                      |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Dermatitis contact                     |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Ecchymosis                             |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |
| Nail dystrophy                         |                |               |                 |
| subjects affected / exposed            | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0               |

|                                                 |                |               |                |
|-------------------------------------------------|----------------|---------------|----------------|
| Rash                                            |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Skin lesion                                     |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Solar lentigo                                   |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Splinter haemorrhages                           |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Urticaria                                       |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Urticaria papular                               |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Endocrine disorders                             |                |               |                |
| Basedow's disease                               |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Hyperthyroidism                                 |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Hypothyroidism                                  |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Musculoskeletal and connective tissue disorders |                |               |                |
| Arthralgia                                      |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 1 / 20 (5.00%) |
| occurrences (all)                               | 0              | 0             | 1              |
| Arthritis                                       |                |               |                |
| subjects affected / exposed                     | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                               | 0              | 0             | 0              |
| Musculoskeletal stiffness                       |                |               |                |

|                             |                |               |                |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Back pain                   |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 1 / 20 (5.00%) |
| occurrences (all)           | 0              | 0             | 1              |
| Osteoarthritis              |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Osteoporosis                |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Trigger finger              |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Infections and infestations |                |               |                |
| Acute sinusitis             |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Adenovirus infection        |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Appendicitis                |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Asymptomatic COVID-19       |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Bordetella infection        |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Bronchiolitis               |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Bronchitis                  |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |

|                             |                |               |                |
|-----------------------------|----------------|---------------|----------------|
| Coronavirus infection       |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| COVID-19                    |                |               |                |
| subjects affected / exposed | 4 / 48 (8.33%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 4              | 0             | 0              |
| Ear infection               |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Croup infectious            |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Eye infection               |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Folliculitis                |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Gastroenteritis             |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Impetigo                    |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| HCoV-OC43 infection         |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Influenza                   |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Metapneumovirus infection   |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |
| Nasopharyngitis             |                |               |                |
| subjects affected / exposed | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)           | 0              | 0             | 0              |

|                                   |                |               |                |
|-----------------------------------|----------------|---------------|----------------|
| Onychomycosis                     |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Oral fungal infection             |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Oral herpes                       |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Otitis media                      |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Parainfluenzae virus infection    |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Otitis media acute                |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Pharyngitis                       |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Pharyngitis streptococcal         |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Respiratory tract infection viral |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Rhinovirus infection              |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Sinusitis                         |                |               |                |
| subjects affected / exposed       | 1 / 48 (2.08%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 1              | 0             | 0              |
| Tonsillitis                       |                |               |                |
| subjects affected / exposed       | 0 / 48 (0.00%) | 0 / 5 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |

|                                                                                             |                     |                    |                     |
|---------------------------------------------------------------------------------------------|---------------------|--------------------|---------------------|
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)       | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                                          |                     |                    |                     |
| Dehydration<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Hypercholesterolaemia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Type 2 diabetes mellitus<br>subjects affected / exposed<br>occurrences (all)                | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 48 (0.00%)<br>0 | 0 / 5 (0.00%)<br>0 | 0 / 20 (0.00%)<br>0 |

| <b>Non-serious adverse events</b>                                                                                                                | Three Injection<br>Placebo in Children<br>(12 to 59 Months) | Cohort 6: mRNA-<br>1345 Dose G in<br>Children (12 to 59<br>Months) | Cohort 5: mRNA-<br>1345 Dose D in<br>Children (12 to 59<br>Months) |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed                                                          | 9 / 15 (60.00%)                                             | 11 / 15 (73.33%)                                                   | 7 / 15 (46.67%)                                                    |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0                                         | 0 / 15 (0.00%)<br>0                                                | 0 / 15 (0.00%)<br>0                                                |
| General disorders and administration<br>site conditions                                                                                          |                                                             |                                                                    |                                                                    |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| Fatigue                                         |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Injection site erythema                         |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Injection site pain                             |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Pyrexia                                         |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Vaccination site pain                           |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Vessel puncture site bruise                     |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Immune system disorders                         |                |                |                 |
| Seasonal allergy                                |                |                |                 |
| subjects affected / exposed                     | 1 / 15 (6.67%) | 1 / 15 (6.67%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 1              | 1              | 0               |
| Drug hypersensitivity                           |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Respiratory, thoracic and mediastinal disorders |                |                |                 |
| Asthma                                          |                |                |                 |
| subjects affected / exposed                     | 1 / 15 (6.67%) | 1 / 15 (6.67%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 4              | 2              | 0               |
| Bronchospasm                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Cough                                           |                |                |                 |
| subjects affected / exposed                     | 0 / 15 (0.00%) | 1 / 15 (6.67%) | 2 / 15 (13.33%) |
| occurrences (all)                               | 0              | 2              | 3               |
| Dyspnoea                                        |                |                |                 |

|                                                                                                                     |                     |                     |                     |
|---------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                                                    | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Respiratory tract congestion<br>subjects affected / exposed<br>occurrences (all)                                    | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Attention deficit hyperactivity<br>disorder<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 |
| Oppositional defiant disorder<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 |
| Investigations<br>Blood pressure increased<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Injury, poisoning and procedural<br>complications<br>Concussion<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Arthropod bite<br>subjects affected / exposed<br>occurrences (all)                                                  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Meniscus injury<br>subjects affected / exposed<br>occurrences (all)                                                 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Limb injury<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Radial head dislocation                                                                                             |                     |                     |                     |

|                                                                                             |                     |                     |                     |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                                            | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 |
| Skin abrasion<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Upper limb fracture<br>subjects affected / exposed<br>occurrences (all)                     | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Cardiac disorders<br>Palpitations<br>subjects affected / exposed<br>occurrences (all)       | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)    | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)                                | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Morton's neuralgia<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Sensory disturbance<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Ear and labyrinth disorders<br>Ear pain<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Tympanic membrane perforation<br>subjects affected / exposed<br>occurrences (all)           | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 |
| Vertigo                                                                                     |                     |                     |                     |

|                                                  |                     |                     |                     |
|--------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Gastrointestinal disorders                       |                     |                     |                     |
| Aphthous ulcer                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Gastrooesophageal reflux disease                 |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 1 / 15 (6.67%)      |
| occurrences (all)                                | 0                   | 0                   | 1                   |
| Diarrhoea                                        |                     |                     |                     |
| subjects affected / exposed                      | 1 / 15 (6.67%)      | 1 / 15 (6.67%)      | 1 / 15 (6.67%)      |
| occurrences (all)                                | 1                   | 1                   | 1                   |
| Large intestine polyp                            |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Nausea                                           |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Teething                                         |                     |                     |                     |
| subjects affected / exposed                      | 1 / 15 (6.67%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                   |
| Tooth disorder                                   |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Toothache                                        |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Vomiting                                         |                     |                     |                     |
| subjects affected / exposed                      | 1 / 15 (6.67%)      | 1 / 15 (6.67%)      | 1 / 15 (6.67%)      |
| occurrences (all)                                | 1                   | 1                   | 1                   |
| Skin and subcutaneous tissue disorders           |                     |                     |                     |
| Actinic keratosis                                |                     |                     |                     |
| subjects affected / exposed                      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      | 0 / 15 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                   |
| Angioedema                                       |                     |                     |                     |

|                             |                |                |                |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Dermatitis atopic           |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 1 / 15 (6.67%) |
| occurrences (all)           | 0              | 0              | 1              |
| Dermatitis contact          |                |                |                |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Ecchymosis                  |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Nail dystrophy              |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Rash                        |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Skin lesion                 |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Solar lentigo               |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Splinter haemorrhages       |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |
| Urticaria                   |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 1 / 15 (6.67%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 1              | 0              |
| Urticaria papular           |                |                |                |
| subjects affected / exposed | 1 / 15 (6.67%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 1              | 0              | 0              |
| Endocrine disorders         |                |                |                |
| Basedow's disease           |                |                |                |
| subjects affected / exposed | 0 / 15 (0.00%) | 0 / 15 (0.00%) | 0 / 15 (0.00%) |
| occurrences (all)           | 0              | 0              | 0              |

|                                                                               |                      |                     |                     |
|-------------------------------------------------------------------------------|----------------------|---------------------|---------------------|
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)           | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                               |                      |                     |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Arthritis<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Musculoskeletal stiffness<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Osteoarthritis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Osteoporosis<br>subjects affected / exposed<br>occurrences (all)              | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Trigger finger<br>subjects affected / exposed<br>occurrences (all)            | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Infections and infestations                                                   |                      |                     |                     |
| Acute sinusitis<br>subjects affected / exposed<br>occurrences (all)           | 2 / 15 (13.33%)<br>2 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
| Adenovirus infection<br>subjects affected / exposed<br>occurrences (all)      | 0 / 15 (0.00%)<br>0  | 0 / 15 (0.00%)<br>0 | 1 / 15 (6.67%)<br>1 |
| Appendicitis                                                                  |                      |                     |                     |

|                             |                 |                 |                |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 0               | 1               | 0              |
| Asymptomatic COVID-19       |                 |                 |                |
| subjects affected / exposed | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 0               | 0               | 0              |
| Bordetella infection        |                 |                 |                |
| subjects affected / exposed | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 1 / 15 (6.67%) |
| occurrences (all)           | 0               | 0               | 1              |
| Bronchiolitis               |                 |                 |                |
| subjects affected / exposed | 1 / 15 (6.67%)  | 2 / 15 (13.33%) | 0 / 15 (0.00%) |
| occurrences (all)           | 1               | 2               | 0              |
| Bronchitis                  |                 |                 |                |
| subjects affected / exposed | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 0               | 0               | 0              |
| Coronavirus infection       |                 |                 |                |
| subjects affected / exposed | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 1 / 15 (6.67%) |
| occurrences (all)           | 0               | 0               | 1              |
| COVID-19                    |                 |                 |                |
| subjects affected / exposed | 1 / 15 (6.67%)  | 1 / 15 (6.67%)  | 1 / 15 (6.67%) |
| occurrences (all)           | 1               | 1               | 1              |
| Ear infection               |                 |                 |                |
| subjects affected / exposed | 2 / 15 (13.33%) | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 2               | 0               | 0              |
| Croup infectious            |                 |                 |                |
| subjects affected / exposed | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 1               | 0               | 0              |
| Eye infection               |                 |                 |                |
| subjects affected / exposed | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 1               | 0               | 0              |
| Folliculitis                |                 |                 |                |
| subjects affected / exposed | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 2               | 0               | 0              |
| Gastroenteritis             |                 |                 |                |
| subjects affected / exposed | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  | 0 / 15 (0.00%) |
| occurrences (all)           | 0               | 1               | 0              |
| Impetigo                    |                 |                 |                |

|                                |                 |                 |                 |
|--------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed    | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 1               | 0               | 0               |
| HCoV-OC43 infection            |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 1               | 0               |
| Influenza                      |                 |                 |                 |
| subjects affected / exposed    | 1 / 15 (6.67%)  | 2 / 15 (13.33%) | 0 / 15 (0.00%)  |
| occurrences (all)              | 1               | 2               | 0               |
| Metapneumovirus infection      |                 |                 |                 |
| subjects affected / exposed    | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 1               | 0               | 0               |
| Nasopharyngitis                |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 0               | 0               |
| Onychomycosis                  |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 0               | 0               |
| Oral fungal infection          |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 0               | 0               |
| Oral herpes                    |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 0               | 0               |
| Otitis media                   |                 |                 |                 |
| subjects affected / exposed    | 2 / 15 (13.33%) | 3 / 15 (20.00%) | 2 / 15 (13.33%) |
| occurrences (all)              | 3               | 3               | 2               |
| Parainfluenzae virus infection |                 |                 |                 |
| subjects affected / exposed    | 2 / 15 (13.33%) | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 2               | 0               | 0               |
| Otitis media acute             |                 |                 |                 |
| subjects affected / exposed    | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 1               | 0               | 0               |
| Pharyngitis                    |                 |                 |                 |
| subjects affected / exposed    | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)              | 0               | 0               | 0               |
| Pharyngitis streptococcal      |                 |                 |                 |

|                                         |                 |                 |                 |
|-----------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed             | 2 / 15 (13.33%) | 2 / 15 (13.33%) | 0 / 15 (0.00%)  |
| occurrences (all)                       | 2               | 2               | 0               |
| Respiratory tract infection viral       |                 |                 |                 |
| subjects affected / exposed             | 2 / 15 (13.33%) | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 2               | 0               | 0               |
| Rhinovirus infection                    |                 |                 |                 |
| subjects affected / exposed             | 3 / 15 (20.00%) | 1 / 15 (6.67%)  | 3 / 15 (20.00%) |
| occurrences (all)                       | 5               | 1               | 3               |
| Sinusitis                               |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  |
| occurrences (all)                       | 0               | 0               | 1               |
| Tonsillitis                             |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 0               | 1               | 0               |
| Upper respiratory tract infection       |                 |                 |                 |
| subjects affected / exposed             | 1 / 15 (6.67%)  | 3 / 15 (20.00%) | 1 / 15 (6.67%)  |
| occurrences (all)                       | 2               | 3               | 1               |
| Urinary tract infection                 |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 1 / 15 (6.67%)  | 1 / 15 (6.67%)  |
| occurrences (all)                       | 0               | 1               | 1               |
| Viral upper respiratory tract infection |                 |                 |                 |
| subjects affected / exposed             | 1 / 15 (6.67%)  | 4 / 15 (26.67%) | 0 / 15 (0.00%)  |
| occurrences (all)                       | 9               | 13              | 0               |
| Metabolism and nutrition disorders      |                 |                 |                 |
| Dehydration                             |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Hypercholesterolaemia                   |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Hyperlipidaemia                         |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |
| Type 2 diabetes mellitus                |                 |                 |                 |
| subjects affected / exposed             | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  | 0 / 15 (0.00%)  |
| occurrences (all)                       | 0               | 0               | 0               |

|                                                                            |                     |                     |                     |
|----------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 | 0 / 15 (0.00%)<br>0 |
|----------------------------------------------------------------------------|---------------------|---------------------|---------------------|

  

| <b>Non-serious adverse events</b>                                                                                                             | Cohort 11: mRNA-1345 Dose F in Older Adults (After Month 12) | Two Injection Placebo in Older Adults (After Month 12) | Cohort 10: mRNA-1345 Dose E in Older Adults (After Month 12) |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                          | 8 / 22 (36.36%)                                              | 43 / 148 (29.05%)                                      | 8 / 22 (36.36%)                                              |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Melanocytic naevus<br>subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| General disorders and administration site conditions<br>Fatigue<br>subjects affected / exposed<br>occurrences (all)                           | 0 / 22 (0.00%)<br>0                                          | 3 / 148 (2.03%)<br>3                                   | 1 / 22 (4.55%)<br>1                                          |
| Injection site erythema<br>subjects affected / exposed<br>occurrences (all)                                                                   | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Injection site pain<br>subjects affected / exposed<br>occurrences (all)                                                                       | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                                                   | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Vaccination site pain<br>subjects affected / exposed<br>occurrences (all)                                                                     | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Vessel puncture site bruise<br>subjects affected / exposed<br>occurrences (all)                                                               | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Immune system disorders<br>Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 22 (0.00%)<br>0                                          | 0 / 148 (0.00%)<br>0                                   | 0 / 22 (0.00%)<br>0                                          |
| Drug hypersensitivity                                                                                                                         |                                                              |                                                        |                                                              |

|                                                  |                     |                      |                     |
|--------------------------------------------------|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1 | 0 / 22 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders  |                     |                      |                     |
| Asthma                                           |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Bronchospasm                                     |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Cough                                            |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Dyspnoea                                         |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Respiratory tract congestion                     |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Rhinorrhoea                                      |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 1 / 148 (0.68%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 1                    | 0                   |
| Psychiatric disorders                            |                     |                      |                     |
| Anxiety                                          |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 1 / 148 (0.68%)      | 1 / 22 (4.55%)      |
| occurrences (all)                                | 0                   | 1                    | 1                   |
| Attention deficit hyperactivity disorder         |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Oppositional defiant disorder                    |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Investigations                                   |                     |                      |                     |
| Blood pressure increased                         |                     |                      |                     |
| subjects affected / exposed                      | 0 / 22 (0.00%)      | 0 / 148 (0.00%)      | 0 / 22 (0.00%)      |
| occurrences (all)                                | 0                   | 0                    | 0                   |
| Injury, poisoning and procedural                 |                     |                      |                     |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| complications               |                |                 |                |
| Concussion                  |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Arthropod bite              |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Meniscus injury             |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Limb injury                 |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all)           | 0              | 0               | 1              |
| Radial head dislocation     |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Skin abrasion               |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 1               | 0              |
| Skin laceration             |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 1               | 0              |
| Upper limb fracture         |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Cardiac disorders           |                |                 |                |
| Palpitations                |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 2 / 148 (1.35%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 2               | 0              |
| Nervous system disorders    |                |                 |                |
| Headache                    |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 3 / 148 (2.03%) | 1 / 22 (4.55%) |
| occurrences (all)           | 0              | 3               | 1              |
| Migraine                    |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 1               | 0              |
| Morton's neuralgia          |                |                 |                |

|                                                                         |                     |                      |                     |
|-------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Sensory disturbance<br>subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Ear and labyrinth disorders                                             |                     |                      |                     |
| Ear pain                                                                |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Tympanic membrane perforation                                           |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Vertigo                                                                 |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Gastrointestinal disorders                                              |                     |                      |                     |
| Aphthous ulcer                                                          |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Gastrooesophageal reflux disease                                        |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 2 / 148 (1.35%)<br>2 | 0 / 22 (0.00%)<br>0 |
| Diarrhoea                                                               |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Large intestine polyp                                                   |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Nausea                                                                  |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 1 / 22 (4.55%)<br>1 |
| Teething                                                                |                     |                      |                     |
| subjects affected / exposed<br>occurrences (all)                        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Tooth disorder                                                          |                     |                      |                     |

|                                                                        |                     |                      |                     |
|------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                       | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Toothache<br>subjects affected / exposed<br>occurrences (all)          | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1 | 0 / 22 (0.00%)<br>0 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)           | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders                                 |                     |                      |                     |
| Actinic keratosis<br>subjects affected / exposed<br>occurrences (all)  | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Angioedema<br>subjects affected / exposed<br>occurrences (all)         | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Dermatitis atopic<br>subjects affected / exposed<br>occurrences (all)  | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Dermatitis contact<br>subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Ecchymosis<br>subjects affected / exposed<br>occurrences (all)         | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Nail dystrophy<br>subjects affected / exposed<br>occurrences (all)     | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Rash<br>subjects affected / exposed<br>occurrences (all)               | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Skin lesion<br>subjects affected / exposed<br>occurrences (all)        | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Solar lentigo<br>subjects affected / exposed<br>occurrences (all)      | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |

|                                                                                                                   |                     |                      |                     |
|-------------------------------------------------------------------------------------------------------------------|---------------------|----------------------|---------------------|
| Splinter haemorrhages<br>subjects affected / exposed<br>occurrences (all)                                         | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1 | 0 / 22 (0.00%)<br>0 |
| Urticaria papular<br>subjects affected / exposed<br>occurrences (all)                                             | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Endocrine disorders<br>Basedow's disease<br>subjects affected / exposed<br>occurrences (all)                      | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)                                               | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)                                                | 2 / 22 (9.09%)<br>2 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0 | 5 / 148 (3.38%)<br>5 | 0 / 22 (0.00%)<br>0 |
| Arthritis<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1 | 0 / 22 (0.00%)<br>0 |
| Musculoskeletal stiffness<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0 | 0 / 22 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                                                     | 0 / 22 (0.00%)<br>0 | 2 / 148 (1.35%)<br>2 | 1 / 22 (4.55%)<br>1 |
| Osteoarthritis<br>subjects affected / exposed<br>occurrences (all)                                                | 2 / 22 (9.09%)<br>2 | 1 / 148 (0.68%)<br>1 | 1 / 22 (4.55%)<br>1 |
| Osteoporosis                                                                                                      |                     |                      |                     |

|                                                                           |                     |                        |                     |
|---------------------------------------------------------------------------|---------------------|------------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                          | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Trigger finger<br>subjects affected / exposed<br>occurrences (all)        | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1   | 0 / 22 (0.00%)<br>0 |
| Infections and infestations                                               |                     |                        |                     |
| Acute sinusitis<br>subjects affected / exposed<br>occurrences (all)       | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Adenovirus infection<br>subjects affected / exposed<br>occurrences (all)  | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Appendicitis<br>subjects affected / exposed<br>occurrences (all)          | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Asymptomatic COVID-19<br>subjects affected / exposed<br>occurrences (all) | 2 / 22 (9.09%)<br>2 | 4 / 148 (2.70%)<br>4   | 0 / 22 (0.00%)<br>0 |
| Bordetella infection<br>subjects affected / exposed<br>occurrences (all)  | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Bronchiolitis<br>subjects affected / exposed<br>occurrences (all)         | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 22 (0.00%)<br>0 | 1 / 148 (0.68%)<br>1   | 0 / 22 (0.00%)<br>0 |
| Coronavirus infection<br>subjects affected / exposed<br>occurrences (all) | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |
| COVID-19<br>subjects affected / exposed<br>occurrences (all)              | 1 / 22 (4.55%)<br>1 | 10 / 148 (6.76%)<br>10 | 2 / 22 (9.09%)<br>2 |
| Ear infection<br>subjects affected / exposed<br>occurrences (all)         | 0 / 22 (0.00%)<br>0 | 0 / 148 (0.00%)<br>0   | 0 / 22 (0.00%)<br>0 |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| Croup infectious            |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Eye infection               |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Folliculitis                |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Gastroenteritis             |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Impetigo                    |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| HCoV-OC43 infection         |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Influenza                   |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 1 / 22 (4.55%) |
| occurrences (all)           | 0              | 0               | 1              |
| Metapneumovirus infection   |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Nasopharyngitis             |                |                 |                |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 1              | 0               | 0              |
| Onychomycosis               |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 1               | 0              |
| Oral fungal infection       |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |
| Oral herpes                 |                |                 |                |
| subjects affected / exposed | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)           | 0              | 0               | 0              |

|                                         |                |                 |                |
|-----------------------------------------|----------------|-----------------|----------------|
| Otitis media                            |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Parainfluenzae virus infection          |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Otitis media acute                      |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Pharyngitis                             |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Pharyngitis streptococcal               |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Respiratory tract infection viral       |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Rhinovirus infection                    |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Sinusitis                               |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 1               | 0              |
| Tonsillitis                             |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 0               | 0              |
| Upper respiratory tract infection       |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 2 / 148 (1.35%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 2               | 0              |
| Urinary tract infection                 |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 3 / 148 (2.03%) | 2 / 22 (9.09%) |
| occurrences (all)                       | 0              | 3               | 2              |
| Viral upper respiratory tract infection |                |                 |                |
| subjects affected / exposed             | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)                       | 0              | 1               | 0              |

|                                    |                |                 |                |
|------------------------------------|----------------|-----------------|----------------|
| Metabolism and nutrition disorders |                |                 |                |
| Dehydration                        |                |                 |                |
| subjects affected / exposed        | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                  | 0              | 0               | 0              |
| Hypercholesterolaemia              |                |                 |                |
| subjects affected / exposed        | 0 / 22 (0.00%) | 1 / 148 (0.68%) | 0 / 22 (0.00%) |
| occurrences (all)                  | 0              | 1               | 0              |
| Hyperlipidaemia                    |                |                 |                |
| subjects affected / exposed        | 0 / 22 (0.00%) | 2 / 148 (1.35%) | 0 / 22 (0.00%) |
| occurrences (all)                  | 0              | 2               | 0              |
| Type 2 diabetes mellitus           |                |                 |                |
| subjects affected / exposed        | 0 / 22 (0.00%) | 3 / 148 (2.03%) | 0 / 22 (0.00%) |
| occurrences (all)                  | 0              | 3               | 0              |
| Vitamin B12 deficiency             |                |                 |                |
| subjects affected / exposed        | 0 / 22 (0.00%) | 0 / 148 (0.00%) | 0 / 22 (0.00%) |
| occurrences (all)                  | 0              | 0               | 0              |

|                                                                     |                                                             |  |  |
|---------------------------------------------------------------------|-------------------------------------------------------------|--|--|
| <b>Non-serious adverse events</b>                                   | Older Adult Cohorts:<br>After Month 24:<br>mRNA-1345 Dose A |  |  |
| Total subjects affected by non-serious adverse events               |                                                             |  |  |
| subjects affected / exposed                                         | 23 / 109 (21.10%)                                           |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                             |  |  |
| Melanocytic naevus                                                  |                                                             |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%)                                             |  |  |
| occurrences (all)                                                   | 0                                                           |  |  |
| General disorders and administration site conditions                |                                                             |  |  |
| Fatigue                                                             |                                                             |  |  |
| subjects affected / exposed                                         | 3 / 109 (2.75%)                                             |  |  |
| occurrences (all)                                                   | 3                                                           |  |  |
| Injection site erythema                                             |                                                             |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%)                                             |  |  |
| occurrences (all)                                                   | 0                                                           |  |  |
| Injection site pain                                                 |                                                             |  |  |
| subjects affected / exposed                                         | 0 / 109 (0.00%)                                             |  |  |
| occurrences (all)                                                   | 0                                                           |  |  |
| Pyrexia                                                             |                                                             |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Vaccination site pain                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Vessel puncture site bruise                     |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Immune system disorders                         |                 |  |  |
| Seasonal allergy                                |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Drug hypersensitivity                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Respiratory, thoracic and mediastinal disorders |                 |  |  |
| Asthma                                          |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Bronchospasm                                    |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Cough                                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Dyspnoea                                        |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Respiratory tract congestion                    |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Rhinorrhoea                                     |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Psychiatric disorders                           |                 |  |  |

|                                                |                 |  |  |
|------------------------------------------------|-----------------|--|--|
| Anxiety                                        |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Attention deficit hyperactivity disorder       |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Oppositional defiant disorder                  |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Investigations                                 |                 |  |  |
| Blood pressure increased                       |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Injury, poisoning and procedural complications |                 |  |  |
| Concussion                                     |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Arthropod bite                                 |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Meniscus injury                                |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Limb injury                                    |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Radial head dislocation                        |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Skin abrasion                                  |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Skin laceration                                |                 |  |  |
| subjects affected / exposed                    | 0 / 109 (0.00%) |  |  |
| occurrences (all)                              | 0               |  |  |
| Upper limb fracture                            |                 |  |  |

|                                                                                                                                                                                                                                                                                                                           |                                                                                                          |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--|--|
| subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                                                          | 0 / 109 (0.00%)<br>0                                                                                     |  |  |
| Cardiac disorders<br>Palpitations<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                     | 0 / 109 (0.00%)<br>0                                                                                     |  |  |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)<br><br>Migraine<br>subjects affected / exposed<br>occurrences (all)<br><br>Morton's neuralgia<br>subjects affected / exposed<br>occurrences (all)<br><br>Sensory disturbance<br>subjects affected / exposed<br>occurrences (all) | 0 / 109 (0.00%)<br>0<br><br>0 / 109 (0.00%)<br>0<br><br>0 / 109 (0.00%)<br>0<br><br>0 / 109 (0.00%)<br>0 |  |  |
| Ear and labyrinth disorders<br>Ear pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Tympanic membrane perforation<br>subjects affected / exposed<br>occurrences (all)<br><br>Vertigo<br>subjects affected / exposed<br>occurrences (all)                                                                   | 0 / 109 (0.00%)<br>0<br><br>0 / 109 (0.00%)<br>0<br><br>0 / 109 (0.00%)<br>0                             |  |  |
| Gastrointestinal disorders<br>Aphthous ulcer<br>subjects affected / exposed<br>occurrences (all)<br><br>Gastrooesophageal reflux disease<br>subjects affected / exposed<br>occurrences (all)<br><br>Diarrhoea                                                                                                             | 0 / 109 (0.00%)<br>0<br><br>2 / 109 (1.83%)<br>2                                                         |  |  |

|                                        |                 |  |  |
|----------------------------------------|-----------------|--|--|
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Large intestine polyp                  |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Nausea                                 |                 |  |  |
| subjects affected / exposed            | 1 / 109 (0.92%) |  |  |
| occurrences (all)                      | 1               |  |  |
| Teething                               |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Tooth disorder                         |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Toothache                              |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Vomiting                               |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Skin and subcutaneous tissue disorders |                 |  |  |
| Actinic keratosis                      |                 |  |  |
| subjects affected / exposed            | 2 / 109 (1.83%) |  |  |
| occurrences (all)                      | 2               |  |  |
| Angioedema                             |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Dermatitis atopic                      |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Dermatitis contact                     |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |
| Ecchymosis                             |                 |  |  |
| subjects affected / exposed            | 0 / 109 (0.00%) |  |  |
| occurrences (all)                      | 0               |  |  |

|                                                 |                 |  |  |
|-------------------------------------------------|-----------------|--|--|
| Nail dystrophy                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Rash                                            |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Skin lesion                                     |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Solar lentigo                                   |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Splinter haemorrhages                           |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Urticaria                                       |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Urticaria papular                               |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Endocrine disorders                             |                 |  |  |
| Basedow's disease                               |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Hyperthyroidism                                 |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Hypothyroidism                                  |                 |  |  |
| subjects affected / exposed                     | 0 / 109 (0.00%) |  |  |
| occurrences (all)                               | 0               |  |  |
| Musculoskeletal and connective tissue disorders |                 |  |  |
| Arthralgia                                      |                 |  |  |
| subjects affected / exposed                     | 1 / 109 (0.92%) |  |  |
| occurrences (all)                               | 1               |  |  |
| Arthritis                                       |                 |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Musculoskeletal stiffness   |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Back pain                   |                 |  |  |
| subjects affected / exposed | 1 / 109 (0.92%) |  |  |
| occurrences (all)           | 1               |  |  |
| Osteoarthritis              |                 |  |  |
| subjects affected / exposed | 1 / 109 (0.92%) |  |  |
| occurrences (all)           | 1               |  |  |
| Osteoporosis                |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Trigger finger              |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Infections and infestations |                 |  |  |
| Acute sinusitis             |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Adenovirus infection        |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Appendicitis                |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Asymptomatic COVID-19       |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Bordetella infection        |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Bronchiolitis               |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| Bronchitis                  |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Coronavirus infection       |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| COVID-19                    |                 |  |  |
| subjects affected / exposed | 2 / 109 (1.83%) |  |  |
| occurrences (all)           | 2               |  |  |
| Ear infection               |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Croup infectious            |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Eye infection               |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Folliculitis                |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Gastroenteritis             |                 |  |  |
| subjects affected / exposed | 1 / 109 (0.92%) |  |  |
| occurrences (all)           | 1               |  |  |
| Impetigo                    |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| HCoV-OC43 infection         |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Influenza                   |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |
| Metapneumovirus infection   |                 |  |  |
| subjects affected / exposed | 0 / 109 (0.00%) |  |  |
| occurrences (all)           | 0               |  |  |

|                                   |                 |  |  |
|-----------------------------------|-----------------|--|--|
| Nasopharyngitis                   |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Onychomycosis                     |                 |  |  |
| subjects affected / exposed       | 1 / 109 (0.92%) |  |  |
| occurrences (all)                 | 1               |  |  |
| Oral fungal infection             |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Oral herpes                       |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Otitis media                      |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Parainfluenzae virus infection    |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Otitis media acute                |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Pharyngitis                       |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Pharyngitis streptococcal         |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Respiratory tract infection viral |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Rhinovirus infection              |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |
| Sinusitis                         |                 |  |  |
| subjects affected / exposed       | 0 / 109 (0.00%) |  |  |
| occurrences (all)                 | 0               |  |  |

|                                         |                 |  |  |
|-----------------------------------------|-----------------|--|--|
| Tonsillitis                             |                 |  |  |
| subjects affected / exposed             | 0 / 109 (0.00%) |  |  |
| occurrences (all)                       | 0               |  |  |
| Upper respiratory tract infection       |                 |  |  |
| subjects affected / exposed             | 2 / 109 (1.83%) |  |  |
| occurrences (all)                       | 2               |  |  |
| Urinary tract infection                 |                 |  |  |
| subjects affected / exposed             | 4 / 109 (3.67%) |  |  |
| occurrences (all)                       | 4               |  |  |
| Viral upper respiratory tract infection |                 |  |  |
| subjects affected / exposed             | 0 / 109 (0.00%) |  |  |
| occurrences (all)                       | 0               |  |  |
| Metabolism and nutrition disorders      |                 |  |  |
| Dehydration                             |                 |  |  |
| subjects affected / exposed             | 0 / 109 (0.00%) |  |  |
| occurrences (all)                       | 0               |  |  |
| Hypercholesterolaemia                   |                 |  |  |
| subjects affected / exposed             | 0 / 109 (0.00%) |  |  |
| occurrences (all)                       | 0               |  |  |
| Hyperlipidaemia                         |                 |  |  |
| subjects affected / exposed             | 2 / 109 (1.83%) |  |  |
| occurrences (all)                       | 2               |  |  |
| Type 2 diabetes mellitus                |                 |  |  |
| subjects affected / exposed             | 1 / 109 (0.92%) |  |  |
| occurrences (all)                       | 1               |  |  |
| Vitamin B12 deficiency                  |                 |  |  |
| subjects affected / exposed             | 0 / 109 (0.00%) |  |  |
| occurrences (all)                       | 0               |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                            |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 18 November 2020 | This amendment was issued to add 3 cohorts (mRNA-1345 or placebo [Cohort 7 to 9]) of healthy adults of 65 to 79 years of age in order to establish the dose in this population. Additionally, the age range of participants in the pediatric cohorts was increased to 12 to 59 months in order to increase the potential pool of seropositive children in the study. |
| 21 April 2021    | This amendment was issued to add 2 cohorts of adults aged 65 to 79 to receive mRNA-1345 or placebo (Cohort 10 and 11) and to include a WOCBP population to enable future studies to address RSV disease in neonates (Cohort 12, Cohort 13, and Cohort 14).                                                                                                           |
| 27 August 2021   | This amendment was issued to include adults of Japanese descent aged 60 years or older (Cohort 15) in order to expand the population and to enable subsequent late-stage clinical studies in Japan.                                                                                                                                                                  |
| 06 December 2021 | This amendment updated dosing in Cohort 6 and participant numbers in Cohorts 5 and 6.                                                                                                                                                                                                                                                                                |
| 22 February 2023 | This amendment was issued to add a second booster injection of mRNA-1345 for Cohorts 7 to 11, 24 months after receiving the primary injection, which allowed for an evaluation of the benefit of a second booster in the older adult population and assessed its impact on waning antibody titers and the durability of conferred immune protection.                 |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported